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DISSERTATION ABSTRACT 
 
Matthew Ryan Ely  
 
Doctor of Philosophy 
 
Department of Human Physiology 
 
September 2019 
 
Title: Histamine and the Exercise Responsome 
 
Histamine, a biogenic amine, commonly associated with the immune and 
inflammatory response is produced and released within skeletal muscle during exercise. 
The exact role(s) of histamine in the exercise response is largely unknown and 
understudied. Histamine’s function in physiological contexts outside of exercise, such as 
its role in the modulation of tissue blood flow and inflammation, has guided the 
formation and interpretation of the studies included in this dissertation. Specifically, this 
research was divided into three separate studies intended to expand upon previous 
research on endurance capacity, exercise/functional hyperemia, and exercise-induced 
inflammation. In summary, the results of the studies suggest that skeletal muscle 
histamine may have a duration and intensity dependent function during exercise. 
Systemically blocking histamine’s interaction with H1 and H2 receptors had no effect on 
low- to moderate-intensity exercise, but compromised the ability of individuals to 
perform exercise of long durations and high intensities. The reduced exercise capacity 
may relate to histamine’s influence on the microvasculature. In immune and 
inflammatory responses, histamine dilates arterioles and increases capillary permeability 
to facilitate blood delivery and nutrient, immune cell, and metabolic byproduct transfer 
between the tissue and circulation. Blocking histamine H1/H2 receptors did not reduce, 
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but in fact increased leg blood flow during exercise. The increased blood flow may have 
been a consequence of alterations within the muscle milieu increasing the hydrogen ion 
concentration, thereby increasing the stimulus for blood flow. The increased blood flow 
and reduced pH suggest a role of histamine in mediating capillary nutrient transfer during 
exercise. Finally, blocking histamine H1/H2 receptors did not affect the systemic immune 
response (circulating leukocytes and cytokines) resulting from muscle-damaging 
exercise, but this study did not address responses within the skeletal muscle tissue where 
histamine is released/produced.  Future research should focus on specific functions of 
histamine within the skeletal muscle, as these studies did not detect alterations in 
systemic function when histaminergic signaling was blocked. The findings of these 
studies suggest that histamine plays vital roles in many physiological pathways 
associated with the stress of exercise within the muscle. Future research expanding upon 
these findings will be important as very little is known about autocrine, paracrine, and 
endocrine role of histamine as part of the exercise responsome. 
This dissertation includes previously published co-authored material.  
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CHAPTER I 
 
INTRODUCTION 
 
Statement of the Problem 
 Histamine is a biogenic amine commonly associated with immune and 
inflammatory reactions, but is also produced and released within skeletal muscle during 
exercise (255). While the role of histamine in the exercise response is largely unknown, 
in vivo analysis of intramuscular fluid during exercise revealed that histamine 
concentrations increase by mast cell degranulation and through de novo synthesis (255) 
which occurred secondary to increased translation, transcription, and activation of the 
histidine decarboxylase (HDC) enzyme (212, 328). Histamine release by mast cell 
degranulation commonly occurs by antigen-immunogloblin interaction during allergic 
reactions, but can also occur with non-immunologic stimuli associated with exercise such 
as hypoxia, hyperosmolality, oxidative stress, chemokines, increased temperature, and 
vibration (97, 213, 279, 294). The HDC enzyme continually synthesizes minute 
quantities of histamine in resting muscle, and increases in HDC histamine formation 
occurs through positive allosteric modulation from hypoxia, temperature elevations, 
decreases in pH, and with increases in interleukin-1 concentrations, all of which may 
occur singularly or in combination with repeated muscle contractions (267, 268, 271). 
Therefore, multiple exercise related stimuli are potentially responsible for the increased 
histamine concentrations, which implies that histamine has an important function in the 
exercise response.  
The importance of histamine in the exercise response can be gleaned from 
investigations in which histaminergic signaling has been disrupted.  In humans, blocking 
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histamine interactions with H1 or H2 receptors had no effect on isokinetic muscle strength 
or endurance, oxygen consumption measures during steady state submaximal exercise or 
maximal aerobic exercise (VO2peak), or the ability to complete high intensity intermittent 
sprint exercises (194, 195). In murine species, blocking histamine’s actions on the H1 and 
H2 receptors diminished the speed and duration components of multi-hour endurance 
gnawing and walking tasks (212, 328). Similarly, reduced endurance walking capacity 
was noted in mice bred without either HDC, mast cells, or H1 receptors (212, 328). Two 
major differences between the results of these studies are the species tested and the 
duration of these tests. First, murine species are often used as surrogates for 
understanding human physiology, but genomic differences often result in divergent 
findings between the species (278). Second, the longest duration of human testing was 
approximately 30 minutes using high-intensity sprint intervals alternated with rest 
periods. The exercise-rest interval study design does not reveal the effect of blocking 
histamine’s actions on sustained endurance performance in humans as tested in the mice. 
A possible physiological explanation for the differing impact of blocking histamine’s 
actions between the short-duration and long-duration tests may be related to the histamine 
forming capacity of HDC. HDC activity is positively correlated to exercise duration as 
the mRNA for the formation of new HDC enzymes increase after 60 minutes of exercise 
and the histamine formation activity of HDC is elevated following 120 minutes of 
exercise (13, 14, 320). Therefore, given the variations in study designs, it is unknown if 
the differing outcomes between the human and murine studies are simply due to 
differences in histamine’s actions between species or indicate that histamine’s importance 
in the exercise response is related to the intensity and/or duration of the exercise tests. 
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The duration of the exercise may be the essential variable to elucidate histamine’s 
role in the exercise response. Histamine is a primary mediator of blood flow in the 
microcirculation during inflammatory and immune responses (18, 270, 272, 273) and has 
also been associated with increased blood flow during reactive hyperemia (10, 72), 
increased skin blood flow during heat stress (325), increased blood flow in tumor 
formation and growth (83, 226), and with sustained post-exercise vasodilation within 
previously active muscles (168, 187, 188). It is unknown if exercise-induced elevations in 
histamine concentrations have a similar vasodilatory influence to facilitate an increased 
blood flow to the contracting skeletal muscle (exercise hyperemia). If exercise-induced 
increases in histamine aid in increasing blood flow during exercise, blocking this action 
would decrease nutrient and oxygen delivery as well as carbon dioxide and metabolite 
removal. The impact of this mismatch of perfusion and metabolism would have a larger 
negative influence on longer-duration exercise compared to short-duration exercise, and 
could be an explanation for the decreased endurance task performances observed in mice 
(82, 84, 212, 328) but not in short-duration exercise studies in humans (194–196, 236).  
The increased skeletal muscle histamine concentrations during exercise may 
contribute to the exercise response beyond facilitating elevations in blood flow. 
Histamine also has many associations with the acute inflammatory response. Histamine 
concentrations are increased locally at sites of tissue damage (203, 291) to promote 
diapedesis of leukocytes by acting directly and indirectly in the production of 
chemokines, cytokines, endothelial adhesion molecules (289), and increasing capillary 
permeability (176, 272). Additionally, in vitro, histamine has been shown to alter the 
expression of a number of cytokines involved with the macrophage M1 (“pro-
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inflammatory”) and M2 (“anti-inflammatory”) phenotype conversion (76, 83). Endurance 
exercise itself initiates an acute systemic inflammatory profile (i.e. leukocytosis and 
elevated chemokines) (229–231) and blocking histamine H1/H2 receptors during exercise 
depresses the mRNA expression of chemokines and cytokines related to inflammation 
within skeletal muscle (254). Therefore, exercise associated elevations in intramuscular 
histamine may be a primary signal to initiate the acute systemic inflammatory response 
following endurance exercise in order to repair damaged tissue from exercise.  
 The studies detailed in this dissertation were designed to gain insight into the role 
of histamine during and following exercise. The proposed research is divided into three 
separate studies intended to expand upon previous research on endurance exercise 
capacity, skeletal muscle blood flow during exercise, and exercise induced inflammation. 
In Chapter IV, the association of histamine to endurance exercise capacity was tested. In 
Chapter V, histaminergic control of blood flow during exercise was examined. In Chapter 
VI, the association between exercise induced histamine release/production and immune 
response following muscle-damaging exercise was investigated.     
 
PURPOSE and HYPOTHOSES 
This dissertation involved three separate studies, detailed in Chapters IV – VI, with the 
following purposes and hypotheses: 
1. Chapter IV: The purpose of this study was to gain insight on histamine’s role in 
endurance exercise in humans and potentially reconcile the contrasting results 
between human and animal studies. Specifically, on multiple days human subjects 
performed short-duration high-intensity exercise performance tests following a 
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time matched period of rest or endurance exercise. Additionally, subjects 
performed the tests when histamine’s interactions with H1 and H2 receptors were 
blocked and in a placebo condition. It was hypothesized that blocking histamine’s 
interactions with H1 and H2 receptors would decrease the time-to-completion of a 
fixed-distance time-trial in comparison to a placebo and the effect would be 
greater following an endurance exercise bout. 
 
2. Chapter V: The purpose of this study was to compare leg blood flow during 
exercise at set increments of exercise intensity before and after a prolonged 
exercise bout, in addition to examining histamine’s influence on blood flow by 
antagonizing histamine H1 and H2 receptors. It was hypothesized that 1) in a 
placebo condition skeletal muscle blood flow would increase with increasing 
exercise intensities, 2) in the placebo condition the rise in skeletal muscle blood 
flow would be greater following a prolonged exercise bout, and 3) blocking 
histamine’s actions on H1 and H2 receptors would attenuate the rise in skeletal 
muscle blood flow with increasing exercise intensities and the attenuation would 
be larger following a prolonged exercise bout.  
 
3. Chapter VI: The purpose of this study was to examine the effect of blocking 
histamine’s actions on H1 and H2 receptors on the inflammatory response 
following exercise-induced muscle damage. It was hypothesized that 1) exercise-
induced muscle damage would elevate pro-inflammation chemokine, cytokine, 
and immune cell concentrations within the blood, and 2) blocking histamine’s 
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actions on H1 and H2 receptors would attenuate the rise in pro-inflammatory 
chemokine, cytokine, and immune cell concentrations within the blood.  
 
SIGNIFICANCE 
 The beneficial effects of exercise are well known but the mechanisms by which 
exercise improves health and prevents disease is largely unknown. Specifically, the 
molecular profiles in cells and tissues in response to exercise, the “Exercise 
Responsome”, remains understudied (205).  For example, approximately 50% of 
protection afforded by exercise to cardiometabolic health remains unexplained (144). The 
studies in this dissertation provide novel insight that histamine may be a contributing 
factor in the “Exercise Responsome” acting as an autocrine and/or paracrine molecular 
transducer of exercise within the skeletal muscle. Specifically, histamine’s involvement 
in endurance exercise capacity, exercise blood flow, and exercise-associated 
inflammation. 
The findings of these studies broadly address important issues identified by The 
National Institutes of Health (NIH) on the interaction of physical activity, inflammation, 
and immune function (205). These studies also address the issue of pharmacotherapy, in 
the interaction between commonly used medications (“antihistamines”) and the exercise-
induced immune response (205). Given the widespread use of common antihistamine 
medications, these studies provide insight into potential interactions between common 
drugs and exercise. These results are of interest to individuals new to exercise, those who 
regularly exercise, as well as competitive athletes in relation to exercise capacity and 
recovery from exercise. 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
Part I: The Exercise Responsome 
The “Exercise Responsome” refers to the molecular profiles within cells and 
tissues in response to physical exercise (205). Understanding these molecular profiles is 
important as very little is known about autocrine, paracrine, and endocrine factors 
operating to facilitate cross talk within and between tissues as part of the exercise 
response (256). Exercise is known to be beneficial to health by reducing morbidity and 
delaying mortality, but the mechanisms contributing to these positive outcomes is largely 
unknown. For example, the sum of all known cardiometabolic health related factors can 
only approximate 50% of the protection afforded by exercise (144). The cellular and 
tissue cross talk likely initiate changes aiding exercise and the healthy adaptions that are 
associated with exercise.    
Skeletal muscle appears to be an integral component of exercise responsome. 
Skeletal muscle, once classified as only the contractile tissue needed for movement, 
functions similar to an “endocrine organ” by producing and releasing molecules that 
influence the functions of other bodily tissues both during and after exercise (43, 185, 
232). For example, the myokine interleukin-6 is produced within the muscle during 
contractions and once it is released into circulation causes an increase in glucogenesis 
within the liver and lipolysis of adipose tissue (185, 232). The circulating glucose and 
fatty acids are in turn metabolized by skeletal muscle for energy during exercise (43, 
232). Therefore, skeletal muscle may mediate some of the beneficial systemic health 
effects, including cardiovascular adaptions, from exercise (185). 
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Along these lines, histamine which is commonly associated with immune and 
inflammatory responses is produced and released within the skeletal muscle during 
endurance exercise (255) but it’s role in contributing to the exercise response is largely 
unknown. Histamine, in immune and inflammatory responses, acts directly and indirectly 
to increase blood flow, increase tissue permeability, attract immune cells (chemotaxis), 
and in the alteration of local cytokine expression. Therefore, skeletal muscle histamine 
production and release during exercise may participate in the cellular cross talk and 
contribute to one or more pathways to facilitate exercise and improve health.  
Evidence that histamine is innately involved in the exercise responsome comes 
from studies investigating the origin and causes of post-exercise hypotension. These 
studies showed that histamine formed within skeletal muscle during exercise activated 
histamine H1 and H2 receptors on the vascular endothelium and smooth muscle, 
respectively, to induce an arterial vasodilation. The vasodilation increased local blood 
flow and reduced systemic mean arterial pressure which lasted multiple hours (187, 188, 
255). The increased blood flow and post-exercise hypotension could be attenuated by 
blocking histamine H1 and H2 receptors (187, 188). Not only did blocking histamine 
interaction with H1 and H2 receptors reduce post-exercise blood flow and hypotension but 
also reduced the expression of skeletal muscle protein-coding genes related to 
inflammation, endothelial and vascular function, metabolism, and cell maintenance (254). 
Furthermore, the blockade of histamine H1 and H2 receptors during muscle damaging 
exercise reduced long-lasting perceptions of muscle soreness and pain (78) which may be 
related to down regulation of two neurotrophic factors (nerve growth factor, glial derived 
neurotrophic factor) within the muscle that are associated with regulation, growth, and 
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survival of neurons (78, 254). Evidently, histamine appears to be a major molecular 
transducer of exercise but the exact, or likely multiple, functions of histamine during 
exercise are only beginning to be understood.   
The following chapter provides a brief overview of the scientific study of 
histamine starting with its identification, formation, and degradation. Thereafter, the 
chapter’s specific focus is on the biological processes and mechanisms of histamine 
within human and animal physiology. The studies presented in this dissertation attempt to 
build upon the pathways presented in the review of literature (Chapter II) to determine if 
histamine production and release is an integral pathway during exercise (Chapter IV), if 
histamine facilitates an increased skeletal muscle blood flow during exercise (Chapter V), 
and/or if histamine is associated with the inflammatory response resulting from muscle 
damaging exercise (Chapter VI).  
 
Part II: Histamine 
Historical Perspective 
In 1910-11 Dale and Laidlaw characterized the effects of a systemically infused 
extract from fungus, β-aminoethylimidazole, on the human vasculature. They 
documented that β-aminoethylimidazole increased vascular permeability, increased limb 
volume, and decreased arterial pressure (56, 57). In 1927 β-aminoethylimidazole was 
identified within liver and lung samples of humans and was subsequently renamed to 
histamine, a derivative of the Greek word histos as it was determined to be a natural 
constituent of tissue (28). Since these early observations, histamine has been linked to 
variety of other physiological actions including the secretion of gastric fluid, cell growth, 
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cell differentiation, wound healing, and in some brain regions histamine is a 
neurotransmitter regulating circadian rhythms (stimulant) and memory formation (131, 
301, 311).  
Specifically, histamine is identified as a biogenic amine (aka nitrogenous 
compound, C5H9N3) with a molecular mass of 111 Dalton. (83, 136).  Histamine is 
present in single cell and multiple cell organisms that have not undergone radical 
evolution in the last 700 million to 1 billion years. In these organisms histamine has 
multiple functions including promoting phagocytosis, cell growth, glucose metabolism, 
and is involved with chemotaxis (52). These findings indicate that the functions of 
histamine in the single cell and multicellular organisms are similar to those in humans 
(172). 
 
Histamine Formation  
Histamine is formed by the actions of a single enzyme, histidine decarboxylase 
(HDC). This enzyme removes carbon dioxide (decarboxylation) from the amino acid 
histidine (Figure 1). Histidine is present in all animal and plant protein, contains an α-
amine group (-NH3
+), a carboxylic acid group (-COO-), an imidazole side chain 
(C3N2H4), and has a positive charge at a physiological pH. HDC is specific in that it only 
converts the L configuration of histamine (L-histidine) and not the D configuration (D-
histidine)(L=left versus right orientation of the amine group on the carbon chain of the 
amino acid)(267, 268).  
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Figure 1. Histamine formation from L-histidine via the histidine decarboxylase (HDC) 
enzyme. 
 
Histidine decarboxylase has been identified in all organ tissue examined including 
the kidney, heart, lungs, intestines, brain, uterus, stomach, endothelial cells, and skeletal 
muscle (72, 125, 270, 272, 273, 312).  Within the skeletal muscle, as evidenced by HDC 
staining of mouse muscle, HDC is concentrated within mast cells, endothelial cells that 
line the circulatory system, and skeletal muscle monocytes (270, 312).  In resting skeletal 
muscle, HDC activity is very low as it continually synthesizes minute quantities of 
histamine (82, 320). Exercise increases the mRNA transcription (138, 254, 328), protein 
abundance (13), and activity of the skeletal muscle HDC (13, 81, 82, 320). The HDC 
activity extends several hours beyond the cessation of exercise with the length of the 
prolonged activity positively correlated to the duration of exercise (14, 212).  
The increased presence and activity of HDC within the muscle may be due to 
changes in temperature, pH, oxygen content, shear stress on endothelial cells, or the 
production of enzymatic modulators formed during exercise.  For example, a rise in 
temperature leads to an immediate increase in HDC histamine synthesis with an optimal 
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operation temperature near 56˚C (268), a temperature conscious humans are unlikely to 
attain. But a temperature change within a physiological range of human muscle 
temperatures (~37 to 42˚C) elevates HDC histamine production approximately two fold 
(267, 268, 271). Similarly, exercise can decrease the pH of skeletal muscle from 
approximately 7.0 at rest to 6.5 at maximal exercise intensities (119). HDC activity is 
increased with a decreasing pH and functions optimally between a pH of 6.6 to 7.0 
(Michaelis-Menton constant of HDC is 0.19mM at a pH of 6.8) (267, 268). Heavy 
exercise results in a cellular hypoxic stress which activates hypoxia inducible factor 
(HIF1) which is another factor that increases HDC activity (138). During exercise there is 
an increased and prolonged shear stress on endothelial cells from elevated blood flows 
which increases HDC activity (61, 124, 125). Additionally, another positive allosteric 
modulator of HDC that increases within skeletal muscle during exercise is interleukin-1 
(IL-1)(13, 81, 82, 320). Interestingly, exercise training may diminish the elevated activity 
of HDC (82) as it was shown “gnawing training” in mice reduced HDC activity 
compared to “non-trained” mice (12). The reduction of HDC activity with training may 
be due to intramuscular adaptations that may buffer reductions in pH and hypoxic stress 
at similar absolute work rates pre- to post-training (12).  
Other positive allosteric modulators of HDC activity, not necessarily associated 
with exercise, include glucocorticoids, intracellular cAMP, calcium ions, protein kinase C 
(PKC), rapidly accelerated fibrosacoma (RAF-), granulocyte-marcophage colony 
stimulating factor (GM-CSF), interleukin -3, -12 and -18 (IL-3, IL-12, IL-18), and tumor 
necrosis factor alpha (TNFa) (206, 274).  
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Histamine Formation, Storage, and Release - Mast Cells 
Mast cells, first identified and described in 1877 by Paul Erlich (211), are derived 
from undifferentiated hematopoietic precursor cells (CD34+)(294) and mature within 
tissues (213). Mast cells form histamine via intracellular HDC that does not appear to be 
inducible, i.e. the enzyme activity does not increase with known positive allosteric 
influences (270, 272, 273). This histamine is stored within cytoplasmic granules with 
other vasoactive substances and inflammatory mediators including prostaglandins, 
leukotrienes, heparin, cytokines, tumor necrosis factor, and proteases (tryptase, chymase, 
carboxypeptidase A) (211, 315). 
Mast cell release of histamine, by way of degranulation, commonly occurs from 
antigen-immunoglobulin interaction during allergic reactions. Mast cell degranulation has 
also been shown to occur with non-immunologic stimuli associated with exercise such as 
mechanical disruption of the mast cell membrane, hypoxia, hyperosmolaility, 
superoxides, chemokines, increased temperature, and vibration (97, 190, 213, 279, 294). 
Other factors, that can lead to mast cell degranulation, not necessarily associated with 
exercise are substance P, bradykinin, and nerve growth factor (NGF) (141, 186).  
Mast cells are predominantly located in close proximity to afferent nerves, lymph 
vessels, and blood vessels in the microcirculation of skeletal muscle (211, 213, 328). Due 
to their location, mast cells have been described as part of the vascular control network 
responsible for maintaining microcirculatory homeostasis (213) as degranulation leads to 
smooth muscle relaxation and increased blood flow, increased capillary leak, and edema 
formation (279, 315).  The histamine release in combination with chemokines and 
cytokines initiate an inflammatory response through leukocyte adhesion to endothelial 
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cells and extravasation from the circulation into the tissue along chemokine gradients 
(279). Mast cells also control key elements of wound healing designed to limit damage, 
initiate revascularization of the damaged tissue, increase epithelization, aid in the 
deposition of temporary connective tissue, and remodeling of the extracellular matrix 
(213). 
 
Histamine Breakdown, Inactivation, and Reabsorption 
 
Histamine, within tissues or in circulation, has a half-life of approximately 100 s 
(130). Histamine is either broken down by diamine oxidase (DAO), inactivated by 
histamine-N-methyltransferase (HNMT), or absorbed into mast cells and basophiles (22). 
DAO is present in high concentrations in the vascular endothelium, blood, white blood 
cells, liver, and the kidney. DAO degrades histamine by removing the amino group and 
forming imidazole acetaldehyde. HNMT is highly concentrated in the liver and 
monocytes where it adds a methyl group (methylenation) to histamine creating N-
methlylimidazole acetic acid (22, 204). HNMT has a higher affinity for histamine 
(Michaelis-Menton constant 6-12 umol) than DAO (Michaelis-Menton Constant 20 
umol/L)(175). The optimal activity of DAO occurs at a pH of 7.2 while HNMT functions 
best from a pH of 7.5 to 9.0 (175).  Histamine is also reabsorbed into mast cells and 
basophils by transport through two membranes (plasma and vesicular) via a bidirectional 
organic cation transporter 3 and vesicular monoamine transporter 2 (as reviewed by 
Ohtsu 2010 (221)). 
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Histamine Receptors 
Histamine acts through four different G-protein coupled receptors: 
H1: H1 receptors are mainly found on the smooth muscle of intestines, bronchi, 
and blood vessels as well as on the endothelium lining blood vessels. H1 receptors 
are G-protein coupled receptors (Gq) with 7 transmembrane domains containing 
amino terminal glycosylation sites which stimulate the formation of inositol-
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) resulting in increased 
intracellular calcium (203). The H1 receptor is known to be involved with 
inflammatory responses, vascular smooth muscle relaxation by stimulating nitric 
oxide (NO) production in endothelial cells (221), and sensory nerve stimulation 
(167).  
 
H2: H2 receptors are found in high concentrations on the gastric mucosa, uterus, 
brain, and vascular smooth muscle. This G-protein coupled receptor (Gs) 
increases intracellular concentrations of cAMP and decreases intracellular 
calcium concentrations (203, 221).  
 
H3: H3 receptors are found in high concentrations in brain and spinal cord on pre-
synapic nerve terminals. The H3 receptor is an autocrine regulator of histamine 
synthesis and release (as well as other neurotransmitters) from histaminergic 
neurons (206, 221). The H3 receptor is a G-protein coupled receptor (Gi) which 
inhibits the adenylate cyclase pathway (203). The H3 receptor is likely involved 
with the central nervous system regulation of circadian rhythms and spontaneous 
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ambulatory activity (261). Histamine H3 receptor antagonists are currently used 
for narcolepsy treatment (206).  
 
H4: H4 receptors are found mainly on peripheral blood mononuclear cells, 
neutrophils, eosinophils, mast cells, and CD4+ T lymphocytes and centrally on 
dendritic cells (206, 220, 274). Little is known about the H4 receptor due to its 
recent discovery in the early 2000s (220) but it may play a role in the chemotaxis 
of mast cells (123) and eosinophils (167) in addition to the expression of adhesion 
molecules on eosinophils (167). The H4 receptor is a G-protein coupled receptor 
(Gi/o) that leads to an increase of intracellular calcium (203, 221).  
 
Note: The studies in this dissertation used histamine H1 and H2 receptor antagonists in an 
effort to target the histamine H1 and H2 receptors which are present in high 
concentrations on the luminal side of endothelial cells near endothelial junctions and the 
vascular smooth muscle of blood vessels within the skeletal muscle, respectively (118). 
However, it is acknowledged that the systemic blockade of these receptors may have 
effects on other organs and tissues during rest and exercise.  
 
Exercise-Induced Elevation of Histamine within Skeletal Muscle 
Skeletal muscle interstitial histamine concentrations are approximately 12 ng/ml 
at rest (255). Histamine concentrations increase with 60 minutes of moderate intensity 
aerobic knee-extension exercise to ~30 ng/ml and remain elevated (~20 ng/ml) for at least 
60 minutes post-exercise while in a rested state (255). The rise of intramuscular histamine 
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concentrations are specific to the exercised skeletal muscle as concentrations in non-
exercised muscle do not rise above resting levels (255). Due to current technology 
limitations, adequate sample volumes for histamine quantification in intramuscular fluid 
by microdilaysis can only be obtained once every ~30 minutes. Therefore, the rate of rise 
of intramuscular histamine concentration after the initiation of exercise are relatively 
unknown. It is possible that histamine concentrations are elevated within minutes of 
exercise onset.   
The increased histamine concentrations are a result of mast cell degranulation and 
de novo production by the HDC enzyme (98, 212, 255). Evidence that the elevated 
skeletal muscle histamine concentrations were from mast cells were made by 
simultaneous detection of tryptase, a proteolytic enzyme co-released with histamine from  
mast cell granules within muscle dialysate (255). The remaining rise in intramuscular 
histamine is likely from increased activity of HDC, as the infusion of α -
flouromethylhistidine hydrochloride (αFMH), an inhibitor of HDC activity, reduced rise 
of interstitial histamine concentrations by approximately 60% (255). 
The exercise signal causing histamine release and production is unknown but as 
noted above, exercise associated increases in muscle temperature, hypoxia, shear stress, 
cytokine release, decreases in pH etc. (61, 110, 124, 125) are all associated with 
degranulation of mast cells and increased HDC activity.  Only one known study has 
attempted to identify the factor within muscle that may be the primary stimulus for the 
increase histamine concentrations (253). In this study, Romero et al. systemically infused 
high doses of N-acetylcysteine, a potent anti-oxidant, to reduce exercise-associated 
oxidative stress. This method did not blunt histaminergic post-exercise vasodilation (253) 
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indicating that oxidative stress is not a major contributor leading to elevated skeletal 
muscle histamine concentrations.  
 
Blood Histamine Concentrations 
Resting plasma histamine concentrations in humans is approximately 0.20 ng/ml 
(73, 130, 251, 255). The source producing this baseline concentration is unknown, but is 
likely continuously produced or released as its breakdown is rapid and occurs on the 
endothelial lining of all blood vessels. Whether blood histamine concentrations rise 
during or after exercise is unknown as some investigations have noted either no change 
(15, 113, 168, 187, 188) or elevations (9, 40, 45, 67, 71, 92, 112, 113, 184, 246) in blood 
histamine concentrations (Table 1). 
The intensity, duration, and/or muscle mass exercised appear to be the difference 
between the studies that document an increase in blood histamine concentrations and 
those that do not. On average, studies that used whole-body high-intensity and/or long-
duration aerobic exercise sessions document elevations in venous plasma histamine 
concentrations in the 4-6 ng/ml range. Studies that do not detect a change in blood 
histamine concentrations exercised single muscle groups and/or employed light to 
moderate exercise intensities (Table 1). For skeletal muscle histamine to contribute to a 
rise in venous blood histamine concentrations, the rate of histamine release or production 
within the skeletal muscle must exceed its removal and breakdown. Additionally, the 
skeletal muscle histamine must diffuse or be transported out of the muscle. It is possible 
that a large amount of muscle mass in combination with high-intensity or long duration 
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exercise increased production of histamine beyond the rate of degradation and removal to 
result in a rise in circulating histamine concentrations.  
Whether exercise induced elevations within skeletal muscle histamine contribute 
to an increased blood histamine concentration is unknown, but a few studies indicate it is 
a possibility. In humans, skeletal muscle interstitial histamine concentrations increase to 
~30 ng/ml during 60 min of moderate-intensity exercise (60% peak power)(255). This 
rise of intramuscular histamine is approximately 30X greater than venous blood 
concentrations providing the concentration gradient necessary for simple diffusion from 
the skeletal muscle to the circulation. Next, in isolated canine skeletal muscle, the arterial 
blood supplying the muscle and the venous blood leaving the muscle contain similar 
histamine concentrations during resting conditions but when the muscle was electrical 
stimulated to contract the venous histamine concentrations increased 3-4 fold while 
arterial concentrations did not change (9). Similarly in humans, restriction of arterial 
blood flow to exercising limbs elevated venous histamine concentrations (9, 10). 
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Table 1. Change in blood histamine concentrations with exercise. 
      
Author Year 
Exercise Histamine Concentration 
Type Intensity Duration Blood/Serum/Plasma Baseline Exercise Change 
McCord et al. 
 
2006a Cycle 
 
60% VO2 
 
60 min 
 
Whole Blood 4.6 ± 0.6 ng/ml 4.9 ± 0.5 ng/ml ↔ 
 
Plasma 0.4 ± 0.1 ng/ml 0.2 ± 0.1 ng/ml ↔ 
 
  Cycle 
 
60% VO2 60 min 
 
Whole Blood 2.9 ± 0.7 ng/ml 
 
3.5 ± 0.9 ng/ml 
 
↔ 
 
Plasma 0.3 ± 0.2 ng/ml 
 
0.5 ± 0.2 ng/ml 
 
↔ 
 
McCord et al. 
 
2006b Cycle 
 
60% VO2 
 
60 min 
 
Whole Blood 4.6 ± 0.6 ng/ml 
 
5.5 ± 0.7 ng/ml 
 
↔ 
 
Plasma 0.4 ± 0.1 ng/ml 
 
0.4 ± 0.2 ng/ml 
 
↔ 
 
Morgan et al. 
 
1983 Treadmill 
 
Unknown-
Moderate 
 
6 min 
 
Plasma 0.22 ± 0.09 
ng/ml 
 
0.33 ± 0.16 ng/ml 
 
↔ 
 
Barnes et al. 
 
1981 Treadmill 
 
Unknown-
Moderate 
 
6 min 
 
Plasma ~0.38 ± 
0.07ng/ml 
 
1.6 ± 0.2 ng/ml 
 
↔ 
 
0.38 ± 0.07 
ng/ml 
 
~0.53 ± 0.02 ng/ml 
 
↔ 
 
Hartley et al. 1981 Cycle 150 bpm 
HR 
8 min Plasma 0.67 ± 0.11 
ng/ml 
1.0 ± 0.11 ng/ml ↑↔ 
 
Garden et al. 1966 Treadmill + 
Heat Stress 
 
3.5 mph 120 min Plasma 5.5 ± 0.5 ng/ml 6.6 ± 1.1 ng/ml ↑ 
Matthews et al. 1970 Stair Running Unknown - 
Hard 
12 min Plasma 4 ± 1 ng/ml 6 ± 1 ng/ml ↑ 
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Table 1. Continued: Change in blood histamine concentrations with exercise. 
 
Author Year Type Intensity Duration Blood/Serum/Plasma Baseline Exercise Change 
Doh et al. 
 
2016 Cycle 
 
60% VO2 
 
12 min 
 
Plasma 
 
1.83 ± 0.14 
ng/ml 
 
2.33 ± 0.23 ng/ml 
 
↑ 
 
Campos et al. 
 
1999 Treadmill 
 
Up to Max ~9 min Whole Blood ~23 ± 1 ng/ml 
(?) 
 
~35 ± 2 ng/ml (?) 
 
↑ 
 
Harries et al. 
 
1979 Outdoor 
Running 
Max 6 min 
 
Plasma  Δ 1.1 ± 1.56 ng/ml 
 
↑ 
 
Whole Blood Δ 31.25 ± 10.4 
ng/ml 
 
↑ 
 
Anrep et al. 
 
1944 Forearm 
Contractions 
Max 
 
2 min Plasma ~12 ng/ml ~70 ng/ml ↑ 
Duner et al. 
 
1958 Cycle 
 
Max 18-24 min Whole Blood ~4.2 ± 0.7 ng/ml ~6.7 ± 0.7 ng/ml ↑ 
Serum ~1.6 ± 0.3 ng/ml 
 
~2.9 ± 0.7 ng/ml 
 
↑ 
 
Anselme et al. 1994 Cycle Up to Max 12 min Plasma 1.2 ± 0.17 nM 4.66 ± 1.03 nM ↑ 
Plasma 1.3 ± 0.23 nM 5.98 ± 0.86 nM ↑ 
 
Charles et al. 
 
1979 Cycle 
 
Moderate 
(HR>140 
bpm) 
8 min Plasma  
~0.73 ng/ml 
 
 
~1.04 ng/ml 
 
 
↑ 
 
Prefaut et al. 
 
1997 
 
Cycle 
 
Max Test 
 
~10 min 
 
Plasma 1.2 ± 0.16 ng/ml 6.02 ± 1.03 ng/ml ↑ 
    
~ = Units were converted, * = Values were estimated from figures, ↑ = Increase, ↓ = Decrease, ↔ = No Change 
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If blood histamine concentrations rise with exercise, the physiological effect of 
this histamine is unknown. It is worth noting that infusion of histamine in the 4-6 ng/ml 
range into circulation of canines results in arteriolar vasodilation of resting muscle 
arteries (9).  A similar infusion of 4-6 ng/ml of histamine in humans would result in a 
decreased diastolic blood pressure, increased heart rate, and increased skin temperature 
(130, 175) (Table 2). For reference, Table 2 provides a description of systemic 
physiological effects with increased plasma histamine concentrations. The approximate 
range of plasma histamine concentrations during light and heavy exercise have been 
added for comparison based off the changes in plasma histamine concentrations during 
exercise (Table 1),  
 
Table 2. Clinical effects according to plasma histamine concentrations  
Histamine (ng/ml) Clinical Effect 
0-1 normal resting 
1-2 increased gastric acid secretion, increased heart rate 
3-5 tachycardia, headache, flush, urticarial, pruritus 
6-8 decreased arterial pressure 
7-12 bronchospasm 
~100 cardiac arrest 
~0.3 - 0.5 light exercise (<60% max) 
~2 - 6 heavy exercise (>60% max) 
Table Modified from Maintz 2007 (175) 
 
 
Histamine and Exercise Capacity/Performance 
 It is clear that histamine is released and produced within exercising skeletal 
muscle but its role in the exercise response it unknown. Previous findings in murine 
species suggest that histamine performs an important role in facilitating endurance 
exercise. In murine species, administration of H1 receptor antagonists decreased gnawing 
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activity (328) in addition to walking speed and duration in a forced multi-hour walking 
task (212). A similar but non-significant reduction in endurance walking duration was 
documented with the administration of H2 receptor antagonists in mice (212, 328). 
Additionally, mice bred to be deficient in HDC (HDC knockout models) or given aFMH 
(an HDC inhibitor) also displayed reduced gnawing activity (328).  The reduced 
endurance is likely associated with H1 and H2 receptors as blocking histamine’s actions 
on the H3 and H4 receptors had no effect on endurance walking (212)(Table 3). 
In contrast to the murine studies, only short-duration high-intensity measures of 
performance have been made while blocking histamine H1 and H2 receptors in humans. 
In humans H1 receptor antagonists had no effect on of skeletal muscle strength, 
endurance (194), VO2 obtained in a cycling peak test, or the total distance covered during 
30 min of high intensity intervals (195) (Table 3). These results suggest that histamine’s 
role in exercise may differ between the murine and human species or that histamine has 
an important function that is exercise intensity and/or duration dependent. This theory is 
examined in Chapter IV.  
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Table 3. The Effect of Histamine Receptor Antagonists on Exercise Performance tests.  
 
Author Year H1 Antagonist H2 Antagonist Species Exercise Type Exercise 
Duration 
Exercise 
Intensity 
Outcome 
Farzin et al. 
 
2002 
 
Diphenhydramine 
(40 mg/kg) 
 
 Mouse 
 
Prolonged 
Walking 
Rota Rod 
 
40 min 
 
light/moderate 
 
↓ 
 
   Ranitidine (100 µg) 
 
Mouse Prolonged 
Walking 
Rota Rod 
 
40 min 
 
light/moderate 
 
↓ 
 
Niijima-Yaoita 
et al. 
 
2012 
 
Fexofenadine      
(20 mg/kg) 
 
 Mouse Prolonged 
Walking 
Rota Rod 
 
up to 5 hrs 
 
light/moderate 
 
↓ 
 
  Fexofenadine      
(40 mg/kg) 
 
 Mouse Prolonged 
Walking 
Rota Rod 
 
up to 5 hrs 
 
light/moderate 
 
↓↓ 
 
 
  Pyrilamine             
(6 mg/kg) 
 
 Mouse Prolonged 
Walking 
Rota Rod 
 
up to 5 hrs 
 
light/moderate 
 
↓ 
 
  Pyrilamine           
(24 mg/kg) 
 
 Mouse Prolonged 
Walking 
Rota Rod 
 
up to 5 hrs 
 
light/moderate 
 
↓↓ 
 
Yoneda et al. 
 
2013 
 
Fexofenadine      
(40 mg/kg) 
 
 Mouse Prolonged 
Gnawing 
 
up to 4 hrs 
 
light/moderate 
 
↓↓ 
 
  Pyrilamine          
(25 mg/kg) 
 
 Mouse Prolonged 
Gnawing 
 
up to 4 hrs 
 
light/moderate 
 
↓↔ 
   Ranitidine   (15 
mg/kg) 
 
Mouse Prolonged 
Gnawing 
 
up to 4 hrs 
 
light/moderate 
 
↔ 
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Table. 3 Continued: The effect of Histamine Receptor Antagonists on Exercise Performance tests. 
Author Year H1 Antagonist H2 Antagonist Species Exercise Type Exercise 
Duration 
Exercise 
Intensity 
Outcome 
Ely et al. 2018 Fexofenadine 
(540 mg) 
Ranitidine (300 
mg) 
Human Isometric 
Contractions 
5 sec Max ↔ 
Saltissi et al. 
 
1981 
 
 Cimetidine (400 
mg) 
 
Human 
 
VO2 max 
(Treadmill) 
~12 min 
 
Max 
 
↔ 
Montgomery 
et al. 
 
1991 
 
Diphenhydramine 
(50 mg) 
 
 Human 
 
Isokinetic 
Strength 
 
<1 min 
 
Max 
 
↔ 
 
  Diphenhydramine 
(50 mg) 
 
 Human 
 
Velocity 
Spectrum test 
 
<1 min 
 
Max 
 
↔ 
 
         
  Diphenhydramine 
(50 mg) 
 
 Human 
 
Muscle 
endurance test 
 
45 sec 
 
Max 
 
↔ 
 
   Terfenadine (60 
mg) 
 
Human 
 
Isokinetic 
Strength 
 
<1 min 
 
Max 
 
↔ 
 
   Terfenadine (60 
mg) 
 
Human 
 
Isokinetic 
Strength 
 
<1 min 
 
Max 
 
↔ 
 
   Terfenadine (60 
mg) 
 
Human 
 
Velocity 
Spectrum test 
 
45 sec 
 
Max 
 
↔ 
 
Montgomery 
et al. 
 
1992 
 
Diphenhydramine 
(50 mg) 
 
 Human 
 
Treadmill 
VO2max 
~12 min 
 
Max ↔ 
 
  Diphenhydramine 
(50 mg) 
 
 Human 
 
Treadmill Steady 
State (55% 
VO2max) 
30 min 
 
Moderate ↔ 
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Table. 3 Continued: The effect of Histamine Receptor Antagonists on Exercise Performance tests. 
         
Author Year H1 Antagonist H2 Antagonist Species Exercise Type Exercise 
Duration 
Exercise 
Intensity 
Outcome 
         
Montgomery 
et al. 
 
1992 
 
Diphenhydramine 
(50 mg) 
 
 Human 
 
High intensity 
intervals (30 sec 
on/off) to fatigue 
 
~30 min Max ↔ 
 
         
   Terfenadine (60 
mg) 
 
Human 
 
Treadmill 
VO2max) 
~12 min 
 
Max ↔ 
 
   Terfenadine (60 
mg) 
 
Human 
 
Treadmill Steady 
State (55% 
VO2max) 
30 min 
 
Moderate ↔ 
 
   Terfenadine (60 
mg) 
 
Human 
 
High intensity 
intervals (30 sec 
on/off) to fatigue 
 
~30 min Max ↔ 
 
↓ = Decrease, ↓↓ = Large Decrease, ↔ = No Change 
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 Part III: Histamine Actions 
 
The following sections start by proposing questions concerning histamine’s 
potential function within skeletal muscle during exercise. The focus is on skeletal  muscle 
because tissue responses to histamine are location and concentration dependent (252). 
The questions are followed by scientific findings on histamine’s function during health 
and disease within different body systems and organs. Specific attention is given to 
histamine’s function in humans while at rest and when possible during exercise. These 
sections are meant to provide a road map for the investigation of histaminergic signaling 
during exercise.   
 
Does Histamine Contribute to Elevated Skeletal Muscle Blood Flow During Exercise?   
It is possible that histamine mediates the increase in skeletal muscle blood flow 
during exercise (exercise hyperemia).  There are multiple lines of research indicating 
vasodilatory properties of histamine ranging from direct injection/infusion, to reactive 
hyperemia responses, sustained post-exercise vasodilation and post-exercise hypotension, 
increased skin blood flow, and the dilation of capillaries. In each of these situations 
application or infusion of H1 and/or H2 histamine receptor antagonists blunt the normal 
hyperemia responses. A summary of each topic is presented below.  
 
Histamine Infusion 
Multiple studies have demonstrated that injection or infusion of 
histamine into the arterial blood (not venous) decreased arteriole 
resistance (74, 104, 252, 273, 316, 321) and increased limb blood flow in a 
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dose response manner (49, 59, 69, 70, 74, 80, 104, 266). This histamine 
induced increase in limb blood flow could be attenuated with the pre-
infusion or co-infusion of histamine H1 and/or H2 receptor antagonists (49, 
58, 70, 115, 266, 321). One study concluded that the initial rise in blood 
flow involved activation of H1 receptors while H2 receptors were 
mediating an extended rise in blood flow once histamine infusion was 
halted (49).  
The dilation of resistance vessels may be an indirect effect of a 
histamine induced increase in nitric oxide and/or a direct action on 
vascular smooth muscle. The arterial intraluminal histamine likely has a 
direct interaction with endothelial cell expressed H1 receptors. The 
endothelial H1 receptors increase nitric oxide synthase (NOS) activity 
leading to production of nitric oxide. The nitric oxide diffuses to the 
surrounding smooth muscle to cause a relaxation of vascular smooth 
muscle and a decrease in resistance to blood flow (164, 252). The 
histaminergic increase in nitric oxide synthase activity occurs in a dose 
and time dependent manner (164). The histamine-nitric oxide pathway 
may be active during exercise as 1) blockade of nitric oxide production 
reduces histamine induced dilation of arteries (252), and 2) mice treated 
with an H1 receptor antagonist display reduced intramuscular production 
of nitric oxide (specifically nitric oxide metabolites) following endurance 
exercise (212). Histamine may also diffuse out of circulation and directly 
interact with H2 receptors on the vascular smooth muscle to induce a 
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relaxed state. Both pathways may be active as “antihistamines”, regardless 
of structure, when applied topically to microcirculation preparations 
constrict smooth muscle cells (273). 
 
Reactive Hyperemia 
Reactive hyperemia refers to the transient elevation in limb blood 
flow following a period of occlusion. Early examinations of venous blood 
exiting the previously occluded limb found elevated plasma histamine 
concentrations (10). It was speculated by Lewis (1927) that the elevated 
histamine concentrations were related to the subsequent vasodilation and 
increased blood flow upon ischemic release (As reviewed by Duner 1960 
and Duff 1964 (70, 72)). This speculation may have been proven true as it 
was later demonstrated that infusion of H1 “antihistamine substances” into 
the occluded limb blunted the normal reactive hyperemic response (69). 
  
Sustained Post-Exercise Vasodilation  
Similar to reactive hyperemia, there is an increase in skeletal 
muscle blood flow following exercise upon returning to a rested state. The 
increased blood flow is due to a drop in vascular resistance below pre-
exercise levels (108, 277). This post-exercise increase in blood flow 
remains elevated for an extended length of time dependent on the type, 
duration, and intensity of exercise (108, 197). The hyperemia can be 
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divided into two phases, an initial short-term phase and a longer phase 
(162).   
The initial phase of elevated blood flow is seconds to minutes in 
duration and involves factors that likely contribute to exercise hyperemia. 
The short-phase factors include increased body temperature, nitric oxide, 
prostanoids, adenosine, oxygen deficits, mechanical compression, and 
release of sympathetically mediated vasoconstriction (108, 162). 
The second phase of increased blood flow has been termed 
sustained post-exercise vasodilation (SPEV) and can last several hours 
into recovery (109). There is a neural (~30%) and vascular (~70%) 
component to SPEV. Neurally, there is a resetting of the barroreflex, a 
reduced sympathetic influence mediated by an internalization of 
neurokinin-1 receptors in the nucleus tractus solitarii (46), and a reduced 
capacity of the smooth muscle to contract to sympathetic stimulation (108, 
109). The vascular component involves a dilation (decreased peripheral 
vascular resistance) that is mediated by activation of histamine H1 and H2 
receptors (187, 188). SPEV is consistently observed following moderate 
intensity (50-60% VO2 peak) and prolonged duration (≥30 minutes) 
exercise. The vascular component can be isolated with small muscle mass 
exercise where neural adjustments do not occur (109).   
The SPEV is 80% blunted with H1 and H2 receptor antagonism 
(187, 188, 197).  Both H1 and H2 receptors appear to independently 
contribute to the SPEV as blockade of just H1 receptors diminishes the 
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first 30 min of SPEV while blockade of the H2 receptors diminishes SPEV 
from 30-90 minutes post-exercise (187, 188). The differential modulation 
of SPEV initially by H1 and a prolonged dilation by H2 receptors is similar 
to earlier observations of decreased vascular resistance and increased limb 
blood flow responses to co-infusion of histamine with H1 or H2 histamine 
receptor antagonists (49). Chipman et al. noted that histamine infusion 
increased limb blood rapidly and the dilation extended beyond the infusion 
cessation. The initial rapid increase in blood flow could be attenuated with 
H1 antagonists and the prolonged dilation could be blunted with H2 
antagonists(49). SPEV is also blunted by infusion of high doses of vitamin 
C which has the ability to directly breakdown histamine (253), and by 
infusion of α-FMH to inhibit histidine decarboxylase activity (255).  
The dilator actions of histamine through infusion and in SPEV not 
only decreases resistance to flow but can also, secondarily, reduce 
systemic blood pressure. Blood pressure, which is a function of blood flow 
and the resistance to flow (Arterial Pressure = Cardiac Output X Total 
Peripheral Resistance) is reduced by SPEV. This reduction in systemic 
pressure from SPEV is termed post-exercise hypotension (72). 
 
Post-Exercise Hypotension 
Post-exercise hypotension (PEH) is primarily driven by reductions 
in vascular resistance (increase vascular conductance) in the previously 
active muscle (277). The hypotension following whole body exercise is 
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primarily the result of a skeletal muscle histamine mediated dilation of 
resistance arterioles (109, 162). In normotensive individuals, hypotension 
of 5-10 mmHg occurs after 30-60 min of moderate intensity exercise (50-
60% VO2peak) and lasts up to 2 hours. In hypertensive individuals, 
hypotension can be up to 20 mmHg and extend beyond 12 hours (108). 
 
Skin Blood Flow 
Human skin blood vessels contain H1 and H2 receptors (99, 100). 
Blocking histamine receptors at rest has no discernable effect on blood 
flow (323, 325). Infusion of either histamine or H1 and H2 receptor 
agonists result in an almost immediate increase in cutaneous vascular 
conductance (99, 100, 102, 143). The rise in cutaneous vascular 
conductance is blunted with either H1 or H2 receptor antagonists (100, 
143, 323). Physiologically, damage to the skin results in a degranulation of 
histamine from mast cells leading to an increase in blood flow to the 
surrounding area (99). Heat stress may also increase histamine 
concentrations in the skin as H1 or H2 receptor antagonists blunt skin 
blood flow during local (102) and whole body heating (326).  
 
Capillary Dilation and Permeability 
Capillary permeability refers to the ease of blood plasma and 
proteins to cross from the circulation through the capillary walls into the 
surrounding tissue. Capillary permeability increases through an increase in 
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hydrostatic pressure secondary to an increase in microcirculatory blood 
flow (decreased vascular resistance) and/or by an increase in the size of 
fenestrations (gaps) between the endothelial and pericyte cells lining the 
capillaries. Regulation of the microcirculatory blood flow and 
permeability of the capillaries is important as this area supplies oxygen 
and nutrients to cells and removes metabolic byproducts.  
Following endurance exercise, the permeability of the capillaries is 
increased for multiple hours in only in the active limbs (114). How 
endurance exercise increases permeability is unknown, but it is possible 
that exercise-associated elevations in histamine concentrations will 
increase both microcirculatory blood flow and the size of intercellular 
gaps contributing to the increase in capillary permeability. 
Histamine is presumed to be the major controller of blood flow to 
microcirculation as minute quantities of histamine are formed at rest 
provide a continuous dilator influence (270–273). During exercise, an 
increased production of histamine may control the vascular permeability 
by increasing blood flow, as there is an inverse relationship between 
peripheral resistance and permeability measures (capillary filtration 
constants) (154). 
Exercise-induced elevations in histamine may also increase 
permeability by widening intracellular gaps. Studies have shown that 
histamine infusion into muscle (cremaster, abdominal) widens intercellular 
gaps between endothelial and pericyte cells (0.1-0.8 to 7-8 micra)(176). 
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The majority of plasma and protein extravasation occurs on the post 
capillary venules where histamine receptors are highly expressed and large 
gaps form (42, 118, 177, 240, 300). The infused histamine causes a 
transient contraction of the endothelial and pericyte cells in a way that  
they gain a globular shape and form projections into the lumen of the 
vessels (178, 191) and produces a partial detachment between endothelial 
and pericyte cells by phosphorylation of adherin proteins (VE-cadherin) 
(177, 240).  
During exercise the increased mechanical shear stress upon 
endothelial cells may result in an elevated endothelial HDC activity and 
histamine production (61, 124, 125). The endothelial histamine may act as 
the coupling signal between elevated shear stress and increased capillary 
permeability (124).  
 
 Lymph flow 
Histamine infusion increases lymph production and flow (105, 
300). The increased lymph production may not be a direct action of 
histamine and may be due to the increased capillary transmural pressure 
and filtration of plasma fluids and proteins.  
 
If histamine is contributing to a skeletal muscle arterial dilation during exercise, it 
may also influence the maintenance and regulation of systemic blood pressures and 
cardiac function. Direct infusion of histamine into isolated animal limbs results in a 
35 
decrease of diastolic pressure (59, 148) along with an elevation of heart rate (59). In 
humans, direct infusion of histamine lowers vascular resistance,  as well as  systolic, 
diastolic, and mean arterial pressures while elevating heart rate (317). The decreased 
arterial pressure with histamine infusion can be attenuated with H1 and H2 receptor 
antagonism (148).  Outside of the reduced blood pressure from infusion of supra-
physiologic doses of histamine, a reduction in arterial pressure is caused by endogenously 
produced histamine after an endurance exercise (PEH), as noted above (109, 110, 172).  
Therefore, blocking histamine’s actions may have a blood pressure elevating 
effect during exercise by preventing the normally occurring histamine mediated dilation 
of skeletal muscle. Studies that examined systemic hemodynamic changes during 
exercise with histamine receptor blockade are presented in Table 4. There does not 
appear to be a clear consensus between the studies, as most show no changes 
hemodynamic variables and others showing varied increases. A well regulated blood 
pressure is not surprising as it is constantly monitored and adjusted through aortic and 
carotid baroreceptor neural pathways and the interaction of many systems and tissues  
(258, 259). These neural pathways reflexively control heart rate, myocyte contractility, 
and peripheral resistance through autonomic control and the influence of a singular 
dilator in skeletal muscle likely has little influence on systemic regulation. 
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Table 4. The effect of histamine receptor antagonists on cardiac and blood pressure measures during exercise. 
  Antagonist Cardiac /Blood Pressure Variable Exercise 
Author Year H1 H2 HR SV SBP DBP MAP TPR CO Type Duration Intensity 
Peterlin et al. 
 
1998 
 
Chlorphiramine 
Maleate (4 mg) 
 
 ↔ 
 
 ↔ 
 
↔ 
 
↔ 
 
↔ 
 
↔ 
 
Cycle 
 
20 min 50% 
VO2 
 
Lockwood et 
al. 
 
2005 
 
Fexofenadine 
(540mg) 
 
 ↔ 
 
   ↔ 
 
  Cycle 
 
60 min 60% 
VO2 
 
Warburton et 
al. 
 
1979 
 
 Cimetidine 
(200mg) 
 
↓↔ 
 
 ↓↔ 
 
 ↓↔ 
 
  Treadmill 
 
10 min Sub-
Max 
Hughes et al. 
 
1989 
 
 Cimetidine 
(300 mg) 
 
↓↔ 
 
 ↔ ↔ 
 
↔ 
 
  Treadmill 
 
~12 min 25, 50, 
75, 
100% 
VO2 
 
Ranitidine 
(150 mg) 
 
↓↔ 
 
 ↔ ↔ 
 
↔ 
 
   ~12 min 25, 50, 
75, 
100% 
VO2 
 
McCord et al. 
 
2006 
 
 Ranitidine 
(300 mg) 
 
↔ 
 
   ↔ 
 
  Cycle 
 
60 min 
 
60% 
VO2 
Saltissi et al. 
 
1981 
 
 Cimetidine 
(400 mg) 
 
↔ 
 
 ↔     Treadmill 
 
~11min 100% 
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Table 4. Continued: The effect of histamine receptor antagonists on cardiac and blood pressure variables during exercise. 
  Antagonist Cardiac /Blood Pressure Variable Exercise 
Author Year H1 H2 HR SV SBP DBP MAP TPR CO Type Duration Intensity 
Doh et al. 
 
2016 
 
 Ranitidine 
(300 mg) 
 
↔ 
 
↔ 
 
↑ 
 
↔ 
 
↑ 
 
↑ 
 
 Cycle 
 
12 min 60% 
VO2 
McCord et al. 
 
2006 
 
Fexofenadine 
(540mg) 
 
Ranitidine 
(300 mg) 
 
↔ 
 
   ↔ 
 
  Cycle 
 
60 min 
 
60% 
VO2 
Emhoff et al. 
 
2011 
 
Fexofenadine 
(540mg) 
 
Ranitidine 
(300 mg) 
 
↓ 
 
   ↑ 
 
  Cycle 
 
60 min 
 
60% 
VO2 
Pellinger et al. 
 
2013 
 
Fexofenadine 
(540mg) 
 
Ranitidine 
(300 mg) 
 
↔ 
 
   ↔ 
 
  Cycle 
 
60 min 
 
60% 
VO2 
Romero et al 
 
2015 
 
Fexofenadine 
(540mg) 
 
Ranitidine 
(300 mg) 
 
↔ 
 
   ↔ 
 
  DKE 60 min 
 
60% 
peak 
power 
↑ = Increased, ↓ = Decreased, ↔  = No Change, HR = Heart Rate, SV = Stroke Volume, SBP = Systolic Blood Pressure, 
DBP = Diastolic Blood Pressure, MAP = Mean Arterial Pressure, TPR = Total Peripheral Resistance, CO = Cardiac 
Output, DKE = Dynamic Kicking Exercise 
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Does Histamine Contribute to Skeletal Muscle Glucose Delivery and Uptake During 
Exercise?  
Histamine H1 receptor blockade in mice reduced endurance walking duration 
which was associated with a significantly lower muscle glycogen content compared to 
control mice (212). It is plausible that blocking the histamine mediated dilator actions in 
the arteries and capillaries during exercise reduced blood flow and therefore glucose 
delivery. The reduced glucose delivery from circulation into the interstitial fluid 
surrounding contracting myocytes would place a greater reliance upon intracellular 
glycogen for energy. Alternatively, histamine may have blunted glucose uptake into the 
myocytes. In either scenario, there would be a greater reliance on intracellular glycogen 
as delivery/uptake of extra-myocellular glucose would be limited. The increased reliance 
on intracellular glycogen would decrease the time to fatigue onset as intramuscular 
glycogen levels diminished.  
There is evidence that glucose delivery and insulin sensitivity are reduced 
following exercise. Following 60 min of endurance exercise blood flow is reduced to the 
previously exercised muscle with histamine H1 and H2 receptor antagonists and this in 
turn reduced interstitial glucose concentrations in the vastus lateralis muscles (79, 234).  
In humans, glucose uptake during exercise is not dependent upon insulin but it is worth 
noting that histamine may activate a currently unknown pathway to increase glucose 
uptake within the skeletal muscle myocytes. As evidence 1) histamine application causes 
an increase in glucose uptake in single cell organisms (156) and 2) histamine application 
to human cardiac endothelial cells in vitro increases glucose uptake that is attenuated 
with H2 receptor antagonism (306). 
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In the previously exercised human, histamine H1 and H2 receptor antagonism 
blunted insulin sensitivity by ~25% during a glucose tolerance test (233). The reduced 
sensitivity to insulin following exercise may be specific to H1 and H2 receptors as mice 
selectively bred without H3 receptors display reduced insulin sensitivity at all times 
(301).  
 
 
Is Histamine Involved in an Exercise-Induced Inflammatory/Immune Response?  
  
Inflammatory or immune responses are initiated to protect tissue and maintain 
function following injury (279). These responses are initiated within the injured tissue 
and are comprised of complex and coordinated reactions involving multiple cell types, 
molecules, and signals (107, 279). The progression of the responses are similar regardless 
of the affected tissue or cause of injury (e.g. bacteria, virus, chemical, heat, or trauma), 
but the intensity of the reaction is proportional to the severity of the injury (279). The 
acute phase of the inflammatory/immune response is characterized by changes in the 
microvasculature, including the vasodilation of blood vessels, increased permeability, 
clotting or leaking of proteins through the capillaries, and migration of leukocytes into 
the tissue (240). 
 The first leukocyte responders to the tissue injury are resident macrophages. Next, 
circulating leukocytes increase in number (leukocytosis) and are recruited to the damaged 
tissue through margination, diapedesis, and chemotaxis. Approximately an hour after the 
injury, circulating neutrophils traverse into the tissue. In the following hours to days 
blood monocytes follow the same route and mature into macrophages under the influence 
of chemical signals from T-helper cells (107, 279). The neutrophils and macrophages 
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protect the tissue by removing invading organisms or damaged tissue and initiate the 
formation of new healthy tissue. Histamine potently influences the initiation and 
modulation of the these inflammatory and immune responses by regulating leukocyte 
recruitment, leukocyte maturation, and cytokine expression (22, 146, 224). 
 
Leukocyte recruitment; margination, diapedesis, and chemotaxis 
In order for leukocytes to pass from the circulation to the area of injury, 
openings need to form in between the cells lining the blood vessels. The widening 
of the gaps between these endothelial and pericyte cells is referred to as 
margination. The gaps widen due to conformational changes in the internal 
cellular structure to form projections into the lumen of the vessels and partial 
detachments with surrounding cells (178, 191). 
Local histamine production may have a significant role in the margination 
process. The endothelial and pericyte cells on the venule side of the capillaries 
contain high concentrations of histamine receptors (42, 118, 177, 240, 300). When 
these receptors are stimulated by histamine, the intercellular gaps increase in size 
(176). The widened gaps are necessary for leukocyte diapedesis into the tissue.  
The leukocytes are traveling with the blood and need a way to attach to the 
blood vessel lining in order to pass through the newly formed intercellular gaps. 
Normally, leukocytes are prevented from attaching to endothelial cells due to a 
lack of binding sites (receptors) and the expression of heparin on the cell surface. 
During inflammation, endothelial cells in close proximity to the injury have 
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increased expression of adhesion molecules (i.e. selectins, ICAM, VCAM) that 
attach to leukocytes, specifically neutrophils and macrophages (203, 240, 291). 
The presence of histamine may also have a significant role in the process 
of leukocyte adhesion. In vivo experiments involving histamine infusion into the 
capillaries have shown an increase in the number of leukocytes attached to the 
endothelium (74). In fact, histamine may increase the expression of adhesion 
molecules on endothelial cells as in vitro models indicate histamine increases the 
intracellular molecule, NF-kB, that is associated with the translocation of 
adhesion molecules (ICAM) to from the cytoplasm to the cell membrane (169, 
203). Additionally, leukocytes exposed to histamine in vitro increase CD11/CD18 
integrins, transmembrane receptors involved with cell adhesion (169). The 
histamine induced expression of ICAM is reduced with H1 receptor antagonists 
(166, 203). 
Once the leukocytes have entered the intercellular space, they move along 
a chemical gradient toward the site of injury. Here, histamine may again play an 
important role. Histamine appears to be chemotactic to neutrophils (22, 24).  
Histamine can also initiate other cells (T-cells) to produce leukocyte 
chemoattractants (e.g. IL-5) (22, 241). The expression of interleukin 
chemoattractants has been attenuated with H1 receptor antagonism (319).  
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Monocyte maturation into macrophages; TH1 and TH2, response 
Monocytes, at the site of tissue injury mature into macrophages under the 
influence of chemical signals from T-helper cells (107) and nerve growth factor 
(186). The T-helper cells can be divided into subsets based on their cell surface 
receptors, production of cytokines, and function. The subsets play distinctive roles 
in the development, initiation, and regulation of the immune response (224).  The 
influence of the T-helper subsets are not predetermined but are influenced by 
signals that drive the cells toward either subset (147). Associated with a TH1 
response is an increased IL-2, INF-y, IL-4, IL5, IL-12, IL-13, and TNFB 
concentrations (206). The TH2 response is associated with elevated IL-4, IL-5, IL-
6, IL-9, IL-10 and IL-13 production (310). 
Similar to the Th1 and Th2 responses, mature macrophages are identified 
using similar nomenclature, M1 and M2 macrophages (201). Broadly categorized, 
the TH1/M1 response is pro-inflammatory and includes phagocytosis or removal 
of dead/dying cells or cellular debris. A greater TH1/M1 compared to TH2/M2 
response is associated with the start of an inflammatory response. A greater 
TH2/M2 compared to TH1/M1 response is considered anti-inflammatory, follows 
the upregulated TH1/M1 response, and is associated with tissue repair/wound 
healing (107, 201).  
Histamine can influence the subpopulation of cell concentrations (22, 83, 
224) and alter the TH1 and TH2 response (147). Specifically histamine, via the H2 
receptor on monocytes, inhibits the production Interleukin-12 (IL-12) and 
enhances Interleukin-10 (IL-10). These interleukins remove the stimulus for TH1 
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and increases the stimulus for TH2 (75, 221, 310).  There also appears to be H1 
receptors on monocyte to directly stimulate the TH2 response (206). In isolated 
murine TH2 cells treated with histamine there is an increase production of IL-13 
via activation of H1 and H2 receptors (76). This shift in TH1/TH2 balance is 
blocked via H1 and H2 receptor antagonists (203, 223). These responses may be 
reversed within the damaged tissue as the predominant expression of histamine H2 
receptors can shift to H1 when monocytes mature into macrophages (274, 302).  
 
Exercise associated leukocytosis 
Following exercise, there is an increase in the number of circulating white 
blood cells (leukocytosis) (39, 51, 210, 230, 280).  The origin of the additional 
circulating white blood cells are unknown but it is theorized that an increase in 
shear forces and blood pressure during exercise cause a flushing of “marginal 
pools” into the circulation, possibly from the spleen, bone marrow, liver and/or 
lungs (280).  In some reports, the rise in leukocyte count produced by vigorous 
aerobic exercise is followed by a decrease in cell count to levels below pre-
exercise (111, 208). This drop in white blood cell count had been interpreted as an 
immune suppression, but it is more likely that these cells were redistributed into 
tissues (39). For example; radio-isotope labeled white blood cells were infused 
into the circulation of individuals prior to performing 300 eccentric one-legged 
knee-extension contractions (173). In the initial hours after exercise , the labeled 
cells showed up in greater number in the exercise quadriceps than the non-
exercised quadriceps (173). 
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The pathway leading to skeletal muscle uptake of white blood cells could 
be due to concomitant increases in monocyte chemoattractant protein-1 (MCP-1) 
and selectin adhesion molecules (51). MCP, produced by endothelial as well as 
skeletal muscle myocytes during contraction, is involved with selective monocyte 
recruitment into tissues (51). Additionally, E-selectin, an inducible adhesion 
molecule that recruits endothelial progenitor cells to ischemic tissue, is also 
increased after strenuous exercise (160). If exercise associated increases in 
histamine influence margination, diapedesis, and chemotaxis of circulating white 
blood cells into the skeletal muscle, then blocking histamine’s actions may delay 
or prevent the fall in circulating white blood cells in the hours after exercise by 
impeding their entry into the previously active musculature.   
Studies indicate that the leukocytosis after exercise is not limited to one 
cell type as increases were noted in neutrophils, lymphocytes (CD19+), 
monocytes (CD14+ & CD16+), mononuclear, T-cells (CD3+), T-helper cells 
(CD4+), and cytotoxic t-cells (CD8+)(209, 232). All cells might not increase in 
the same proportion as there have been decreased overall percentages of 
lymphocytes and natural killer cells after 60 min of cycling at 65% of VO2peak 
(122). In addition, it was shown that type I monocyte percentages decreased while 
type II monocyte percentages increased. The change in the predominant cell types 
indicate a shift in toward the proangiogenic over the phagocytotic type monocytes 
(160). As the number of circulating leukocytes represent only 1-10% of the total 
cell population, small increases/decreases are of clinical significance (280).  
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Exercise associated changes in cytokines/myokines 
Immediately after acute intense exercise, there is an increase in a number 
of circulating cytokines such as IL-6, TNFa, CRP, IL-1B, MCP-1, IL-8, IL-1ra, 
and IL-10 (47, 85, 210, 232, 291). A number of these cytokines may originate 
from skeletal muscle myocytes or the surrounding tissue (232). The increase in 
these muscle-derived cytokines (myokines) are, at least in part, due to increases 
mRNA transcription (IL-6, IL-8, IL-15) (170). The cytokines that are upregulated 
have strong ties to metabolism, inflammation, tissue growth and development, 
and cell death (43).  
Exercise-associated increases in skeletal muscle histamine may be an 
initial trigger for short and long-term alterations in myokine expression. It was 
recently shown that blocking histamine H1 and H2 receptors during exercise 
reduced the expression of myokine genes associated with inflammation, 
endothelial and vascular function, metabolism, and cell maintenance (e.g. IL-6, 
TNFa, IL-10 and MCP-1) within the skeletal muscle (254).  This is important as 
very little is known about the cross talk between muscle and other organs that 
could underlie the effects of exercise on systemic health (185, 205). In the short 
term, increases in myokines (e.g. IL-6) appear to mediate substrate utilization and 
availability. Long term, the myokines may influence metabolic adaptions 
resulting from exercise training (232) and may be involved with mediating the 
health benefits of exercise including cardiovascular adaptions (185).  
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Wound healing/tissue damage  
Tissue damage activates an acute inflammatory response (291). At the site of the 
damage, there is a high concentration of histamine (177) likely liberated from resident 
mast cells (213) and increased histidine decarboxylase activity (214). This histamine 
appears to play a critical role in the healing response especially in areas of rapidly 
growing tissue (166, 214). For example, mice that are bred without histidine 
decarboxylase, and those treated with H1 receptor antagonists have extended skin wound 
healing times (221). Associated with the extended healing time was a reduced 
macrophage infiltration and formation of blood vessesls (angiogenises) at the wound 
edge (221). Conversely, mice treated with histamine, or the mast cell degranulator  
(48/80), at the site of damage have accelerated cutaneous wound healing times (54, 55, 
221).  The faster healing times were associated with increased collagen formation (54) 
and tensile strength of skin surface (55, 329). Therefore, exercise-associated increases in 
histamine concentrations may be involved with the repair process of skeletal muscle 
following strenuous exercise (231).  
 
Is Histamine a Consequence of Exercise Induced Muscle Damage and Regulator of 
Inflammation? 
 Unaccustomed, strenuous, and/or eccentric muscle contractions can result in 
injury to muscle and connective tissue (174, 219, 289, 290). The injury is characterized 
by myofibrillar disruption, loss of muscle strength, increased muscle soreness, (delayed 
onset muscle soreness; DOMS), and the presence myocellular enzymes and proteins 
(creatine kinase, myoglobin, lactate dehydrogenase) in the blood (37, 210, 290). This 
trauma activates an acute inflammatory response (37). As evidence, with increased 
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creatine kinase levels after muscle damaging exercise, there is an associated increase in 
neutrophils, monocytes, and cytokines in circulation (66, 202, 210). In addition, 
immediately after exercise, there is an  accumulation of neutrophils and macrophage in 
the exercised muscle (66, 231). Interestingly, in a model of exercise-induced muscle 
damaged, an isolated muscle undergoing rhythmic electrical stimulation displays 
evidence of mast cell degranulation and an elevated number of monocytes in areas with 
widened space between fibers (296). Although, many aspects of the regulation of muscle 
regeneration remain unclear and involve unknown molecules, the primary purpose of the 
inflammatory response is to repair damaged tissue and regenerate muscle (174, 231, 289, 
307–309).  
Therefore, exercise resulting in muscle damage can provide a model to study 
histamine’s potential association with exercise related inflammation. Uncovering 
histamine’s role in the recovery process resulting from muscle damage may provide 
information concerning the regulation of muscle degradation and repair (37). The few 
studies examining inflammation and muscle repair have demonstrated that blocking 
inflammatory signals (IL-10, COX blockers) have resulted in reduced leukocyte 
(neutrophils and macrophages) recruitment into the muscle, as well as, delayed recovery 
(30).   
 
Strength loss 
Loss of muscle strength is an indicator of exercise-induced muscle damage 
(231). Immediately after exercise, there is a reduction in maximal volitional force.  
The strength loss is not the greatest immediately after damaging exercise but 
peaks 24-48 hrs after exercise (78, 173). This indicates that structural damage is 
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not the only factor limiting force. Besides a reduction of muscular force due to 
disruption of sarcomeres and reduced actin and myosin overlap, force loss can be 
caused by a decreased excitation of the muscle sarcomere, decreased calcium 
release, or a reduced neural input into the contracting muscle. These contractile 
properties normally recover within the first ~24 h and voluntary force still 
remains depressed > 24 hrs following exercise (248). 
A portion of the prolonged decrease in muscle force  may be a neutrally 
mediated protective mechanism to limit further muscle damage through reduced 
motor unit  recruitment (78). The neural input, or descending drive, from the 
motor cortex is a major determinant of voluntary strength. Sensations of 
pain/discomfort, experienced following muscle damaging exercise, are known to 
inhibit the descending drive from the motor cortex (217).  Sensations of 
pain/discomfort are a result of increased activity of group III/IV afferent neurons 
(11, 30, 35, 45). The skeletal muscle group III/IV afferent fibers express 
histamine H1 and H2 receptors which, when activated, lower the threshold for 
stimulation. Therefore, a portion of the reduced muscle strength may be due to 
direct histaminergic activation of afferent fibers, along with the associated 
sensations of pain/discomfort (DOMS), inhibiting motor unit recruitment.  
 
Is Histamine Related to Delayed Onset Muscle Soreness and sensations of Pain? 
 
Delayed onset muscle soreness (DOMS) is the sensation of discomfort or 
pain associated with movement or palpitation of skeletal muscle. This pain 
normally peaks 24-48 hours after strenuous and/or unaccustomed exercise. The 
molecular and cellular responses that induce DOMS are largely unknown but 
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likely involve direct stimulation and/or alterations in group III/IV afferent nerve 
sensitivity (150, 217).  The group III/IV afferent fibers are polymodal, have small 
diameters, are lightly to non-myelinated, and appear as a triad with the capillary 
and mast cells within muscle tissue (269, 279). Both in vivo and in situ 
examinations of afferent fibers suggest that histamine may directly stimulate 
(primary hyperalgesia) and indirectly alter the sensitivity of these afferent fibers 
(secondary hyperalgesia) (279).  
The possible role of histamine as a mediator of pain was suggested by 
Rosenthal and Minard in 1939 (257). In their early experiments, it was noted that 
exogenous histamine induced sensations of cutaneous pain, which increased with 
histamine concentrations (257, 330).  Since these early experiments, histamine H1 
receptors have been identified on a subgroup type III/IV afferent fibers and a 
further subgroup exhibits increased expression of the H1 receptors during 
inflammation following injury (151, 269). Activation of the H1 receptor 
stimulates/lowers the firing threshold, increases pain sensation, and results in pain 
induced motor impairment in rodents (179). Conversely, administration of H1 
receptors antagonists resulted in anti-nociception with histamine infusion (179). 
Following exercise in which histamine H1 and H2 receptors were 
antagonized, there was a reduction in the expression nerve growth factor (NGF) 
and glial cell line-derived nerurotrphic factor (GDNF) (78, 254). These two 
factors are believed to play a central role as modulators of pain in secondary 
hyperalgesia (181, 237, 298, 318, 327), as well as aid in the maintenance and 
functioning of neural circuits (6, 254). NGF and GDNF are produced in inflamed 
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tissue and skeletal muscle after ischemia and nerve injury (231, 313) and are 
present within muscle 2-h to 2 days after exercise (140). These factors are taken 
up into the nerve terminals of afferent fibers and transported centrally (6, 163). 
Within these neurons there is an increase in H1 receptor expression 24-hrs after 
the initial injury (150), an increased expression of voltage gated sodium channels 
(NaV1.8) (25, 279, 305, 330, 331), and an increase in the synthesis and release of 
neurotransmitters (substance P and CGRP) from the afferent nerves in the central 
nervous system (137, 158, 260, 269). The time course of cellular changes to the 
afferent fibers are similar to the peak pain experienced from exercise-induced 
muscle damage. Additionally, experiments blocking NGF revealed a blunting of 
pain only when the blocking occurred before/during exercise, but not following 
exercise (202). 
These results suggest that histamine may exert a direct and indirect 
influence on skeletal muscle pain resulting from exercise. The increased afferent 
feedback can inhibit motor neuron output and may be involved with the 
reductions in strength, as they appear to follow similar time lines. Although, 
previous studies seem to suggest that strength loss is due to reduced voluntary 
activation not due to muscle soreness per se (244). However, the association of 
histamine, pain, and alterations of muscle strength following muscle damage has 
not been fully explored.  
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Antihistamines and Antihistamine Use  
In 1937, pyrilamine, the first antihistamine, was produced by Dr. Daniel Bovet 
(281). This drug was viewed as a major achievement in treating allergic diseases and for 
his work Dr. Bovet received the 1957 Nobel Prize in Medicine (189, 288). Since the 
production pyrilamine, countless other antihistamines have been developed (288). The 
newest forms of antihistamines became established in the early 1980s (265, 288) and they 
have high receptor specificity.   
Worldwide, these histamine-blocking agents are the largest selling drug group 
(75). In 1984, it was reported that 30 million Americans took an antihistamine at some 
point during the year. Endurance athletes use of anti-allergy medication is five times 
greater than the general population and they are two times more likely to use 
antihistamines than sprint/power athletes (1, 2). Antihistamine use in endurance athletes 
may be due to their higher incidence of allergies compared to other sub populations of 
athletes and the general public (2, 116, 117). Additionally, oral antihistamines are 
frequently used by marathon and ultramarathon runners to treat gastrointestinal reflux, 
ulcers, exercise induced anaphylaxis, GI bleeding, and stress ulcers (18, 196, 199). 
The widespread use of histamine blocking agents in the public and especially in 
endurance athletes suggest the need to further examine the role of histamine in the 
exercise response.  
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CHAPTER III 
 
EXPLAINATION OF THE METHODOLOGY 
 
The experimental protocols described in this dissertation were approved by the 
Institutional Review Board of the University of Oregon (Protocol# 05262016.047 and 
02022017.003) and the University of Utah (Protocol#000308100). Written and informed 
consent was obtained by all volunteer subjects following an explanation of experimental 
procedures for each individual study. The studies were run in accordance with the 
guidelines set by the Office of Human Subjects Compliance of the University of Oregon, 
University of Utah, and of the Declaration of Helsinki.  
 
General Experimental Approach 
The studies detailed in Chapters IV and VI were completed at the 
University of Oregon, in the Evonuk Environmental Physiology Core Laboratory 
and the Bowerman Sports Science Clinic. The study detailed in Chapter V was 
completed at the University of Utah, Veterans Administration Medical Center in 
the Geriatric Research, Education, and Clinical Center.  
All studies were conducted as randomized double-blind placebo-
controlled cross-over interventions.  Volunteer subjects completed the testing 
once under placebo conditions (Placebo) and again under histamine H1 and H2 
receptor antagonism (Blockade) conditions. This experimental approach is highly 
recommended for intervention based studies (193) to control for intrasubject 
variability and increase the likelihood of identifying physiological differences 
between the Placebo and Blockade interventions. Additionally, blinding the 
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investigators as well as the subjects to the drug treatment limited potential 
preconceived bias on study outcomes. In all studies, investigators were unblinded 
to the treatments upon completion of data analysis.  
In the study detailed in Chapter IV, the importance of the exercise-induced 
elevation in skeletal muscle histamine concentration to the endurance exercise 
response was evaluated, i.e. is histaminergic signaling an important pathway in 
facilitating endurance exercise in humans? Eleven competitive cyclists performed 
six 10-km time trials on separate days. The first two trials served as 
familiarization trials. The next two were performed after consuming either 
Placebo or Blockade and resting for 120 min prior to the trial. The final two trials 
were performed after consuming either Placebo or Blockade and cycling at a 
workload eliciting a VO2 of 50% of peak for 120 min prior to the trial. The main 
outcome variable was the time to completion of the 10-km time trials. Value 
added variables include heart rate, blood pressure, blood lactate and glucose, 
cardiac output, isometric muscle strength of the quadriceps, and rating of 
perceived exertion. The value added variables were collected during the 120 min 
of rest and exercise preceding the time trials. In addition, blood lactate and 
glucose, isometric muscle strength of the quadriceps, and rating of perceived 
exertion were measured prior to and following the time trials.    
Chapter V examined the potential relationship between the exercise-
induced increase in intramuscular histamine concentration to the elevation in 
skeletal muscle blood flow during exercise, i.e. is the exercise-induced elevation 
in skeletal muscle histamine acting as a vasodilator to contribute to exercise 
54 
hyperemia?  This study was completed in conjunction with the University of 
Utah.  In this study, sixteen volunteers performed dynamic single-leg knee 
extension exercise on two separate days. After receiving either the Placebo or 
Blockade, subjects performed exercise of increasing intensity from 20, 40, 60, and 
80% of peak power output.  This step-wise increase in exercise intensity was 
followed by a 60 min bout of single-leg knee-extension exercise at 60% of peak 
power output. Then subjects performed another step-wise increase in exercise 
intensity at the same 20, 40, 60, and 80% of peak power output. The main 
outcome variable was femoral blood flow, which was compared between each 
exercise intensity, before and after a 60 min sustained bout of exercise, during the 
60 min of sustained exercise, and between Placebo and Blockade conditions. 
Value added variables were VO2, intramuscular pH, intramuscular oxygen 
saturation, blood pressure, cardiac output, and rating of perceived exertion. The 
value added variables were collected during each step-wise increase in exercise 
intensity and during the 60 min of steady state knee-extension exercise.  
Chapter VI of this dissertation examined whether the exercise-induced 
elevation in skeletal muscle histamine concentration is related to the elevation in 
circulating leukocytes and cytokines following exercise, i.e. is the exercise-
induced elevation in skeletal muscle histamine concentration a signal to initiate a 
systemic inflammatory response? In this study, 12 volunteers completed two 
rounds of a 72 hr study observation period, one following Placebo the other after 
Blockade. Subjects initially completed a bout of muscle damaging exercise and 
were evaluated 6, 12, 24, 48, and 72 hrs after exercise to capture the time course 
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of inflammation, strength change, and muscle soreness. The main outcome 
variables of this study were the concentrations and types of circulating 
inflammatory cells and inflammatory signaling molecules. Value added variables 
included measures of muscle force and muscle soreness.  
 
Volunteer subjects 
A total of 39 subjects completed the three studies and no subject participated in 
more than one study. Subjects were deemed healthy following standard screening and 
were free of any medical condition with known associations or influence on blood 
pressure or blood flow (e.g. diabetes, anxiety/depression, atherosclerosis, chronic 
obstructive pulmonary disease)(44, 103, 165, 216). All subjects were asked to abstain 
from caffeine and alcohol consumption as well as strenuous exercise for 24 hrs before 
data collection due to their acute influence on blood pressure (132, 218, 322). No subjects 
were using over-the-counter medications at the time of the study, with the exception of 
oral contraceptives for females. In the study detained in Chapter V and Chapter VI, 
female subjects were studied in the early follicular phase of their menstrual cycle or 
during the placebo phase of their or oral contraceptive. Controlling for menstrual cycle 
phase in Chapter V and VI was done to reduce potential sex hormone influence on blood 
flow (Chapter V) and on muscle damage and inflammation (Chapter VI).  For Chapter 
IV, menstrual cycle phase was not controlled for in the female volunteers. All females 
had negative pregnancy tests prior to any data collection.  
 
 
56 
Specific Methods 
Subject Characterization 
In the studies included in this dissertation, a combination of demographic 
and anthropometric measures including age, height, weight, and body 
composition in addition to aerobic capacity, anaerobic power, and muscle strength 
were used to portray the subjects and generalize the study findings to the public. 
Subject weight was measured using a digital scale (Sartorius model MAPPIU-
150FE-L, Elk Grove IL, Chapter IV and VI) or balance scale (Health-o-Meter, 
Continental Scale Corp, Bridgeview IL, Chapter V) and height was measured 
using a stadiometer (SECA North America, Chino CA, Chapter IV, V, VI).  
 
Body Composition 
Assessment of body composition of the subjects represents a global 
characterization of health and fitness. Body composition was estimated using a 
two-component model of measuring fat mass and fat-free mass. Fat mass was 
estimated using the skin fold technique in which calipers of a set tension are used 
to obtain the thickness of subcutaneous fat. Thickness measures were made on the 
right side of the body at the triceps, suprailiac, and thigh sites for females and 
chest, abdominal, and thigh sites for males according to the American College of 
Sports Medicine guidelines (8). The sum of the three site thickness measurements 
in addition to the volunteer’s age and race were used in regression equations to 
calculate body density and the percentage of fat mass. The regression equations 
were initially developed by Jackson and Pollock (133, 135) to predict body 
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density in comparison to measures obtained from hydrostatic weighing. This 
method was only used describe subject characteristics within Chapter IV and VI. 
Body fat was not calculated with the skin fold technique in Chapter V, as it is not 
part of the University of Utah usual screening procedures. 
More accurate estimates of body composition can be made by expanding 
beyond the three-site to a seven-site model which includes the triceps, chest, 
midaxillary, subscapular, suprailiac, abdominal, and thigh site measurements 
(134). Other techniques to quantify body composition include calculations of 
body density through underwater weighing or air displacement plethysmography 
(BODPOD). Bioelectrical impedance is a non-density based measurement in 
which the resistance of an electrical current through the body is used to estimate 
fat mass (60, 239). One of the most accurate techniques to measure body 
composition is dual energy X-ray absorptiometry (DEXA). This technique uses an 
X-ray tube with a filter to generate low-energy (40kV) and high-energy (70-
100kV) photons. The photons are absorbed as they pass through the body and the 
resulting energy states of the rays are used to quantify tissue densities (239). The 
DEXA method is sensitive enough for an assessment of bone mineral content as 
well as fat mass and fate-free mass (three-compartment model). The added 
accuracy of techniques such as the BODPOD and DEXA would not likely alter 
the characterization of the subject pool. Therefore, the relatively simple three-site 
skin-fold estimate of body composition was the preferred method in the present 
studies as it was not a main outcome measure and only used to depict the subject 
population.  
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Anaerobic Power 
The amount of power (work per unit time) of the subjects legs were 
measured using a 10 s Modified Wingate on a cycle ergometer (Excalibur Sport 
V2; Lode BV, Groningen, The Netherlands). Subjects pedaled at a maximal rate 
(distance 6m per pedal revolution) against a fixed resistance (force equal to 0.70 
Nm; Wingate for Windows software version 1; Lode BV, Groningen, The 
Netherlands) to calculate work (force · distance).  The maximal work over a 1 s 
time interval was taken as the peak anaerobic power. This measure was performed 
in the study outlined in Chapter IV. Other tests of anaerobic power include the 
velocity spectrum test on a computer integrated load cell resistance machine (e.g. 
Biodex) and sprint running tests.  The cycle Wingate test was selected as it is the 
identical mode of exercise used in the time trials and due to the ease of calculating 
power.  
 
Aerobic Capacity 
Cardiopulmonary fitness was assessed by calculating the highest rate of 
oxygen transport from the environment to the working muscles during exercise 
(VO2peak). The normal oxygen consumption of humans at rest is approximately 
3.5 ml·kg-1·min-1 and can rise to 70-90 ml·kg-1·min-1 in elite endurance athletes at 
maximal work rates. Oxygen consumption of the skeletal muscles during exercise 
is a function of delivery (heart rate (HR) + stroke volume (SV)) and extraction 
(oxygen difference between arterial and venous blood (ΔAVO2)). Measurement of 
arterial and venous blood gas saturations at the skeletal muscle is an invasive 
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procedure involving catheters. A non-invasive substitute is to measure the fraction 
of inspired (FIO2) and expired (FEO2) oxygen, which approximates the amount 
transported into and used by muscle. 
Oxygen consumption was measured in the studies presented in Chapter IV 
and V.  The exercise used to obtain VO2peak was specific to each study, cycling in 
Chapter IV and single-leg knee extension in Chapter V. Both studies measured 
oxygen uptake via a mixing chamber system (Parvomedics, Sandy, UT) either as 
a standalone unit (Chapter V) or in combination with a mass spectrometer 
(Marquette MGA 1100, MA Tech Services, St. Louis, MO; Chapter IV).  
Measurement of maximal rate of oxygen consumption (VO2) during large 
muscle mass exercises (running, swimming) is considered the gold standard of 
integrated cardiopulmonary-muscle oxidative function (242). Tests of oxygen 
consumption that utilize small muscle mass exercises (arm crank, single-leg knee 
extension) do not represent the aerobic capacity of the whole body but are specific 
to muscle groups (exercises) and are referred to as peak measures (VO2peak). True 
max tests should be accompanied by high ratings of perceived exertion (19-20), 
heart rate (>95% of predicted), a respiratory exchange ratio greater than 1.0, 
plateau of VO2 measures with increasing workloads, and/or no rise in VO2 during 
a verification phase (110% of VO2peak work rate)(242). The oxygen consumption 
measurements can be made with open circuit techniques, which require 
knowledge of gas concentrations in the room air (inspired) and expired air, but 
can also be made with closed circuit measures where the subject breathes a 
predetermined volume of oxygen from a bag over a set time period. Additional, 
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yet less precise, tests to estimate oxygen consumption include the use of workload 
or the length of time to complete a task. The workloads or time variables are used 
as inputs into previously derived regression analyses to predict maximal oxygen 
consumption.  For example, tests may involve stair stepping (i.e. Harvard Step 
Test) or walking/running set distances (i.e. Rockport Walking Test, 1.5 mile Run 
Test).  The more precise measure of oxygen consumption using open circuit 
spirometry was chosen due to the ease of obtaining the measurement and the 
accuracy provided to determine workloads in the exercise interventions for 
Chapter IV and VI.  
 
Strength Testing 
The primary function of skeletal muscle is to generate force for movement 
or joint stabilization. Measurement of muscle force generation is also a measure 
of muscular fitness. Maximal voluntary isometric torque of the knee extensors 
was determined with a rehabilitation dynamometer (Biodex, System 3, Shirley, 
NY). Isometric knee extension at 30 degrees was selected for measurement of 
torque. An isometric muscle contraction was preferred over isokinetic/isotonic 
contractions in order isolate and gain an accurate measure of force while 
removing a velocity component present in isokinetic and isotonic contractions. 
Additionally, these studies were interested in the activation of the quadricep 
muscles and an isometric contraction allowed for comparison of forces produced 
voluntarily and with force changes resulting from evoked potentials. Torque 
testing was performed at 30 degrees of knee flexion because 1) the knee is in mid 
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extension, 2) it is at an angle where large torque forces are generated and near 
maximal recruitment (EMG) occurs, and 3) there is a large portion of actin and 
myosin myofibril overlap (106).  The Biodex system provides high temporal 
resolution and allows for repeat measures between multiple study days. Isometric 
strength testing using the dynamometer was performed in the study detailed in 
Chapter VI as this method.  
 
Drug intervention  
Histamine H1- and H2-Receptor Blockade  
To uncover histamine’s role in the exercise responsome, the studies in this 
dissertation used the second/third generation histamine H1 and H2 receptor 
antagonists, fexofenadine hydrochloride (NDC 41167-4122, C32H39NO4 ·HCL) 
and ranitidine hydrochloride (NDC 0173-0393-40, C13H22N4O3S· HCL) to disrupt 
histaminergic signaling in humans. Volunteers were given an oral dose of 540 mg 
of fexofenadine and 300 mg ranitidine 60 min prior to exercise. The quantity of 
fexofenadine and ranitidine are the manufacturer recommended upper limit of a 
single dose. Fexofenadine is a selective H1-receptor antagonist, which reaches 
peak plasma concentrations within 1 hr after consumption. This dosage of 
fexofenadine has a 12 hr half-life (263). Ranitidine is a selective H2-receptor 
antagonist which reaches peak plasma concentration within 2 hrs after 
consumption and has a 3 hr half-life (93). This dosage of histamine-receptor 
antagonists results in more than 90% inhibition of histamine H1 and H2 receptors 
lasting for 6 hours after administration (93). These two antagonists are not 
62 
thought to cross the blood brain barrier and affect central histaminergic signaling, 
unlike first generation antagonists (e.g. diphenhydramine aka Benadryl) which 
cross the blood brain barrier and cause a reduction in alertness (sedative 
effects)(263). Importantly, fexofenadine and ranitidine have not been shown to 
alter blood flow, heart rate, blood pressure, or smooth muscle tone at rest (78, 
187, 254). 
Histamine H3 and H4 receptors were not antagonized as there are limited 
medications available and these receptors are primarily found within the central 
nervous system (H4) or act as self-regulating inhibitors of histamine release (H3). 
The studies documented in this dissertation focused on how exercise-induced 
histamine affected the skeletal muscle and surrounding tissue during exercise. 
Skeletal muscle and the surrounding tissue are areas where there are a high 
concentration of H1 and H2 receptors (187, 188).  
The studies in this dissertation used medications that prevent the ligand, 
histamine, from interacting with its target receptor by physically covering the 
receptor and thereby disrupting histaminergic signaling but not altering the 
baseline cellular activity of the receptor. In contrast, another form of 
“antihistamine” is an inverse agonist, which is a molecule that binds to the target 
receptor and decreases cellular activity.  Other methods to disrupt histaminergic 
signaling would be to prevent histamine formation from HDC (e.g. a-
fluoromethylhistidine dihydrochloride (a-FMH)), bind histamine to prevent it 
from interacting with its receptors (histamine reverse antagonists), or prevent 
histamine from being released from mast cells (e.g. chromolyn). Conversely, to 
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study histaminergic signaling, the pathway could be stimulated by increasing 
histamine concentrations without exercise. Increasing histamine concentrations 
could occur through 1) direct injection, 2) increased release from mast cells 
(compound 48/80) or, 3) drugs could be given to mimic histamine (histamine 
receptor agonists). The use of systemic histamine injection or mimetic drugs is 
not a preferred method to study histamine signaling due to potentially life 
threatening reductions in blood pressure (similar to anaphylactic responses).   
 
Placebo 
 
A placebo intervention was used to test the normal physiological response 
in comparison a condition where histaminergic signaling on H1 and H2 receptors 
is blocked. The use of a placebo medication blinds both the subjects and 
researchers to the trial conditions. The placebo pills used in these studies were 
manufactured by a compounding pharmacy (Creative Compounds, Wilsonville, 
OR) or by the Pharmacy at the Veterans Administration Hospital (University of 
Utah, Salt Lake City, UT). The placebo pills contained the inert fillers of the 
fexofenadine and ranitidine tablets (silicone dioxide, croscarmellose sodium, 
hypromellose, iron oxide blends, magnesium stearate, microcrystalline cellulose, 
polyethylene glycol, povidone, pregelatinized starch, titanium dioxide, triacetin). 
These fillers are not known to have any cardiovascular effects.  
Placebo pills were used instead of no medication to reduce potential 
subject bias on subjective measures of pain/discomfort and effort as histamine has 
the potential to influence afferent neurons. Specifically, group III/IV afferent 
fibers possess both H1 and H2 receptors and when stimulated increase sensations 
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of discomfort/pain. Specific to Chapter VI, previous reports suggest that blocking 
histaminergic signaling reduces subjective assessment of muscle soreness 
associated with muscle damage (78).  In order to control for subject pre-conceived 
bias of subjective measurements, psychological studies sometimes employ five 
groups of subjects. The psychological studies group subjects to receive either 1) 
no medication, 2) a placebo and told they received a placebo, 3) a placebo and 
told they received the active medication, 4) an active ingredient and told it was a 
placebo, or 5) an active ingredient and told it was the active medication (See 
Kienle and Kiene 1997 for review (153)). Although, the validity of overly 
complex randomization schemes has been questioned as current literature reviews 
and metaanalysis suggest that the “placebo effect” may not be an important 
confounding factor for drug intervention studies (153). Regardless, a practical 
limitation of running a study involving multiple subject groups is the large 
number of subjects needed for biological studies comparing physiologic 
responses.   
The studies in this dissertation assessed the subjective measurements of 
discomfort/pain and exercise effort as value added variables; therefore, the 
addition of extra subject groups to test subjective measures may be useful for 
follow up studies if exercise effort or muscle soreness/pain are markedly different 
between Placebo and Blockade groups.    
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Exercise Interventions 
Performance Testing 
Performance testing is a common and important measure in sport science 
and physiology research (53). A good performance test has validity, reliability, 
and sensitivity. Validity, reliability, and sensitivity refer to the testing protocol 
simulating the real world performance, the variation from repeat testing, and the 
ability to detect small but important changes in test outcomes, respectively (53). 
Time trials and time to exhaustion tests are the two most common forms of 
performance tests. In time trials, subjects complete a set distance as fast as 
possible, During time to exhaustion tests, subjects exercise at a set intensity for as 
long as possible. Time trials are preferred over time to exhaustion tests as they 
have demonstrated low variability between repeat trials (120, 126, 127) and lower 
coefficients of variation when compared to time to exhaustion tests (53). 
Additionally, time trials have greater validity than time to exhaustion tests as they 
simulate and have a high correlation to real world performances (225). Therefore, 
time trials were the main performance test used in the study detailed in Chapter 
IV. 
A 10-km time-trial distance was selected as the duration of time to 
complete the task was approximately 15-20 min and was of sufficient duration to 
primarily challenge the aerobic system where muscle blood flow is an important 
performance determinant, but not so long as to introduce confounding influences 
on performance (i.e. dehydration, mental fatigue). Additionally, many cyclists 
have experience performing hard efforts of this duration providing “real world” or 
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ecological validity and these tests are commonly used in human 
performance/exercise physiology performance literature (127). The 10-km time-
trials were performed on a computer-integrated cycle ergometer (CompuTrainer, 
RacerMate Inc., Seattle, WA, USA) using the manufacturer’s ergometer computer 
program that provided a race simulation (Figure 2). All time-trials were 
performed adhering to the standards outlined by Currell (53). During the time-
trials there was: 1) no feedback on performance, 2) no distractions, 3) no 
encouragement, 4) no physiological measures (except for heart rate), 5) no 
performance cues, 6) temperature and humidity were controlled, and 7) subjects 
always used their own bike equipment.  Tests using these guidelines are highly 
reproducible (coefficient of variance = 1.1 ± 0.9 % ), and highly correlated with 
on-the-road competitions (r = 0.98)(225). 
 
 
Figure 2. An example set-up of the bike and time trial simulator used to test the 
association of histaminergic signaling in endurance exercise performance 
(Chapter IV).  
 
Single-leg dynamic knee-extension exercise  
 
This exercise set-up was designed at the Muscle Research Center in 
Copenhagen, Denmark (7). The single-leg knee-extension exercise effectively 
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isolates the quadricep muscle group and positions the subject in a semi-reclined 
position in which Doppler ultrasound can be used to assess femoral artery blood 
flow. In this set-up, the subject is seated in a chair with a boot connected to the 
crank arm of a cycle ergometer. Contraction of the quadriceps muscles extend the 
leg and rotates the ergometer crank-arm. The force of the muscle contraction is 
monitored by a force traducer connected to the flywheel (Figure 3). The 
momentum of the flywheel allows for passive extension of the quadriceps 
muscles following contraction. The single-leg knee-extension set-up was used as 
an exercise intervention due to the isolation of the quadricep muscle group, the 
relative ease to monitor blood flow to the exercising muscle, as well as 
comparison to the existing literature examining femoral artery blood flow (5, 16, 
17, 68).   This exercise intervention was used in the study detailed in Chapter V. 
 
Diagram adapted from Andersen 1985 (7) and Osada 2011 (222) 
 
Figure 3. Diagram of the single-leg knee extension exercise and the variables 
measured in examining the association histaminergic signaling with let blood flow 
(Chapter V). 
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Muscle damaging protocol 
 
An eccentric muscle contraction occurs when the muscle is attempting to 
contract but the opposing force is greater than the muscle force resulting in a 
lengthening of the muscle. This type of muscle contraction causes disruptions 
(damage) in the muscle (actin and myosin myofibril connection and Z-disc) and 
results in a phenomenon termed delayed-onset muscle soreness (DOMS). This 
type of exercise was performed in Chapter VI. 
Previous studies have shown that intramuscular histamine concentrations 
increase with endurance type exercise where the muscle rhythmically contracts.  
This study attempted to combine the rhythmic contractions of conventional 
endurance exercise with eccentric contractions. The combination of eccentric and 
endurance exercise will provide a model to simultaneously study histamines 
association with DOMS and immune function. The subjects in this study 
performed 300 eccentric contractions of the quadriceps on a resistance 
dynamometer (Biodex, System 3, Shirley, NY). The 300 knee-extensions were 
divided into 10 sets of 30 repetitions with a 60 s rest period in between each set. 
Subjects sat with their back supported, pelvis strapped into the seat, and the 
resistance pad was placed at 75% of the length of the shank. The knee joint 
moved through a 75°range from a joint angle of ~20° to 95° of knee flexion. The 
angular velocity was set to 60°·s-1 for set 1 and 110°·s-1 for set 2 through 10. The 
resistance force of the dynamometer was set at 140% of each subject’s maximal 
isometric force measured at a joint angle of 30° of flexion. This protocol is 
modeled after Newham et al.(207) in which a moderate level of muscle damage 
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arose from the 300 eccentric contractions. The whole protocol was completed in 
approximately 40 min. Preceding and following the eccentric contractions 
subjects completed 3 maximal voluntary contractions (MVCs) and 3 maximal 
voluntary contractions + evoked potentials. Between each effort, subjects 
remained seated at rest for 60 s. The length of time to complete the maximal 
contractions was approximately 10 min. Therefore, the total amount of exercise 
time was approximately 60 min, a time duration intended to match the endurance 
exercise tasks known to elicit a rise in intramuscular histamine concentrations 
(187, 188, 255). 
The eccentric contraction of single-leg knee extension approach using a 
calibrated dynamometer was preferred over other muscle damaging exercise 
protocols such as downhill running, calf lowering, and eccentric cycling. The use 
of single-leg knee extensions isolated a muscle group, allowed for repeated testing 
on the same individual (left vs right leg; Placebo vs Blockade), permitted a 
precise measure of total work, and was practical for repeat measures of muscle 
strength and soreness. Downhill running and eccentric cycling to induce lower 
body muscle damage are common protocols (38, 78, 230) but these methods are 
not optimal for cross-over study designs as there are reduced soreness and cellular 
responses upon future exercise, termed the repeated bout effect, which may last 
up to 9 weeks (38). 
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Hemodynamic Measures  
The term hemodynamic refers to the movement of blood within the human 
body. The movement of blood is primarily determined by the heart. The heart’s 
main purpose is to increase pressure within the arterial system (Blood Pressure) 
so that blood will flow from a place of high pressure (Arterial System) to a place 
of low pressure (Venous System). The amount of pressure the heart produces is a 
function of cardiac contraction (Heart Rate), the amount of blood pumped with 
each heart beat (Stroke Volume), and the resistance to blood flow (Total 
Peripheral Resistance/ Systemic Vascular Conductance).  
Histamine acts as a vasodilator during immune/inflammatory responses, 
during reactive hyperemia, during tumor formation and growth, during heat stress 
within the skin, and with post-exercise vasodilation (9, 187, 188, 226, 273, 325). 
If histamine may also acts as a vasodilator during exercise this could reduce total 
peripheral resistance and alter hemodynamic measures. Therefore cardiac output, 
heart rate, arterial pressure, stroke volume, total peripheral resistance and 
systemic vascular conductance were measured during steady state exercise in 
Chapter IV. Additionally, Chapter V measured blood flow within the femoral 
artery, heart rate, arterial pressure, total peripheral resistance, and systemic 
vascular conductance at multiple exercise intensities and during extended 
exercise.  
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Heart rate and Arterial pressure 
Heart rate was monitored using a three-lead electrocardiogram in the 
studies described in Chapter IV and Chapter V. Arterial pressure was measured 
on the left brachial artery using an automated auscultometric sphygmomanometer 
(Tango+, SunTech Medical, Raleigh, NC, USA) and in Chapter IV and using 
finger photoplethysmoraphy (Finometer, Finapres Medical Systems BV, 
Amsterdam, The Netherlands). The finapres provides an indirect assessment of 
brachial arterial pressure based on volume/pressure changes at the index/middle 
finger (finapres = finger arterial pressure) (129).  This method has been validated 
against intra-arterial pressure transducers within the brachial artery at rest and 
during Valsalva maneuvers in normotensive and hypertensive individuals (129).  
Beat-by-beat arterial pressure waveforms were used to calculate stroke volume 
and in conjunction with heart rate as inputs in the “modelflow method” then 
estimate cardiac output and provides a reliable value for the change in cardiac 
output with exercise (299). This method has a high correlation coefficients (0.91-
0.98) and low errors <2.0 L compared to echocardiography (299). Mean arterial 
pressure was calculated as diastolic pressure plus 1/3 pulse pressure (systolic 
pressure - diastolic pressure).   
 
Cardiac Output 
Cardiac Output is the absolute amount of blood pumped by the heart over 
time. Assuming minimal right to left heart shunting (absence of a patient foramen 
ovale and 2 to 3% of cardiac output from bronchial and thebesian circulations at 
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rest (107)) the total amount of blood pumped systemically also traverses through 
the pulmonary system.  Therefore, indirect estimates of cardiac output can be 
made with the measurements of inhaled and exhaled gasses. In the study in 
Chapter IV, cardiac output was estimated by using an open-circuit acetylene 
(C2H2) washin method in which subjects breathed a gas mixture containing 0.6% 
acetylene, 9.0% helium, 20.9% oxygen, and balanced nitrogen for 8 breaths via a 
two-way non-rebreathing valve attached to a pneumatic sliding valve. During the 
washin phase, breath-by-breath acetylene and helium uptake were measured by a 
respiratory mass spectrometer (Marquette MGA 1100, MA Tech Services, St. 
Louis, MO) and volume was measured via a pneumotach (model 3700, Hans 
Rudolph, Kansas City, MO) linearized and calibrated by using test gases before 
each testing day. Gas concentrations of inspired and expired helium and acetylene 
were measured with each breath. The difference between inhalation and 
exhalation concentrations of the gases is assumed to be the volume absorbed into 
the blood in the pulmonary circulation. This method is limited by the assumption 
of solubility of acetylene in the blood (solubility may change based on blood 
temperature (as summarized by 18) and that there is limited/no shunting of blood 
past pulmonary circulations. This method is based on the Fick principle in that the 
total uptake and release of any substance in an organ/tissue/system is the product 
of blood flow to the region and arterial to venous difference of the substance. 
Gases such as carbon dioxide (CO2) and nitrous oxide (N2O) have also been used 
for the washin breathing method. As cardiac output is a determinant of exercise 
performance, the accuracy of the acetylene wash-in method was required to detect 
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potentially subtle differences in cardiac output between the Placebo and Blockade 
conditions that might affect exercise capacity (Chapter IV). 
Cardiac output was also estimated non-invasively via finger 
photoplethysmoraphy (Finometer, Finapres Medical Systems BV, Amsterdam, 
The Netherlands) and recorded via a data acquisition device (Medwave Vasotrac 
APM250A; Biopac, Goleta, CA). This method estimates cardiac output based on 
the difference in systolic and diastolic blood pressures measured in the finger. The 
finapres system is not as accurate as the acetylene wash-in technique but provides 
a reasonable measure when assessing changes in cardiac output and can be 
integrated with ease into the single-leg knee extension exercise set-up (Chapter 
V). 
Alternatives for estimating cardiac output include 1) dilution methods that 
involve arterial injections of an indicator of known volume and concertation (dye 
or thermal) with the analysis of downstream concentrations to obtain a time 
dilution curves, 2) an echocardiogram to obtain the volume of the left ventricle in 
combination with heart rate, and 3) impedance cardiography which measures 
transthoracic impedance and changes in electrical conductivity due to blood flow 
in the chest.  
 
Femoral artery blood flow 
Femoral artery blood flow, Chapter V, was determined via duplex 
ultrasonography using a linear-array ultrasound transducer (Logiq e9, GE Medical 
Systems, Milwaukee, WI).  This method uses a probe, which produces sound 
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waves that bounce off tissues and the difference between outgoing vs incoming 
wave velocities to create a 2-dimensional image (Figure 4). The image allows for 
the measurement of artery diameter and the shift in sound waves (Doppler Shift) 
is used to calculate the velocity of blood flowing past the probe (Figure 4). The 
width of the common femoral artery was made 2-3 cm proximal to the bifurcation 
of the superficial and deep femoral artery branches of the leg when the subjects 
were seated in an upright position. Diameter measurements were made during 
diastole using digital calipers that are integrated into the ultrasound system 
software.  
 
Figure 4. Example of the ultrasound image of the common femoral artery and 
blood flow velocity produced by the Doppler shift. 
 
  Blood flow velocities were calculated from the forward and reverse 
Doppler frequency shifts using an intensity-weighted algorithm from the Doppler 
ultrasound that were then corrected for errors associated with the thin beam 
measurements specific to the ultrasound system (36). Femoral blood flow was 
75 
calculated as artery cross sectional area multiplied by the mean femoral blood 
velocity over a 60 sec duration and reported as milliliters per minute.   
Femoral blood flow was calculated as: 
𝐹𝑒𝑚𝑜𝑟𝑎𝑙 𝑏𝑙𝑜𝑜𝑑 𝑓𝑙𝑜𝑤 =  (
diameter
2
)
2
× 𝑚𝑒𝑎𝑛 𝑏𝑙𝑜𝑜𝑑 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 × 60, 
Where femoral blood flow is in ml·min-1, the mean blood velocity is in cm·s-1, the 
femoral diameter is in cm, and 60 was used to convert from ml·s-1 to ml·min-1. 
Peripheral resistance was calculated as the mean arterial pressure divided by 
femoral blood flow (expressed as mmHg·min·ml-1) and systemic vascular 
conductance as the reciprocal of resistance (expressed as ml·min-1·mmHg-1). 
Doppler ultrasound derived blood velocity measures of the common 
femoral artery are common in research. The femoral artery is easily accessible, 
has a large diameter reducing errors in estimating blood flow due to small 
deviations in diameter, and because the femoral artery is located outside the 
muscle and is not compressed during muscle contractions (249). The 
measurement of blood flow using Doppler ultrasound provides high temporal 
resolution, is non-invasive, is highly correlated with the thermodilution technique 
(r = 0.996), and has a low coefficient of variation between multiple measures 
(249). 
Local or limb blood flow can also be made using plethysmography, 
Plethysmography is a non-invasive estimate of limb blood flow based on the rate 
of limb volume/girth expansion with the occlusion of venous blood flow. 
Disadvantages of plethysmography is that there are no differentiations of limb 
blood flow to specific tissues (muscle, bone, skin etc.), the venous occlusion may 
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restrict arterial blood inflow, and measures can only be made at rest and not 
during muscle contractions (324).  
Indicator methods have also been used to estimate blood flow. These 
methods involve diffusing a set volume and concentration of an indicator, such as 
a dye (Evans Blue Dye, indocyanine green) or cold saline (~0°C) into the arterial 
blood leading to the tissue of interest and then analyzing the concentration of the 
dye or temperature of the blood exiting the tissue. This method assumes the tissue 
blood flow is proportional to the change in dye concentration or temperature 
relative to the infusion concentration or temperature. A drawbacks to this method 
includes the invasive catheterization of arteries and veins (259). A spectroscopy 
unit with duel-channel laser diodes (NIRS) in combination with indocyanine 
green can also estimate local blood flow without the use of catheters but the use 
of this technology is less reliable than direct sampling (33). 
 
Skeletal muscle pH and oxygenation index 
Skeletal muscle pH and oxygen saturation are related to the 
microcirculatory blood flow and nutrient/metabolite transfer between the tissue 
and circulating blood (292). Near-infrared spectroscopy, the act of measuring the 
absorption and reflectance of near infrared light (~ 700 nm to 1,000,000 nm) can 
be used to estimate tissue oxygenation and pH. This technique was developed in 
the 1930s by Millikan (as reviewed by 22). Tissue oxygenation is estimated based 
on the absorption properties of hemoglobin. Oxygenated and deoxygenated 
hemoglobin absorb light at 800 nm and deoxygenated hemoglobin absorbs light at 
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760 nm, the difference between the two can give an indication of the oxygenation 
state of the tissue (180). The infrared light penetrates approximately 2.5 cm deep 
and due to the relatively small thickness of the skin, skin blood flow has a 
minimal influence on light absorbance, therefore the NIRS absorption indicates 
the tissue oxygenation of the small blood vessels, capillaries, and intracellular 
fluid (180). Spectra in the 725-880 nm wavelength range are used for 
determination of pH (293) and a correlation of spectral shifts to changes in pH 
during exercise using this technique were validated against invasive intramuscular 
pH probes (293). Importantly, this method of evaluating skeletal muscle oxygen 
saturation and pH has been validated during exercise, tissue ischemia, and 
following pharmacologic alterations in blood flow (180, 292, 293). 
Specific to Chapter V, muscle pH and oxygen saturation were made with a 
near-infrared spectroscopy device (Reflectance Medical Inc. Oximeter 1100, 
Westborough, MA). This near-infrared spectrometer measured interstitial pH and  
oxygenation (SmO2) of the vastus lateralis muscle (293). The sensor was placed 
1/3 the distance between the greater trochanter and the knee joint and held in 
place by a special mounting pad that conformed to the shape of the thigh and 
prevented the sensor from moving on the skin during exercise. The sensor was 
further held in place with black self-adherent wrap (Coban, 3M, Maplewood MN) 
to minimize ambient luminosity.  
Reliance on NIRS as a primary outcome measure has been debated. Many 
investigators have relied on NIRS to provide an estimate of skeletal muscle 
oxygen saturation, but this method requires the light to penetrate the skin and 
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assumes a minimal skin blood flow. If skin blood flow is minimal, the NIRS may 
provide a reasonable estimate of skeletal muscle oxygen saturation but if skin 
blood flow is elevated, the extra red blood cells and hemoglobin passing under the 
sensor and will alter the NIRS measures. The elevation in skin blood flow that 
occurs with elevated body temperature during extended exercise bouts would 
artificially inflate values that are attributed to skeletal muscle. Additionally, 
myoglobin has similar infrared light absorption properties to hemoglobin and the 
saturation of myoglobin may have an impact on the accuracy of NIRS (180). 
Finally, increased blood temperature during exercise may also affect the 
absorption of infrared light due to increased kinetic energy of hemoglobin (292).  
As a result of these confounding variables influence on infrared light absorption, 
it has been recommended that NIRS be used an indicator of trends in muscle 
oxygenation and not as a precise measures of oxygen saturation.  
 
Blood Testing 
Blood is a fluid that is circulated around the body to transfer nutrients and 
metabolic byproducts from one tissue to another. Blood is primarily composed of 
water but also contains soluble gases, mineral ions, proteins, hormones, and cells. 
Analysis of blood can provide a systemic snapshot of the internal environment. 
Exercised-induced increases in skeletal muscle histamine may affect glucose 
delivery and/or lactate removal from skeletal muscle during exercise, which 
would then influence exercise duration and intensity. Therefore, in the study 
described in Chapter IV, blood was analyzed for glucose and lactate 
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concentrations. Histamine may also directly and indirectly influence the type and 
concentration of white blood cells and inflammatory chemokines within the 
blood. Therefore, in Chapter VI, the type and concentration of white blood cells 
and inflammatory chemokines were measured. Lastly, histamine may be linked to 
the quantity of muscle damage incurred during exercise; therefore, markers of 
muscle damage in circulation were quantified in Chapter VI.  
In the time trial studies detailed in Chapter IV, blood samples were 
obtained from the left and right earlobes with single use safety lancets (Unistik 3, 
Owen Mumford, Oxfordshire, UK). The blood was immediately analyzed for 
glucose (Precision Xtra, Abbot Diabetes Care, Alameda, CA) and lactate (Nova 
Biomedical, Waltham, MA). Samples of glucose and lactate were made in 
duplicate and values were averaged. Ear sticks were chosen due to the fast 
sampling time and convenience for the subject.  
During the delayed onset muscle soreness and inflammation study detailed 
in Chapter IV, a venipuncture method was used to collect blood from the veins in 
the antecubital space of the left and right arm. Blood was collected before, 
immediately after and 6, 12, 24, 48, and 72 hours after exercise using a Saftey-
Lok blood collection set (Becton, Dickinson and Company, Franklin Lakes NJ, 
USA). Blood was collected into three 3 mL vacutainers coated with K2EDTA 
(BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes NJ, USA). 
Blood was then aliquoted for separation and quantification (See Appendix A for 
step by step procedures) of white blood cell populations via flow cytometry 
(Gallios, Beckman Coulter Life Sciences, Indianapolis IN, USA) using the 
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manufactures data acquisition software (Kaluza, Beckman Coulter Life Sciences, 
Indianapolis IN, USA)(Figure 5). A separate aliquot was immediately centrifuged 
(Marathon 3200R, Fisher Scientific, Pittsburg PA) for 10 min at 1000 RCF and 
the plasma was extracted and frozen at -80°F until analysis.  
Plasma was analyzed for inflammatory cytokines via a bead based flow 
cytometry kit (Biolegend, LEGENDplex Human Inflammation Panel 1, multi-
analyte flow assay kit). This method of cytokine identification uses beads of 
varying size coated with antigens specific to cytokines of interest (IL-1B, INFα2, 
IFN-γ, TNFα, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-
33). The size and fluorescence of the beads allows for separation and 
quantification of the cytokine by flow cytometry (Gallios, Beckman Coulter Life 
Sciences, Indianapolis IN, USA). Plasma was also analyzed for creatine kinase, a 
marker of muscle damage, using an activity assay (Sigma-Aldrich, St. Louis MO, 
USA.  
Muscle Pain, Discomfort, and Soreness 
Pain and discomfort are an inherent part of exercise and sport but they 
have been under appreciated in exercise science education and research (217). 
The neurobiological mechanisms that contribute to the pain/discomfort sensations 
may be different during exercise and following muscle-damaging exercise 
(DOMS) but histamine may be involved in both sensations. Histamine has been 
shown to stimulate peripheral nociceptors (Group III/IV afferent fibers) and 
initiate the sensation of cutaneous pain in both murine and human studies (151, 
217). These afferent fibers are present in high amounts within skeletal muscle and 
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Figure 5. A representative gating procedure to identify A) leukocytes (CD14+), 
B) Monocytes (CD 86+, CD66-), C) Monocyte 1, 2, & 3 sub-populations, D) 
Granulocytes and Neutrophils. 
  
the receptors associated with the nerves terminate along the walls of arterioles and 
surrounding connective tissue. These fibers receive algesic signals from active 
and damaged skeletal muscle (217). As histamine concentrations increase within 
the skeletal muscle during exercise, it would be of importance to study 
histamine’s association with exercise-induced pain and discomfort. The studies in 
this dissertation assessed exercise effort, pain, and discomfort during and after 
exercise using a rating of perceived exertion, a visual analog scale, and algometry. 
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These methods allowed for the quantification of the subjective measures of 
pain/discomfort and exercise effort.   
 
Rating of Perceived Exertion: 
The concept of perceived exertion refers to the strain on the 
musculoskeletal, cardiovascular, and pulmonary systems at rest and during 
exercise (32). This concept is related to exercise intensity and the method to 
assess the strain involves asking volunteers to rate their level of exertion “right 
now” on a Likert Scale (31, 32). A 0-10 sale for exertion was employed for the 
study detailed in Chapter V while a 6-20 scale was used for the study in Chapter 
IV. An advantage of the 6-20 scale is that the numbers approximate heart rate.  
Both scales were developed by Gunner Borg (32). Other exertion scales have 
been made over the years but all rely on the premise of taking a subjective 
measure and applying a quantitative value so that statistical analysis could be 
made.  
 
Visual Analog Scale 
Muscle pain and discomfort were evaluated by means of a visual analog 
scale (VAS) questionnaire (217). The scale allows the subjects to provide a 
subjective rating of their general muscle soreness by marking a single vertical line 
along a 100 mm continuous scale with descriptive anchors at 0 mm indicating “no 
pain/discomfort”, 50 mm “moderate” pain/discomfort,” and 100 mm “severe 
pain/discomfort” (Figure 6). The distance from the left end (0 mm) of the scale to 
the vertical mark allowed for quantification of the pain/discomfort level. 
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Assessments of pain/discomfort were focused on the quadriceps muscle group 
that underwent the muscle damaging protocol in Chapter VI. The use of a VAS 
was sensitive enough to detect changes in muscle soreness following muscle 
damaging exercise (78) as well as between drug interventions in exercising 
protocols (78, 182, 200, 218). 
 
 
Figure 6. A visual analog scale (VAS) used for evaluating muscle pain and 
discomfort. Adapted from O’Connor et al.(217) 
 
Algometry, Pain pressure threshold  
The pain pressure threshold is the minimum pressure which induces pain 
or discomfort (86). The pain pressure threshold was evaluated using algometry at 
the vastus lateralis and rectus femoris of the subject’s exercised leg in Chapter VI. 
The rectus femoris was evaluated along the midline of the front of the leg and 
between 8 to 15 cm above the patella and the vastus lateralis was evaluated 10 to 
20 cm above the lateral epicondyle of the femur (Figure 7). The sites were marked 
with a pen for visit-to-visit repeatability. Pain pressure threshold was evaluated 
with a Wagner digital algometer (Model FPX25, Wagner Instruments, Greenwich 
CT, USA), according to the methods of Fischer (86) in which the 1 cm2 flat 
rubber tip is pressed firmly and perpendicularly into the muscle with an increasing 
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force of approximately 5 N s-1. Pressure was stopped when the volunteer indicated 
the onset of pain/discomfort. Each site was evaluated 2 times and values within 5 
N were accepted, if not additional trials were performed and all values were 
averaged. Of note, the use of algometry does not in itself change perception of 
pain, as multiple measures made to the same site over a three-day period did not 
affect pain scores (215).  
 
 
Figure 7.  Sites of pain pressure threshold testing and the algometer. 
 
There is no “Gold Standard” for measuring pain, but current guidelines 
suggest that the use and integration of several pain measures as a way to 
understand its complexity and interindividual variance (217). Methods to initiate 
pain include electrical, pressure, thermal, and chemical stimuli and pain 
parameters such as threshold (onset of pain), tolerance (length of time a stimulus 
can be tolerated), and intensity (category scales) can all be used to quantify the 
overall state of being.  
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Muscle function & damage 
The primary function of skeletal muscle is to generate force for movement 
or joint stabilization. When muscle damage occurs, the ability to generate force is 
decreased. The decrease in muscular force may be due to either a decrease in actin 
and myosin overlap resulting from disruption of sarcomeres, a decreased 
excitation of the muscle sarcomere, a decreased calcium release, or to a reduced 
neural input into the contracting muscle. The neural input, or descending drive, 
from the motor cortex is a major determinant of the timing and strength of 
voluntary contractions. Inhibition of neuronal firing from the motor cortex is 
known to increase with increased sensation of pain (217). Blocking histamine 
interaction with group III/IV afferent fibers may decreased sensations of pain and 
reduce the motor neuron inhibition (151, 285) allowing greater voluntary force 
production, as speculated in previous DOMS research (78). Additionally, motor 
neuron drive parallels the sense of effort and inhibitory feedback from group 
III/IV afferent neurons may alter the motor neuron drive and influence muscle 
contractile force. Therefore, voluntary strength tests in conjunction with 
peripheral stimulation of motor neurons, in an attempt to bypass central motor 
neuron recruitment, were performed to differentiate the strength loss from muscle 
ultrastructure damage from the decreased motor neuron activity in the study 
detailed in Chapter VI.  
Serial Strength Testing 
Strength testing is used as an indirect measure of muscle damage (50, 78, 
173, 174) and was previously used to assess histamines effect on muscle function 
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(78, 194). In the study detailed in Chapter VI, serial maximal strength tests of the 
quadricep muscles were made pre, 2, 4, 20, 24, 48 and 72 hours after an eccentric 
bout of exercise. Subjects performed 3 maximal contractions on a dynamometer 
(Biodex, System 3, Shirley, NY) with a 60 s rest period between each trial.  
 
Evoked potentials and supramaximal stimulation 
To gauge the amount of motor neuron activation to the quadricep muscles, 
the femoral nerve was stimulated with a single pulse to activate the musculature 
when the subject was at rest and while performing a maximal voluntary 
contraction. Volitional activation of a muscle occurs when force is produced by 
the recruitment of motoneurons through increased drive from the motor cortex. A 
stimulation of the femoral nerve, near the peak in voluntary force, may provide an 
acute increase in force production (Figure 8). The increase in force production 
represents the amount of musculature that has not been voluntarily activated by 
the central nervous system (23, 245). The combination of evoked twitch force at 
rest and the increase in force upon a maximal stimulation (supramaximal 
stimulation) can be used to evaluate strength changes during fatigue and muscle 
damage (23, 26, 244, 248). The increase in force may reflect inhibition of 
motorneurons by afferent feedback or reduced recruitment starting in the motor 
cortex (217, 244). A central activation ratio (CAR) was calculated by comparing 
the superimposed evoked force against the force output of a voluntary contraction 
(MVC+Stimulated force))(192). A CAR of 1.0 indicates a complete voluntary 
activation of the muscle. Other researchers in this field prefer the term central 
activation failure (1-CAR) as they feel the measure is more accurate of what the 
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central nervous system is failing to accomplish (23). Regardless, the intrasubject 
variability using this technique in healthy subjects is 7.0 ± 1.2% and is sensitive 
enough to parse out central vs peripheral mediated reductions in voluntary 
strength (-20 to -40%) that occurs with DOMS (192). Additionally, the 
superimposed evoked force was compared against the resting evoked twitch to 
calculate an interpolated twitch (IT ratio = superimposed twitch / resting evoked 
twitch force X 100)(23, 245).  
The use of single stimulations superimposed on a MVC may not provide a 
precise estimate of muscle activation (23).  Other techniques involve giving 
stimuli doublets, producing tetany, and using stimulations superimposed upon 
multiple sub-maximal intensity isometric contractions obtain insight into the 
mechanisms of fatigue and damage. The use of single superimposed stimuli were 
preferred due to the ease of obtaining the measure and as it is a gross measure of 
muscle activation during isometric contractions (23).  
Specifically, in Chapter VI, the initial stimulation intensity was 
determined using a specially devised stimulator (Digitimer Constant Current 
Stimulator Model DS7AH, Welwyn Garden City, Hertfordshire, UK) over the 
femoral nerve on the cutaneous surface. The stimulation area was medial to the 
anterior-superior iliac spine, proximal to the inguinal crease, and was marked for 
reference for follow-up testing. The stimulator provided a single monophasic 
square-wave stimulus of a 200 watt voltage for a 200 ms duration. The amperage 
was progressively increased to provide the largest M-Wave and twitch torque. 
The M-Wave was detected on an oscilloscope (Tetronix TDS 210, Beaverton 
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OR). A stimulation amperage of 130% of that to produce a maximal twitch force 
was then used for testing (245). The stimulation amperage was adjusted for each 
subject and between each testing session.  
 
 
Figure 8. Representative tracing of the maximal voluntary contraction (MVC) 
force of the quadricep muscles with a force increase from a superimposed 
stimulation of the femoral nerve (Top). The electromyographical activity of the 
vastus lateralis muscle during the MVC and super imposed stimulation (Bottom).   
 
 
Limitations to this technique are that stimulation does not just activate 
motor neurons but may also cause antidromic as well as orthodromic potentials 
which may inhibit the voluntary stimulation in addition to possibly stimulating 
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synergistic or antagonist muscles (95, 303). Additionally, the stimulus intensity 
and location to elicit a maximal M-wave over the femoral nerve was made at rest 
while the superimposed stimulation was made during muscle contraction. During 
a maximal contraction, there is movement of the muscle tissue and possibly the 
associated motor nerves under the skin. The movement of the nerve will influence 
the amount of stimulus reaching the nerve, and therefore the stimulus intensity 
may not be consistent with repeat trials.  
 
Electromyography  
 
Electromyography (EMG) is the process of recording the electrical 
activity of the muscle. Myoelectric signals are generated by active muscle fibers 
that are associated with action potentials from motor neurons. The size and 
duration of the EMG signal give an indication of the activity of the muscle. In the 
study in Chapter VI, surface electromyography (EMG) was used evaluate the 
amount of muscle activated during maximal voluntary contractions and from 
stimulated muscle contractions.  
A single muscle, the vastus lateralis, was evaluated with an EMG (Motion 
Lab Systems Inc. Baton Rouge, LA) which included a built-in amplifier and 
ground. The electrode was placed in parallel to the approximate axis of the muscle 
fibers at a distance approximately 25% of the distance between the anterior 
superior iliac spine and the Gerdy prominence (29) and was held in place with 
adhesive tape. The location of the electrode was marked with ink for placement of 
the electrodes on future evaluations. The maximal amplitude of the EMG signal 
was compared between maximal contractions. Unfortunately, the area under the 
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EMG curve could not be analyzed as the duration the subjects were able to hold a 
contraction diminished as muscle soreness peaked.   
Limitations of using EMG are the relatively unknown area and depth of 
tissue that are sensed by the electrodes and whether there is background electrical 
signals (crosstalk) from co-activated muscles or inactive muscles in the vicinity of 
the electrode (29).  
Hydration 
 
Dehydration and hypohydration are causes of fatigue. During extended exercise 
bouts subjects will lose body water as sweat and water vapor in the process of 
humidifying air as it enters the lungs. Body weight is a simple and crude way of assessing 
hydration changes. Therefore, body weights were monitored to exclude/account for 
dehydration as a possible causative factor of fatigue during the 10-km time-trials in 
Chapter IV. Nude body weight was recorded before and after all testing visits. Weights 
were recorded to the nearest 0.1 g (Sartorius model CIS IS64FEG-S, Elk Grove IL). Fluid 
intake/loss was documented with the combination of measured body weights, including 
those taken before and after urination/defecation, and changes in water bottle weights. 
 
Statistical Analysis 
Statistical inferences were drawn from a combination of paired t-tests, 2-way and 
3-way repeated measures analysis of variance (ANOVAs) using SigmaPlot (v12, 
Systat,San Jose, CA, USA) or Statistical Analysis Software (SAS version 9.2; SAS 
Institute. Cary, NC, USA). F-values were corrected for sphericity where appropriate and 
Tukey’s post hoc tests were used when main or interaction effects were observed. 
Regression models were run using SAS Proc GLMSELECT (Proc MIXED, SAS version 
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9.2; SAS Institute. Cary, NC, USA). For all tests, significance was set at P < 0.05. 
Variables describing the distribution of the subject population, including anthropometric 
and demographic measures are presented as means ± standard deviation (SD). Data 
describing physiological variables between conditions and changing over time are 
presented as means ± standard error of the mean (SEM) to display the precision of the 
interventions.  
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CHAPTER IV 
 
HISTAMINE RECEPTOR-ANTAGONISTS SLOW 10-KM CYCLING 
PERFORMANCE IN COMPETITIVE CYCLISTS 
 
 This study could not have been completed without the contributions of Dylan C. 
Sieck, Joshua E. Mangum, Emily A. Larson, Leandro C. Brito, Christopher T. Minson, 
and John Halliwill. Dylan, Josh, Emily, and Leandro provided much needed assistance on 
all the data collection sessions and contributed to the intellectual development of the 
manuscript. ChristopherT. Minson and John R. Halliwill assisted in the intellectual 
development and the writing of the manuscript. I was involved with all aspects of this 
project including the development of the protocol, completion of all data collection, 
compilation of the data, analysis of the data, and development of the manuscript.  The 
manuscript for this study is currently published online and will be available in print form 
in the July 2019 issue of the Journal Medicine and Science in Sport and Exercise.  
 
Introduction 
Skeletal muscle interstitial histamine concentrations are low at rest, but increase 
in active musculature during moderate-intensity endurance exercise as histamine is 
released by mast cell degranulation and through de novo synthesis (255), secondary to 
increased activity of the enzyme histidine decarboxylase (HDC) (13, 255). Mast cell 
degranulation has been shown to occur with stimuli associated with exercise such as 
hypoxia, increased temperature, vibration, and hyperosmolality (190, 279, 294). While 
HDC is present in high concentrations within mast cells, there is also evidence it may be 
expressed within skeletal muscle myocytes (13, 270) and endothelial cells (270, 312). 
HDC continually synthesizes minute quantities of histamine in resting muscle (270, 320), 
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but further activity can be induced by stimuli associated with exercise such as hypoxia 
(138), increased temperature (267, 271), and decreased pH (267). Along these lines, 
experiments in exercising mice or using repeated electrically stimulated contractions in 
isolated muscle have demonstrated that the magnitude of increased HDC activity is 
proportional to the duration of exercise (14, 82). Since histamine is rapidly degraded by 
cytosolic and membrane bound enzymes or reabsorbed by mast cells, it has a short half-
life (~100 s) (22, 130, 204). Therefore, histamine may have an important autocrine and 
paracrine action within skeletal muscle during sustained activity (212, 328). 
In mice, blocking histamine’s actions negatively affected moderate-intensity long-
duration exercise tasks, but did not affect outcomes of short-duration high-intensity 
activities in humans. Specifically, histamine H1 receptor antagonism in mice decreased 
multi-hour duration gnawing activity (328), and the speed and duration components of 
multi-hour walking tests (84, 212). Similarly, blocking histamine H2 receptors tended to 
reduce walking endurance in mice, but the effect was smaller than blockade of H1 
receptors (212). In contrast to the exercise studies in mouse models, blocking H1 
receptors in humans had no effect on isokinetic muscle strength or endurance (194), 
maximal aerobic exercise, steady state submaximal exercise, or high intensity intermittent 
exercise (195, 196, 236). However, because the maximum length of human testing was 
brief (at most, 30 min, using high-intensity intervals alternated with rest periods), these 
studies do not reveal the effect of histamine on sustained endurance task performance. It 
is unknown if the different outcomes between human and mouse studies are due to 
differences in histamine’s actions between species or are related to the intensity and/or 
duration of the exercise tests. 
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In humans, 60 min of moderate-intensity exercise increased histamine 
concentrations within skeletal muscle (255). This intramuscular histamine activated H1 
and H2 receptors on the vascular endothelium (164) and smooth muscle, respectively, to 
induce a dilation of resistance arterioles, and increase local blood flow for several hours 
following exercise (187, 188). Histamine plays a similar vasoactive role in immune and 
inflammatory responses, in which increased local histamine concentrations increase 
blood flow and capillary permeability (56, 57, 177). It is unknown if histamine has a 
similar vasodilatory influence on blood flow within the muscle during endurance 
exercise. Given the proximity of histamine containing and producing cells to the skeletal 
muscle vasculature and the physiological actions of histamine, it is a reasonable premise 
that exercise induced increases in intramuscular histamine contribute to dilation and 
increased blood flow during exercise. 
If histamine aids in increasing blood flow during exercise, blocking this action 
could decrease nutrient and oxygen delivery as well as carbon dioxide and metabolite 
removal. This perfusion to metabolism mismatch  may have a larger impact on longer-
duration exercise compared to short-duration exercise, and could be an explanation for 
the decreased endurance task performances observed in mice (82, 84, 212, 328) but 
absent in short-duration exercise studies in humans (194–196, 236) in response to 
histamine blockade.  
Therefore, the purpose of this study was to gain insight into histamine’s role in 
endurance exercise in humans, and potentially reconcile the contrasting results between 
human and animal studies. Specifically, on multiple days, human subjects performed 
short-duration high-intensity exercise performance tests following a time-matched period 
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of rest or endurance exercise. Subjects performed the tests in a condition where 
histamine’s effects on H1 and H2 receptors were blocked and in a placebo condition. Prior 
to the study, it was hypothesized that blocking both H1 and H2 receptors would increase 
the time-to-completion of a fixed-distance time-trial compared to placebo, and the effect 
would be greater following an endurance-exercise bout. 
Methods 
Subjects 
This study was approved by the Institutional Review Board of the University of 
Oregon. Eleven (3 female, 8 male) healthy, non-smoking individuals volunteered for the 
present study. Each volunteer gave written and informed consent prior to participation 
and the study conformed to the principles of the Declaration of Helsinki. All volunteers 
were competitive cyclists with a USA cycling race Category 1, 2, or 3 classification and a 
history of racing within the past year. No subjects were using over-the-counter or 
prescription medications at the time of the study, with the exception of oral 
contraceptives. The multi-day study was organized around training, work, and family 
schedules, therefore for female volunteers, menstrual cycle phase was not controlled for 
within or between subjects.  
 
Experimental design 
The study consisted of seven visits: one screening, two familiarization, and four 
double-blind placebo-controlled testing visits. All volunteers were required to abstain 
from caffeine, alcohol, and strenuous exercise for 24 h prior to each visit. A 24-h food 
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diary was provided to the subjects prior to the first testing visit, and food intake was 
matched as close as possible by the subjects before testing visit 2, 3, and 4. 
 
Screening visit 
An initial screening visit was completed to expose the subjects to all testing 
procedures and obtain demographic and anthropometric information (age, height, weight) 
including measurement of 3-site skin-fold body-fat estimate (triceps, supra-iliac, and 
mid-thigh for females; chest, abdominal, mid-thigh for males) according to the American 
College of Sports Medicine guidelines (161). Subjects then completed a 10-s Wingate 
test for anaerobic power, a cycling VO2Peak test for aerobic capacity, and an isometric 
knee-extension strength test.  
 
Familiarization Visits 
Subjects performed two familiarization 10-km cycling time-trials that were 
separated by 3 to 7 days. Prior to each time-trial, an isometric knee-extension strength 
test was performed. Following a 10-min warm-up at a self-selected pace, blood glucose 
and lactate as well as rating of perceived exertion were measured, and then subjects 
performed a 10-km time-trial. If the difference in time-to-completion of the two visits 
was large (~30 s), subjects were asked to perform a third familiarization (this was done 
for one subject, as noted in the results). Immediately following the time-trials (within 30 
s) blood glucose and lactate as well as rating of perceived exertion were measured. 
Isometric knee-extension strength was measured 3 min following the time trial 
completion.  
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Testing Visits 
All testing visits were scheduled so that the 10-km time-trials occurred at the 
same time of day as the familiarization time-trials to reduce the potential influence of 
circadian rhythms on muscle blood flow (34) and exercise performance (247). Subjects 
were randomized after the familiarization visits to complete testing visits 1, 2, 3 and 4, in 
one of four possible orders (A, B, C, D), as shown in Table 5. Subjects completed a 10-
km time-trial after 120-min seated rest (Rest) in the first two testing visits (1 and 2) and 
after 120-min cycling exercise (Exercise) in the last two visits (3 and 4), as shown in 
Figure 9. Subjects either received placebo pills (Placebo) or combined H1/H2 histamine 
receptor antagonists (Blockade) for the first two visits (Rest) and again for the second 
two visits (Exercise).  
 
Table 5. Order of testing visits 
Testing visit 1 2 3 4  
Activity prior to time-trial 
(Preceding Condition) 
120-min Rest 120-min Exercise n  
Order A Placebo Blockade Placebo Blockade 3 
Order B Blockade Placebo Blockade Placebo 3 
Order C Placebo Blockade Blockade Placebo 3 
Order D Blockade Placebo Placebo Blockade 2 
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Figure 9. Study time line. After ingestion of Placebo or Blockade (Rx), volunteers 
performed either 120-min seated Rest (Visit 1 and 2) or 120-min cycling Exercise at 50% 
of VO2peak (Visit 3 and 4). Each arrow () represents a time where isometric knee-
extension strength and body weight were measured. The blood drop () indicates a time 
point where blood was sampled. The black triangle (▲) represents a 5-min period when 
VO2, cardiac output, blood pressure, and perceived exertion were recorded. Testing visits 
1 and 2 included a 10-min warm-up period in preparation for the 10-km time-trial; this 
was not included following the 120-min of cycling exercise.  
 
Upon arriving to the lab, subjects ingested either Placebo or Blockade pills with 
~90 ml of water and were seated in a temperate room (19-22°C) for 60-min before the 
start of Rest/Exercise. A measure of nude body weight was obtained, and then subjects 
were moved to an environmental chamber controlled at 18°C and 45% relative humidity 
(Tescor, Warminster, PA) for the remainder of the visit. Baseline measures of isometric 
knee-extension strength, heart rate, blood pressure, cardiac output, blood glucose and 
lactate, and rating of perceived exertion were made before 120-min seated Rest/Exercise. 
For Rest, subjects sat in a padded phlebotomy chair. For Exercise, subjects were seated 
on their own bikes on a CompuTrainer (RacerMate Inc., Seattle, WA, USA) computer-
integrated cycle ergometer and the workload was set at a wattage corresponding to 50% 
of peak oxygen uptake. The CompuTrainer was set to vary resistance to maintain a 
constant work output, allowing the subjects to self-select and vary pedal cadences 
throughout the 120-min. Measures of cardiac output, heart rate, blood pressure, blood 
glucose and lactate, and perceived exertion were made at 15, 60, and 105 min during 
Rest/Exercise. Subjects were provided with ~ 90 ml of Gatorade every 20 min, for a total 
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of 533 ml (18 oz) during the 120-min. In addition to Gatorade, subjects were given water 
ad libitum during Exercise. At the completion of Rest/Exercise, a measure of isometric 
knee-extension strength was recorded. After Rest, subjects completed a 10-min warm-up 
at a self-selected power output prior to the time-trial (Visit 1 and 2), whereas after 
Exercise, subjects transitioned directly to the time-trial without additional warm-up (Visit 
3 and 4). Immediately after the time-trial, perceived exertion, blood glucose and lactate, 
isometric knee-extension strength, and nude body weights were obtained (Figure 1). For 
the majority of subjects (7 of 11), each testing visit was performed 7 days apart, and for 
all subjects, they were separated by at least 72 h. 
The objective of the time-trial was to finish as quickly as possible, with time 
being the criterion measure of performance. The time-trials were performed adhering to 
the standards outlined by Currell (53). During the time-trials there was: 1) no feedback on 
performance, 2) no distractions, 3) no encouragement, 4) no physiological measures 
(except for heart rate), 5) no performance cues, 6) temperature and humidity were 
controlled, and 7) subjects always used their own bike equipment. Time-trials using these 
guidelines often have a low day-to-day coefficient of variation and are likely to show 
meaningful differences for an intervention (53). Time-trials in competitive cyclists also 
have a high logical validity as they are “real world” type tests, are highly reproducible 
(coefficient of variance = 1.1 ± 0.9 % ), and highly correlated with on-the-road 
competitions (r = 0.98)(225).  
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Measurements 
10-s Wingate 
Subjects were seated on a cycle ergometer (Excalibur Sport V2; Lode BV, 
Groningen, The Netherlands) and performed a 5-min warm-up at power output of 100 
Watts at a self-selected cadence. Immediately following the warm up, subjects completed 
a modified (10 s) Wingate test of anaerobic power. The torque factor was set to 0.70 Nm 
(Wingate for Windows software version 1; Lode BV, Groningen, The Netherlands). The 
final two subjects were unable to complete the Wingate test due to computer-ergometer 
interface malfunctions (reported in Table 1).  
 
VO2Peak 
After the Wingate test, subjects performed an additional 5- to 10-min warm‐up, 
cycling at 1.5 Watts per kilogram of body weight at a self-selected pedal cadence. 
Subjects then performed an incremental cycle ergometer exercise test (Lode Excaliber, 
Groningen, The Netherlands) comprised of 1‐min workload increments of 25-30 watts to 
determine peak oxygen uptake (VO2peak). The workload increment was based on the 
subject’s self-reported training load and intensity. Whole‐body oxygen uptake was 
measured throughout the test via a mixing chamber system (Parvomedics, Sandy, UT) 
integrated with a mass spectrometer (Marquette MGA 1100, MA Tech Services, St. 
Louis, MO). The test was terminated when subjects were unable to maintain a pedal 
cadence of 40 revolutions per min. Subjects had obtained a respiratory exchange ratio of 
1.13 ± 0.06 (mean ± SD), a heart rate of 95 ± 4% (mean ± SD) of age-predicted 
maximum, and reached subjective exhaustion [rating of perceived exertion on the Borg 
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scale of 19–20, (31)]. The VO2peak test was performed for estimation of a 50% workload 
for testing visits 3 and 4. 
 
Knee-Extension Strength Testing 
Maximal voluntary isometric force of the right knee extensors was determined 
using a custom-built knee-extension apparatus and interfaced with a commercially 
available strain gauge (DP25-S, Omegadyne Inc. Sunbury, OH, USA). The knee angle 
was set to 45˚ of knee extension and subjects performed two to three maximal knee 
extension contractions with ~30 s rest between attempts. The greatest contractile force 
was accepted as a maximal value using the other trials as verification. Additional trials 
were performed as needed if trials did not agree within 10%.  
 
10-km Time-Trial 
The 10-km time-trials were performed on a computer-integrated cycle ergometer 
(CompuTrainer) using the subjects own racing bike. The time-trial was implemented 
using a manufacturer cycle ergometer computer program that provided a race simulation. 
Subjects were instructed to complete the time-trial as rapidly as possible and were 
blinded to feedback (i.e. time, pedal cadence, heart rate, power) but were given verbal 
cues indicating remaining distance at each 1 km, and at 500 m remaining. At the 
completion of each 1 km, split time and heart rate (H1 heart rate sensor, Polar, Lake 
Success, NY) were recorded but not shared with the subject. 
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Histamine H1- and H2-Receptor Blockade 
Oral administration of 540 mg of fexofenadine, a selective H1-receptor antagonist, 
reaches peak plasma concentrations within 1 h and has a 12 h half-life (263). Oral 
administration of 300 mg ranitidine, a selective H2-receptor antagonist, reaches peak 
plasma concentration within 2 h and has a 3 h half-life (93). This dosage of histamine-
receptor antagonists results in more than 90% inhibition of histamine H1 and H2 receptors 
lasting for 6 h after administration (93, 287). Fexofenadine and ranitidine are not thought 
to cross the blood-brain barrier or to have sedative effects (93, 263, 287). Importantly, 
histamine H1- and H2-receptor antagonism does not alter blood flow, heart rate, blood 
pressure, or smooth muscle tone at rest (78, 79, 187, 188, 254).  
 
Placebo 
The placebos were manufactured by a compounding pharmacy (Creative 
Compounds, Wilsonville, OR) and contained the inactive ingredients of the fexofenadine 
and ranitidine tablets. 
 
Body Weight 
Nude body weight was recorded before and after all testing visits. Weights were 
recorded to the nearest 0.1 g (Sartorius model CIS IS64FEG-S, Elk Grove IL). Body 
weights were monitored to exclude/account for dehydration as possible causative factor 
of fatigue during the 10-km time-trials. Fluid intake/loss was documented with the 
combination of measured body weights, including those taken before and after 
urination/defecation, and changes in water bottle weights. 
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Rating of Perceived Exertion 
A subjective rating of exertion was documented on a 6-20 scale before and at 15, 
60, and 105 min Rest/Exercise, and before and immediately following each time-trial 
(31).  
 
Blood Glucose/Lactate 
Blood was obtained from the left and right earlobes with single use safety lancets 
(Unistik 3, Owen Mumford, Oxfordshire, UK). Blood was analyzed for glucose 
(Precision Xtra, Abbot Diabetes Care, Alameda, CA) and lactate concentrations (Nova 
Biomedical, Waltham, MA) in duplicate and values were averaged.  
 
Heart Rate and Arterial Pressure 
Heart rate was monitored using a three-lead electrocardiogram and arterial 
pressure was measured on the right brachial artery using an automated auscultometric 
sphygmomanometer (Tango+, SunTech Medical, Raleigh, NC, USA). Mean arterial 
pressure was calculated as diastolic pressure plus 2/3 pulse pressure (systolic pressure - 
diastolic pressure) and reported in mmHg. 
  
Cardiac Output, Stroke Volume, Total Peripheral Resistance, and Systemic Vascular 
Conductance 
Cardiac output was estimated by using an open-circuit acetylene washin method. 
This method allows for noninvasive estimation of cardiac output. Subjects breathed a gas 
mixture containing 0.6% acetylene, 9.0% helium, 20.9% oxygen, and balanced nitrogen 
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for 8 breaths via a two-way non-rebreathing valve attached to a pneumatic sliding valve. 
During the washin phase, breath-by-breath acetylene and helium uptake were measured 
by a respiratory mass spectrometer (Marquette MGA 1100, MA Tech Services, St. Louis, 
MO) and total volume was measured via a pneumotach (model 3700, Hans Rudolph, 
Kansas City, MO) linearized and calibrated by using test gases before each testing day. 
Stroke volume was determined by dividing cardiac output by heart rate. Total peripheral 
resistance was calculated as the mean arterial pressure divided by cardiac output 
(expressed as mmHg·min·ml-1) and systemic vascular conductance as the reciprocal of 
resistance (expressed as ml·mmHg-1·min-1).  
 
Statistical Analysis 
Results were not separated for a sex comparison as only 3 females volunteered for 
the study. Menstrual cycle phase was not controlled for in the females as there is a strong 
consensus that there is no change in aerobic (77, 89, 282) nor anaerobic performance (94) 
over the menstrual cycle, and females train and compete throughout all phases of their 
menstrual cycle.  
Statistical inferences were drawn from a combination of paired t-tests and 2- or 3-
way repeated measures ANOVAs with a priori contrasts, depending on the sampling of 
outcome measures, and models were run using SAS (Proc MIXED, SAS version 9.2; 
SAS Institute Inc. Cary, NC, USA). For all tests, significance was set at P < 0.05. All 
data are presented as mean ± SEM, unless stated otherwise (i.e., Table 1).  
In addition, the practical importance of the time-to-completion was examined by 
the following procedures. First, a change score and 95% confidence interval (CI) between 
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Blockade and Placebo time-to-completion was calculated. Second, the change score and 
95% CI were compared to a zone of indifference, determined as the coefficient of 
variation from the familiarization time-trials (i.e., a metric of day-to-day variability), as a 
test for equivalence (238). This procedure provides insight into the likely range of true 
population differences beyond statistical inference, using a comparator that is more 
meaningful than zero (i.e., null change) (19). Third, the taxonomic classification of the 
change score and confidence intervals for the strength of the effect was identified, based 
on the work of Batterham and Hopkins (19) and Piaggio (238). In this construct, 
performances outside of the day-to-day variation, regardless of statistical inference tests, 
represent a meaningful change in performance, as noted previously in the performance 
literature (48, 152, 276). Lastly, a traditional effect size (Cohen’s dz) was calculated for 
each preceding condition as well as a common language effect size (CLES, (159)), an 
expression of the probability of an outcome, for ease of understanding for the non-science 
public.  
 
Results 
Subject characteristics 
Subject’s demographic and anthropometric characteristics obtained from the 
screening visit including age, height, weight, body fat percentage, peak power, VO2peak, 
isometric knee-extension strength, and 50% VO2peak workload are presented in Table 6. 
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Table 6. Subject Characteristics 
n 11 (3F, 8M) 
Age (years) 27 ± 5, (19-33) 
Height (cm) 176.6 ± 9.2, (135.5-196) 
Weight (kg) 71.29 ± 12.44, (50.84-95.96) 
Body Fat (%) 16.1 ± 9.6, (4.7-38.5) 
Peak Anaerobic Power (W)* 897 ± 262, (526-1303) 
VO2 peak (ml·kg
-1·min-1) 58.7 ± 6.3, (49.2-70.1) 
Isometric knee-extension Force (N) 603.7 ± 224.4, (202.4-1030.8) 
50% VO2 peak Workload (W) 160 ± 30, (100-220) 
Values are means ± SD, (Range). * n = 9 for Peak Anaerobic Power, n = 11 for all 
others. 
 
 
Responses during Familiarization Visits and Time-Trial Reproducibility 
One subject performed three familiarization time-trials, as their time-to-
completion in the second familiarization was 27.7 s slower than the first. For this subject, 
only the two fastest times were used for analysis. There were no differences in time-to-
completion between the first and second familiarization time-trial (1008.6 ± 25.9 s vs. 
1001.7 ± 26.7 s; P = 0.128). The subjects demonstrated consistency in their efforts as the 
coefficient of variation between trials was 0.97%. The last kilometer of the time-trial was 
the fastest and the first kilometer was the slowest (P < 0.05), but pacing for each 
kilometer of the time-trial did not differ between trial 1 and 2 (P = 0.504)(Figure 10). 
Likewise, while heart rate increased within the time-trials (main effect for time P < 0.05), 
it did not differ between trial 1 and 2 (P = 0.381)(Figure 10). There were no differences 
in blood glucose and lactate concentrations or strength change between trials (Table 6). 
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Figure 10. Familiarization time-trials. Upper panel: Comparison of the two visits for 
split time at 1-km increments, with 10-km time-to-completion shown as inset. * denotes 
slower than at 2-10 km (P < 0.05); # denotes faster than 1-9 km (P < 0.05) within the 
trials. Lower panel: Comparison of the two visits for heart rate at 1-km increments. 
Values are means ± SEM. 
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Table 7: Familiarization Trials 
    P value 
  Trial 1 Trial 2 Trial Time Trial*Time 
Glucose (mg/dl) Pre 77 ± 3 81 ± 5 0.895 <0.05 0.198 
 Post 98 ± 8 95 ± 6    
Lactate (mmol/l) Pre 1.2 ± 0.1 1.2 ± 0.1 0.476 <0.05 0.912 
 Post 11.8 ± 0.8 11.9 ± 0.9    
Muscle Strength (N) Pre 607 ± 13 593 ± 13 0.814 <0.05 0.403 
 Post 546 ± 13 555 ± 13    
RPE Pre 6 ± 1 6 ± 1 <0.05 <0.05 <0.05 
 Post 18 ± 1 19 ± 1    
Values are means ± SEM. RPE, Rating of Perceived Exertion 
 
 
 
Responses during 120-min Rest and Exercise 
During 120-min Rest, there were no changes in any hemodynamic or metabolic 
measure in either Placebo or Blockade (Table 7). During 120-min Exercise, subjects 
cycled at a power output of 160 ± 30 W (mean ± SD) and, as expected, all hemodynamic 
and metabolic measures were elevated above pre-exercise and were higher than Rest (P < 
0.05), with the exception of blood lactate concentrations (P = 0.819) and stroke volumes 
(P = 0.448) which did not differ between Exercise and Rest. There were no differences in 
hemodynamic, metabolic, or perceptual measures within or between the Placebo and 
Blockade conditions during 120-min of Exercise.  
109 
Table 8. 120-minutes of Rest and Steady State Cycling 
Phase Drug Pre 10 60 110 Drug   Phase  Drug*Phase   Time  Drug*Time  Phase*Time Drug*Phase*Time 
Heart Rate (beats·min
-1
) Rest     Placebo 
Blockade 
Exercise  Placebo 
Blockade 
57 ± 1 
55 ± 3 
63 ± 3 
63 ± 3 
56 ± 2 
55 ± 3 
134 ± 5 
127 ± 7 
58 ± 2 
56 ± 3 
138 ± 5 
134 ± 5 
54 ± 2 
55 ± 2 
141 ± 6 
138 ± 6 
0.281   <0.05 0.518 <0.05 0.904 <0.05 0.879 
 
VO2 (l·min
-1
) 
 
Rest     Placebo 
Blockade 
Exercise  Placebo 
 
0.301 ± 0.018 
0.276 ± 0.018 
0.385 ± 0.028 
 
0.289 ± 0.017 
0.294 ± 0.013 
2.225 ± 0.120 
 
0.297 ± 0.018 
0.303 ± 0.013 
2.259 ± 0.148 
 
0.300 ± 0.016 
0.291 ± 0.016 
2.301 ± 0.143 
 
0.405   <0.05 0.345 <0.05 0.889 
 
<0.05 
 
0.944 
  Blockade    0.362 ± 0.025      2.342 ± 0.140 2.385 ± 0.176 2.453 ± 0.188  
Respiratory Exchange Ratio Rest      Placebo 
Blockade 
0.84 ± 0.02 
0.83 ± 0.02 
0.79 ± 0.02 
0.83 ± 0.02 
0.83 ± 0.03 
0.83 ± 0.02 
0.82 ± 0.02 
0.84 ± 0.01 
0.820 <0.05 0.208 0.563 0.961 0.119 0.709 
 
Exercise Placebo 
Blockade 
0.86 ± 0.02 
0.86 ± 0.02 
0.89 ± 0.02 
0.87 ± 0.01 
0.87 ± 0.02 
0.85 ± 0.03 
0.84 ± 0.02 
0.83 ± 0.02        
 
Respiratory Rate (breaths·min
-1
) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
15 ± 1 
16 ± 1 
15 ± 1 
14 ± 1 
 
14 ± 1 
16 ± 2 
22 ± 1 
23 ± 1 
 
14 ± 1 
14 ± 1 
22 ± 1 
24 ± 1 
 
14 ± 1 
14 ± 1 
23 ± 1 
24 ± 1 
 
0.126 
 
<0.05 
 
0.792 
 
<0.05 
 
0.409 
 
<0.05 
 
0.683 
 
Systolic Pressure (mmHg) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
127 ± 5 
129 ± 5 
137 ± 5 
134 ± 4 
 
128 ± 5 
126 ± 4 
190 ± 8 
190 ± 7 
 
126 ± 5 
126 ± 4 
193 ± 10 
181 ± 9 
 
132 ± 5 
130 ± 4 
185 ± 9 
185 ± 8 
 
0.483 
 
<0.05 
 
0.628 
 
<0.05 
 
0.933 
 
<0.05 
 
0.827 
 
Diastolic Pressure (mmHg) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
74 ± 2 
73 ± 2 
77 ± 2 
77 ± 2 
 
74 ± 2 
76 ± 2 
61 ± 3 
61 ± 3 
 
77 ± 2 
75 ± 3 
64 ± 5 
60 ± 3 
 
78 ± 2 
81 ± 3 
59 ± 4 
63 ± 4 
 
0.991 
 
<0.05 
 
0.824 
 
<0.05 
 
0.444 
 
<0.05 
 
0.995 
 
Mean Arterial Pressure (mmHg) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
91 ± 3 
92 ± 3 
97 ± 2 
96 ± 2 
 
92 ± 2 
92 ± 3 
104 ±4 
104 ± 3 
 
94 ± 2 
92 ± 3 
107 ± 4 
100 ± 3 
 
96 ± 2 
97 ± 2 
101 ± 4 
103 ± 5 
 
0.624 
 
<0.05 
 
0.635 
 
0.064 
 
0.569 
 
0.264 
 
0.893 
 
Cardiac Output (l·min
-1
) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
6.43 ± 0.46 
6.39 ± 0.45 
6.55 ± 0.34 
5.79 ± 0.63 
 
6.04 ± 0.51 
5.75± 0.30 
14.29 ± 0.59 
14.18 ± 0.90 
 
5.68 ± 0.46 
5.81 ± 0.40 
14.70 ± 0.64 
14.80 ± 1.07 
 
6.30 ± 0.63 
5.72 ± 0.35 
14.51 ± 0.70 
15.09 ± 1.29 
 
0.706 
 
<0.05 
 
0.821 
 
<0.05 
 
0.948 
 
<0.05 
 
0.783 
 
Stroke Volume (ml) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
113 ± 8 
121 ± 12 
108 ± 9 
94 ± 7 
 
109 ± 9 
108 ± 9 
107 ± 5 
114 ± 9 
 
99 ± 7 
106 ± 10 
107 ± 5 
111 ± 9 
 
118 ± 12 
108 ± 10 
104 ± 6 
110 ± 101 
 
0.829 
 
0.448 
 
0.999 
 
0.900 
 
0.880 
 
0.282 
 
0.450 
 
Toal Peripheral Resistance (mmHg·min·l
-1
) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
14.6 ± 0.6 
15.0 ± 1.0 
15.2 ± 0.7 
16.9 ± 0.7 
 
15.9 ± 0.8 
16.4 ± 0.8 
7.4 ± 0.4 
7.7 ± 0.6 
 
17.0 ± 0.8 
16.4 ± 1.0 
7.5 ± 0.5 
7.1 ± 0.6 
 
16.1 ± 0.9 
17.6 ± 1.1 
7.2 ± 0.5 
7.2 ± 0.6 
 
0.287 
 
<0.05 
 
0.985 
 
<0.05 
 
0.495 
 
<0.05 
 
0.627 
 
Systemic Vascular Conductance (ml·mmHg
-1
·min
-1
) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
70 ± 4 
70 ± 4 
67 ± 3 
60 ± 2 
 
65 ± 5 
62 ± 3 
140 ± 9 
138 ± 10 
 
61 ± 4 
64 ± 4 
138 ± 9 
149 ± 11 
 
65 ± 6 
59 ± 3 
143 ± 9 
148 ± 12 
 
0.983 
 
<0.05 
 
0.642 
 
<0.05 
 
0.679 
 
<0.05 
 
0.796 
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Table 8 Continued. 120-minutes of Rest and Steady State Cycling 
 
 
Glucose (mg/dl) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
81 ± 5 
85 ± 4 
82 ± 5 
80 ± 3 
 
89 ± 3 
90 ± 5 
67 ± 3 
66 ± 3 
 
98 ± 4 
93 ± 4 
72 ± 2 
71 ± 3 
 
93 ± 4 
93 ± 4 
72 ± 2 
72 ± 2 
 
0.674 
 
<0.05 
 
0.809 
 
0.115 
 
0.829 
 
<0.05 
 
0.754 
 
Lactate (mmol/l) 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
1.1 ± 0.1 
1.1 ± 0.1 
1.2 ± 0.1 
1.2 ± 0.1 
 
1.0 ± 0.1 
1.0 ± 0.1 
1.3 ± 0.2 
1.4 ± 0.2 
 
1.2 ± 0.1 
1.3 ± 0.1 
1.2 ± 0.1 
1.2 ± 0.1 
 
1.5 ± 0.1 
1.5 ± 0.1 
1.1 ± 0.1 
1.2 ± 0.1 
 
0.424 
 
0.819 
 
0.789 
 
0.195 
 
0.934 
 
<0.05 
 
0.982 
 
Rating of Perceived Exertion 
 
Rest 
Exercise 
 
Placebo 
Blockade 
Placebo 
Blockade 
 
6 ± 0 
6 ± 0 
6 ± 0 
6 ± 0 
 
6 ± 0 
6 ± 0 
9 ± 1 
10 ± 1 
 
6 ± 0 
6 ± 0 
11 ± 1 
11 ± 0 
 
6 ± 0 
6 ± 0 
12 ± 1 
12 ± 1 
 
0.560 
 
<0.05 
 
0.560 
 
<0.05 
 
0.982 
 
<0.05 
 
0.982 
Values are means  SEM.              
111 
Responses during Time-Trials 
Time-to-completion of the time-trial was slower for Blockade compared to 
Placebo (+10.5 ± 3.7 s, Range -15.9 to +53.1 s, P < 0.05), as shown in Figure 11. There 
was a trend for time-to-completion to be slower after 120-min Exercise versus Rest (P = 
0.057), but this was not further compounded by Blockade in comparison to Placebo (P = 
0.716). The pattern of pacing (Figure 11) was similar to the familiarization time-trials, the 
first km was the slowest, the last km was the fastest (P < 0.05), and was not different in 
Blockade versus Placebo (P = 0.307). On average, pacing of each km was slower 
following Exercise versus Rest (P < 0.05) but did not differ between Blockade and 
Placebo (P = 0.926). Heart rate during the time-trial was higher after 120-min Exercise 
versus Rest (P < 0.05) and lower for Blockade compared to Placebo (P < 0.05), as shown 
Figure 11. Heart rate increased throughout the time-trial (P < 0.05), but the pattern was 
not affected by Blockade versus Placebo (P = 0.566) or by prior Exercise versus Rest (P 
= 0.998).  
Changes in Body Weight 
There were no differences in nude weight at the beginning of the testing visits (P 
= 0.547). There was a trend for lower nude weights upon completion of 120-min 
Exercise compared to Rest (P = 0.081), but this was not affected by Blockade versus 
Placebo (P = 0.846). Subjects completed the Exercise trials slightly hypohydrated 
(Placebo -1.25 ± 0.18%, Blockade -1.46 ± 0.18% of pre-trial body weight). In five of the 
time-trials that were preceded by 120-min exercise, subjects exceeded a 2% weight loss 
by the end of the time-trial. The distribution of those five trials included two subjects on 
both their Placebo and Blockade visits, and one subject during only their Blockade visit. 
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The one subject that exceeded 2% weight loss in only the Blockade condition completed 
the time trial 15.9 s faster than the Placebo condition, opposite of the general trend of the 
other subjects. Therefore, in consideration of the overall pattern across subjects, as 
described above, dehydration exceeding a 2% body weight loss does not appear to be an 
important confound for interpreting the effect of Blockade versus Placebo. 
 
Analysis of Change Scores 
As noted above, the coefficient of variation between repeat performances from the 
familiarization time-trials was 0.97%. This was compared to a change score, calculated 
from time-to-completion as [(Placebo – Blockade) / Placebo)] and expressed as percent 
(%) change  95% CI, along with individual change scores (Figure 12). Following 120-
min Rest, the mean change score was -0.87% (95% CI: -2.02 to 0.29%) and following 
120-min Exercise, the mean change score was -1.20% (95% CI: -2.45 to 0.05%). Based 
on the taxonomic classifications of Batterham and Hopkins (19) and Piaggio (238), these 
change scores represent a “possibly trivial” effect of Blockade compared to Placebo 
following Rest but a “likely harmful” effect following Exercise. The size of the effects 
were 0.505 and 0.646 for Rest and Exercise, respectively. Using the common language 
effect size (159), one can state that there is a 69% chance of Blockade slowing 10-km 
time-trial performance when preceded by Rest and a 75% chance of Blockade slowing 
10-km time-trial performance when preceded by 120-min Exercise.  
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Figure 11. Testing visit time-trials. Upper panel: Effect of prior Exercise versus Rest 
and Blockade versus Placebo on 10-km time-to-completion. Values are means ± SEM, as 
well individual values. Middle panel: Effect of prior Exercise versus Rest and Blockade 
versus Placebo on split time at 1-km increments. The first km was the slowest and the last 
km was the fastest (P < 0.05). Values are means ± SEM. Lower panel: Effect of prior 
Exercise versus Rest and Blockade versus Placebo on heart rate at 1-km increments. 
Values are means ± SEM. 
114 
Slowing
Change in 10-km Time-to-Completion (%)
-6 -4 -2 0 2
P
r e
c
e
d
in
g
 C
o
n
d
i t
io
n
R
es
t
E
xe
rc
is
e
A
ll
Trivial
 
 
Figure 12. Effect of Blockade versus Placebo as a percent change in 10-km time-to-
completion, with and without prior exercise (Exercise or Rest). Values are means ± 95% 
confidence intervals, as well as individual values. Yellow shaded area represents a zone 
of indifference (± 0.97%) based on performance variability measured during the 
familiarization trials.  
 
Additional Outcome Measures 
 
There were no differences in blood glucose, blood lactate, rating of perceived 
exertion, or isometric knee-extension muscle strength preceding the time-trial in any 
condition (Table 9). Blood glucose increased from before to after Rest (P < 0.05), 
decreased from before to after Exercise (P < 0.05), but was not affected by Blockade 
versus Placebo (P = 0.809). Blood lactate increased from before to after the time-trial (P 
< 0.05). The rise was greater following Rest versus Exercise (P < 0.05), but there was no 
effect of Blockade versus Placebo (P = 0.496). Rating of perceived exertion increased 
from before to after the time-trial (P <0.05), but there was no effect of Exercise versus 
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Rest (P = 0.663) or of Blockade versus Placebo (P = 0.827). Isometric knee-extension 
strength was highly variable within and between subjects and therefore showed no clear 
indication of any change based on prior exercise (P = 0.586) or drug condition (P = 
0.722).  
 
Subjective observations  
Upon completion of both time-trials within the Rest and Exercise conditions, 
cyclists were asked to subjectively assess if they believed one medication resulted in an 
easier/faster, harder/slower, or no change in time-trial performance. Of the 22 
comparisons, there were 5 reports of “no change” between the medications, 6 reports of 
“harder/slower” for Placebo, and 11 reports of “harder/slower” for Blockade.  
 
Discussion 
The main finding of the present investigation was that taking combined histamine 
H1 and H2 antihistamines slowed time-to-completion of a 10-km time-trial in competitive 
cyclists. These results corroborate the evidence suggesting blocking histamine’s actions 
reduces endurance in mice, and expands the observations in humans beyond the prior 
reports that were restricted to short-duration high-intensity tasks. A strength of the 
research design was the use of highly fit competitive cyclists and repeated familiarization 
trials. The cyclists demonstrated low variability in the 10-km familiarization trials (CV = 
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Table 9. Time Trials  
  Rest Exercise P value 
  Placebo Blockade Placebo Blockade Drug Phase Drug* 
Phase 
Time Drug* 
Time 
Phase* 
Time 
Drug*Phase* 
Time 
Glucose 
(mg/dl) 
Pre 76.6 ± 1.5 72.5 ± 3.9 85.2 ± 2.9 80.7 ± 4.2 0.185 0.490 0.500 0.350 0.971 < 0.05 0.463 
 Post 92.3 ± 4.8 83.8 ± 5.1 75.2 ± 6.1 75.5 ± 4.9        
Lactate 
(mmol/l) 
Pre 1.5 ± 0.1 1.5 ± 0.1 1.1 ± 0.1 1.3 ± 0.1 0.496 <0.05 0.512 <0.05 0.390 <0.05 0.711 
 Post 11.2 ± 0.8 10.0 ± 0.7 7.1 ± 1.1 6.8 ± 1.0        
Muscle 
Strength (N) 
Pre 525 ± 52 511 ± 52 504 ± 60 504 ± 61 0.722 0.586 0.862 0.902 0.994 0.946 0.997 
 Post 530 ± 57 516 ± 54 496 ± 55 487 ± 58        
RPE Pre 7 ± 1 6 ± 0 7 ± 1 7 ± 1 0.827 0.663 0.513 <0.05 0.528 1.00 0.827 
 Post 18 ± 0 18 ± 0 18 ± 0 19 ± 0        
Values are means ± SEM. RPE, Rating of Perceived Exertion. 
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0.97%), and this metric allowed for an in-depth analysis of performance, beyond 
traditional statistics, into the importance of the outcomes. This innovative approach 
supports our statement that blocking histamine’s actions would result in a 69% chance of 
slowing, and the slowing would have a “possibly trivial” effect on time-to-completion in 
a cycling 10-km time-trial, when not preceded by significant exercise activity. In 
contrast, blocking histamine’s actions in a 10-km time-trial preceded by a period of 
sustained exercise would result in a 75% chance of slowing of performance, and the 
slowing would have a “likely harmful” effect on time-to-completion. These results 
suggest that exercise-induced skeletal muscle histamine production plays an integral role 
in endurance exercise capacity. Additionally, in the setting of competitive athletics, the 
combination of common over-the-counter H1 and H2 receptor antihistamines have 
negative influences on performance that are as large as the performance enhancing effects 
of altitude training or caffeine ingestion.  
 
Sources of histamine during exercise 
Mast cells synthesize, amass, and release histamine (211). Due to their location, in 
close contact with nerve endings and of the microcirculation of skeletal muscle, mast 
cells have been described as part of the vascular control network responsible for 
monitoring microcirculatory homeostasis (213). In response to exercise in humans, 
histamine is both released by mast cells and produced de novo by HDC within skeletal 
muscle (255). Mast cell degranulation commonly occurs in response to antigen-
immunogloblin interactions during allergic reactions, but has also been shown to occur 
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with non-immunologic stimuli such as direct disruption of the cell membranes (213) and 
exposure to substance P, bradykinin, adenosine, nerve growth factor (141), chemokines, 
hypoxia (279), hyperosmolaility, superoxides, increased temperature, and vibration (97, 
190, 294). In resting skeletal muscle, HDC enzyme activity generates minute quantities 
of histamine (271, 320). HDC mRNA expression, protein abundance, and activity are 
increased with exercise (14, 82, 255).  HDC activity appears to be enhanced by increased 
temperature (267, 271), decreased pH (267), hypoxia (138), and several signaling 
molecules such as interleukin-1 (13, 81, 82, 320), all of which may play a role during 
repeated muscle contractions. Along these lines, in response to exercise, HDC activity is 
positively correlated with the duration of muscle activity (212).  
 
Role of histamine in exercise responses 
Histamine has a short half-life (~ 100 s) (130), as it is degraded rapidly by 
diamine oxidase in the vascular endothelium and blood (22). Therefore, histamine likely 
acts as a local autocrine and/or paracrine signal within exercising skeletal muscle, as 
there is evidence that interstitial levels do not change within inactive skeletal muscle 
(e.g., arms during leg exercise)(255). While its specific actions during exercise are 
unknown, some insight can be gained from studying histamine in other contexts, such as 
stimulation of afferent fibers, recovery from exercise, and pathophysiological reactions.  
 
Contributing to afferent feedback 
Histamine has the potential to modulate feedback from exercising skeletal muscle 
carried by muscle afferent Group III/IV nerve fibers. The Group III/IV afferent fibers, 
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also termed chemo- and metabo-receptors are associated with the exercise pressor 
response (151), and are one third of a “triad” in that they are in close proximity to mast 
cells and capillaries (27). These afferent fibers express both H1 and H2 histamine receptor 
subtypes (151) that, when bound to histamine, increase firing rate of the nerves and, 
through a reflexive central autonomic loop, increase heart rate. Thus, it is possible that 
histamine receptor antagonism reduced the activity of afferent nerves, diminishing their 
stimulation of the cardiovascular control centers. This would be consistent with the 
reduced heart rate seen during time-trials with histamine-receptor antagonism (Figure11). 
With reduced afferent feedback, it is possible that muscle perfusion was not well matched 
to metabolic demands of the exercising muscle.  
 
Contributing to vasodilation 
During inflammatory and immune responses, histamine binds to H1 and H2 
receptors, causes vascular dilation by relaxation of smooth muscle, and increases the size 
of inter-cellular gaps between endothelial and pericyte cells within post-capillary venules 
(31, 36, 45, 58, 59). The vasodilation and increased size of the gaps results in plasma 
effusion into tissues. Similarly, following a moderate-intensity bout of endurance 
exercise, histamine interacts primarily with H1 receptors on the vascular endothelium and 
H2 receptors on the vascular smooth muscle, leading to a sustained vasodilation of 
resistance arterioles (sustained post-exercise vasodilation), and contributes to post-
exercise hypotension (110, 187, 188). Germane to the present study, histamine blockade 
in endurance-exercised mice resulted in a reduced presence of nitric oxide metabolites in 
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the quadriceps muscles (212), suggesting that endothelium-mediated vasodilation may be 
stimulated by histamine during exercise. 
If histamine has a vasodilatory effect within active skeletal muscle vasculature 
during exercise, this could facilitate oxygen delivery, nutrient delivery, and metabolite 
clearance during exercise. Thus, blocking these local effects may influence systemic 
blood flow, oxygen uptake kinetics, and skeletal muscle metabolism (e.g. glucose uptake, 
lactate production/removal) and, in doing so, have a negative effect on exercise 
performance. In this investigation, we did not attempt to measure skeletal muscle blood 
flow, but given the large vascular bed of exercising skeletal muscle, histamine-mediated 
vasodilation could affect arterial pressure. However, we did not detect any change in 
systemic hemodynamics (total peripheral resistance or systemic vascular conductance) 
during 120 min of moderate-intensity steady-state exercise (Table 8). Since arterial blood 
pressure is highly regulated at rest and during exercise, it is possible that the impact of 
any potential reduction in skeletal blood flow was masked by an offsetting increase in 
blood flow in another vascular bed, mediated by arterial baroreflex pathways.  
Similarly, there were no changes in oxygen uptake (Table 8) or any other 
hemodynamic or metabolic measure during exercise (Table 8). These results are similar 
to those presented by Peterlin (236) who showed no change in total peripheral resistance 
or respiration after H1 receptor antagonism in individuals performing 20 min of cycling at 
50% VO2 peak. Thus, it remains to be seen whether histamine contributes importantly to 
exercise hyperemia, and whether histamine-receptor antagonists reduce skeletal muscle 
blood flow during exercise. However, such an effect would be consistent with the 
reduced performance that was observed in the present study. 
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Contributing to glucose delivery 
Histamine is presumed to be a major controller of the microcirculation, and may 
play a role in facilitating movement of glucose (and other nutrients) from the 
microcirculation to active myocytes. During recovery from exercise, histamine receptor 
antagonists were found to decrease intramuscular glucose concentrations (as assessed via 
microdialysis) (234). Further, blocking histaminergic vasodilation following endurance 
exercise reduced skeletal muscle glucose delivery and blunted whole body insulin 
sensitivity by 25% (233, 234). Interestingly, reduced glucose delivery to skeletal muscles 
may have a larger impact on muscle glucose uptake in individuals with the highest VO2 
(79). In mice, histamine H1 receptor antagonists have been shown to reduce intramuscular 
glycogen content following a 3 h prolonged walking task (212). Thus, several studies in 
mice and humans suggest the possibility that histamine receptor blockade could affect 
muscle glucose uptake during exercise. However, in the present study, we found no 
differences in circulating blood glucose concentrations either during the steady state 
conditions or following the time-trial in response to histamine blockade. Of note, because 
glucose was sampled from the ear in this study, it served as an indicator of systemic 
concentrations and did not reflect uptake within the skeletal muscle. Thus, it may be that 
blood glucose is well maintained, but less is functionally available to the exercising 
muscle. If so, one would predict a greater reliance (and use) of muscle glycogen, as seen 
in mice (212).  
Overall, we note that performance in an endurance task is diminished, and we 
have identified several potential mechanisms that could explain why, but we were unable 
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to pinpoint a mechanism for the slower performance based on currently available 
information.  
 
Methodological considerations 
The open-circuit acetylene wash-in method produced reasonable and 
physiological estimates of cardiac outputs, as well as calculated values for stroke volume, 
total peripheral resistance, and systemic vascular conductance during the 120-min of 
Exercise. However, resting values are somewhat elevated and more variable than what is 
generally reported, and are suggestive of an anticipatory response to upcoming exercise. 
Although we took great care in performing this procedure, the variability in the measure 
indicates that these non-exercise values should be interpreted with caution.  
The 10-km distance for the time-trial for a number of reasons. First, as the 
duration of time to complete the task was approximately 15-20 min, it was of sufficient 
length to primarily challenge the aerobic system where muscle blood flow is an important 
performance determinant, but not so long as to introduce confounding influences on 
performance (i.e. dehydration, mental fatigue). Second, many cyclists have experience 
performing hard efforts of this duration, providing “real world” or ecological validity. 
Third, for comparison purpose, it is a common test in the human performance/exercise 
physiology literatures (127). Lastly, the 10-km time-trial using laboratory cycle 
ergometry has been shown to be highly reproducible with a low day-to-day coefficient of 
variation (1-5%) in highly fit cyclists (120, 126, 127). Indeed, important to the 
interpretation of the findings was that the subjects displayed low day-to-day variability in 
their 10-km efforts from the familiarization trials. The volunteers in this study had a day-
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to-day variability in performance of 0.97%. This is similar to that reported in other 
studies examining highly fit competitive athletes (19, 120, 121, 126, 139, 228, 297). This 
is especially impressive given that the subjects were not given feedback on heart rate, 
power output, 1 km split time, or time-to-completion. The 0.97% CV was used as a zone 
of indifference for comparing changes between the placebo and blockade conditions, i.e., 
comparison of the slowing of time-to-completion from placebo to blockade compared to 
the day-to-day variation. The slowing of performance when in the Rest preceding 
condition was -0.87% (95% CI -2.02 to 0.29%) (Figure 12). In contrast, following a 120 
min period of cycling, the change in performance from placebo to blockade conditions 
was -1.2% with a 95% CI -2.45 to 0.05%. Based on the classification system set up by 
Batterham and Hopkins (19) and equivalence testing by Piaggio (238), the slowing of 
performance from the blockade is “possibly trivial” (ES = 0.505) following a period of 
rest and “likely harmful” following the exercise bout (ES = 0.646) (Figure 12).  
 
Importance 
This study demonstrates the importance of histamine in endurance exercise. This 
discovery of histamine, commonly associated with immune and inflammatory responses, 
as being intimately involved with endurance exercise, may open up new avenues of 
research as the field of physiology attempts to account for the beneficial effects of 
exercise beyond the improvement of traditional risk factors (205). Additionally, these 
findings have implications for competitive athletes, as the difference between a gold and 
silver medal can be a mere 0.52%, while a fourth place finish may trail as little as 2% 
behind the winning time (225). In an effort to capture the valuable seconds that determine 
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athletic victories, competitive athletes are continuously optimizing training methods and 
exploring legal ergogenic aids. For example, endurance athletes partake in altitude 
training, carbohydrate supplementation, and caffeine ingestion which have been 
demonstrated to improve performance ~2%, 2-3%, and up to 5% respectively (91, 140). 
However, competitive athletics has largely ignored the potential for antihistamines 
(potential ergolytic drug), commonly used to treat allergies and acid reflux, to hinder 
performance. The volunteers in the current study received a one-time dose of 
antihistamines prior to exercise and were asymptomatic for allergies and gastrointestinal 
reflux; therefore, the current findings may not apply to symptomatic athletes or those 
taking daily antihistamine medications.  But, this question is of particular relevance to 
endurance athletes, as they are more likely to be diagnosed with allergies and/or allergic 
rhinitis than the general population (2), are five-times more likely to use allergy 
medication than non-athletes (1), and are two-times more likely to use oral antihistamines 
than sprint athletes or the general population (2). Additionally, oral antihistamines are 
frequently used by marathon and ultramarathon runners to treat gastrointestinal reflux 
and ulcers (196). The present study suggests that histamine plays an important role during 
endurance exercise. Furthermore, when this role is disturbed, it may have detrimental 
effects for competitive athletes chasing narrow margins of victory.  
 
Conclusion 
In conclusion, blocking histamine’s actions had a “possibly trivial” effect” on 10-
km time-trial performance following a period of rest and a “likely harmful” effect 
following 120 min of cycling. These findings corroborate prior observations in mice 
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regarding the effect of antihistamines on endurance exercise, and expand the work in 
humans beyond the scope of earlier studies that focused on short-duration high-intensity 
tasks.  
The results from the experiment performed in Chapter IV entitled “Histamine-
Receptor Antagonists slow 10-km cycling performance in competitive cyclists” suggests 
that exercise-induced skeletal muscle elevations in histamine concentrations serve an 
important purpose in the endurance exercise response.  This study measured multiple 
systemic hemodynamic and metabolic variables and only detected a difference in heart 
rate between Placebo and Blockade conditions. Given that histamine is produced within 
the active skeletal muscle, it likely exerts local effects that are buffered by other 
pathways so systemic processes are not disturbed.  The study outlined in Chapter V will 
further investigate the potential role exercise-induced increases in skeletal muscle 
histamine and histaminergic signaling at the muscle to influence the leg blood flow and 
the exercise response.  
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CHAPTER V 
 
EFFECT OF HISTAMINE RECEPTOR-ANTAGONISTS ON LEG 
BLOOD FLOW DURING EXERCISE 
 
 This study was completed in conjunction with Dr. Stephen Ratchford, Dr. Heather 
Clifton, Taylor La Salle, Dr. Joel Trinity, and Dr. Walter Wray of the Department of 
Exercise and Sport Science of the University of Utah. Dr. John Halliwill, Dr. Joel Trinity, 
and Dr. Walter Wray assisted in the intellectual development of the protocol.  All 
individuals contributed to the data collection process. Dr. Halliwill assisted in the data 
analysis. 
 
INTRODUCTION 
Histamine, an important component of immune and inflammatory responses, is 
released and produced within the affected tissue to increase blood flow by its 
vasodilatory actions on arterioles and capillaries (22, 176–178, 271, 273, 290). Beyond 
immune and inflammatory responses, endogenously produced histamine is associated 
with increased skin blood flow during heat stress (325), with elevated limb blood flow in 
reactive hyperemia (9, 10, 243), with elevated limb blood flow during sustained post-
exercise vasodilation (187, 188), and with increased tissue blood flow during tumor 
growth (226). In all these situations, histamine receptor antagonists have attenuated the 
elevations in blood flow (58, 69, 70, 80, 226, 243, 266, 321, 325). Recent evidence shows 
that histamine concentrations increase within the skeletal muscle interstitial fluid during 
exercise (197, 255), however, no known study has explored the role of histamine in 
contributing to the rise of exercising skeletal muscle blood flow. 
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Histaminergic contribution to exercise hyperemia may be dependent on the 
duration or intensity of muscle contractions. The duration of repeated muscle contractions 
may be an important aspect of histamines influence on blood flow as the enzymatic 
activity of histidine decarboxylase, the enzyme which produces histamine, appears to be 
positively correlated with exercise duration (14, 212). Along these lines, blocking of 
histaminergic signaling did not affect the performance outcomes of exercises that lasted 
seconds (single muscle contractions) to few minutes in duration (194, 195) and instead 
appear to decrease the ability to perform tasks that are 15 minutes to hours long in 
duration (Chapter IV (212, 328)). The tests that were of short duration were of maximal 
exercise intensity and relied primarily on anaerobic metabolic pathways while those that 
were of longer duration were performed at sub-maximal intensities. Sub-maximal 
intensity exercises require adequate skeletal muscle blood flow for nutrient delivery and 
metabolite removal, which is integral in staving off many factors implicated in fatigue 
(e.g. hydrogen ion build up, reduced oxygen delivery, intramuscular glycogen depletion) 
and maintaining exercise output. It is possible that skeletal muscle histaminergic 
pathways are a link in the normal rise in skeletal muscle blood flow to maintain nutrient 
delivery and metabolite removal during repeated contractions typical of endurance 
exercises.  
Therefore, the purpose of this experiment was to examine histamine’s influence in 
the regulation of skeletal muscle blood flow during exercise. As histamine’s contribution 
to hyperemia may be exercise intensity and/or duration dependent, limb blood flow was 
quantified at multiple intensities before and after an extended bout of exercise. 
Specifically, femoral blood flow was measured in subjects who performed knee-
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extension exercise at 20, 40, 60, and 80% of peak power output before and after 60 min 
of knee-extension exercise at 60% of peak power in a condition where histamine’s effect 
on the H1 and H2 receptors were blocked and in a placebo-controlled condition. Prior to 
the study, it was hypothesized that blocking histamine’s actions would decrease femoral 
artery muscle blood flow at high exercise intensities and the effect would be greater 
following a bout of endurance exercise.  
 
METHODS 
Subjects 
This study was approved by the Institutional Review Board of the University of 
Utah and the Salt Lake City Veterans Affairs Medical Center. Each volunteer gave 
written and informed consent prior to participation and the study conformed to the 
principles of the Declaration of Helsinki. No subjects were using over-the-counter or 
prescription medications at the time of the study, with the exception of oral 
contraceptives. Female participants were studied during the early follicular phase of their 
menstrual cycle or during the placebo phase of their oral contraceptive to minimize any 
potential cardiovascular effects of sex-specific hormones. All testing was performed in a 
temperate environment (21-23°C, 13-46% rh) at the Veterans Affairs Salt Lake City 
Geriatric, Research, Education, and Clinical Center in the Utah Vascular Research 
Laboratory (altitude ~1400 m).  
Screening visit 
An initial screening visit was completed to expose the subjects to all testing 
procedures and to obtain demographic and anthropometric information (age, height, 
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weight). Subjects also completed a unilateral knee-extension test to determine peak 
power output.  
Experimental design 
This study consisted of two double-blind placebo-controlled testing visits. 
Subjects performed experiments after a 4 h fast and abstaining from caffeine, alcohol, 
and strenuous exercise for 24 hours. 
Testing Visits 
 Subjects completed two testing visits that were performed at least 7 days apart 
and at the same time of day to reduce the potential for circadian rhythms to influence 
skeletal muscle blood flow (34). Initially, 60 min before the start of unilateral knee-
extension exercise, subjects ingested either placebo pills (Placebo) or combined H1 and 
H2 histamine receptor antagonists pills (Blockade) with approximately 90 ml of water. 
Subjects were then seated on the ergometer for the remainder of the visit. After 60 
minutes of seated rest baseline measures of femoral blood flow, blood pressure, heart 
rate, cardiac output, oxygen consumption (VO2), muscle pH, muscle oxygenation index, 
and a rating of perceived exertion were measured. 
Absolute femoral blood flow values as well as the rate of rise in blood flow was 
measured at 20, 40, 60, and 80% of single-leg knee-extension peak power.  Femoral 
blood flow was then measured every 10 min during 60 min of steady state exercise at 
60% their individual peak power. Following the steady state exercise, femoral blood flow 
was again measured at 20, 40, 60, and 80% of single-leg knee-extension peak power. 
Exercise was held at each exercise intensity for 5 min and blood flow was recorded in the 
final 1-2 minutes. Each increase in workload (20, 40, 60, 80%) was separated by 2 min of 
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seated resting recovery (Figure 13). A 20 min seated rest period was provided before and 
following the steady state exercise. Additionally, blood pressure, cardiac output, VO2, 
muscle pH, and muscle oxygen saturation were measured with each increase in exercise 
intensity and VO2, muscle pH, and muscle oxygenation index were measured for 3 min at 
10, 30, and 50 min during the steady state exercise (Figure 13).  
 
 
Figure 13. Study time line. After ingestion of Placebo or Blockade (Rx), volunteers 
performed three phases of exercise. Phase 1 and 3 included 3 min of knee-extension at a 
rate of 60 contractions per min at 20, 40, 60 and 80% of peak power. Phase 2 consisted of 
60 min of knee-extension at a rate of 60 contractions per min at 60 % of peak power. 
Each phase was separated by 20 minutes of seated rest. Each arrow () represents a time 
point where blood flow, blood pressure, heart rate, cardiac output, VO2, muscle 
oxygenation index, tissue pH, and perceived exertion were measured. 
 
Measurements 
Knee-extension peak test 
Subjects were seated on an adjustable chair with a cycle ergometer (Monark 
828E, Vansbro, Sweden) positioned behind the chair. Resistance was created with a 
friction driven flywheel turned upon knee extension via a metal bar connected between a 
crank arm of the bike and a boot worn by the subject. Resistance was increased 5 W 
every minute until the subject reached volitional fatigue. This peak test was performed 
for estimation of workload increments in testing visits 1 and 2.  
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Knee-extension exercise 
Subjects were seated in a semi-recumbent position on the same chair-monarch 
bike equipment interface as the peak test. Subjects exercised for 3 minutes at 20, 40, 60, 
and 80% of peak power and rested for 2 minutes between each workload. For steady state 
subjects exercised at 60% of peak power for 60 min. In all phases, subjects were required 
to maintain a leg extension rate of 60 per minute.  
Histamine H1- and H2-Receptor Blockade 
Oral administration of 540 mg of fexofenadine, a selective H1-receptor antagonist, 
reaches peak plasma concentrations within 1 h and has a 12 h half-life (262). Oral 
administration of 300 mg ranitidine, a selective H2-receptor antagonist, reaches peak 
plasma concentration within 2 h and has a 3 h half-life (93). This dosage of histamine-
receptor antagonists results in more than 90% inhibition of histamine H1 and H2 receptors 
lasting for 6 h after administration (93, 287). Fexofenadine and ranitidine are not thought 
to cross the blood-brain barrier or to have sedative effects (93, 264, 287). Importantly, it 
has been shown that histamine H1- and H2-receptor antagonism does not alter blood flow, 
heart rate, blood pressure, or smooth muscle tone at rest (78, 79, 187, 188, 254).  
Placebo 
The placebos were manufactured by the University of Utah pharmacy and 
contained the inactive ingredients of the fexofenadine and ranitidine tablets. 
 
Doppler Ultrasound 
Measurements of blood flow velocity and vessel diameter were measured from 
the common femoral artery in the exercising leg, 2-3 cm proximal of the bifurcation of 
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the superficial and deep branches of the femoral artery. Vessel diameter was determined 
at a perpendicular angle along the central axis of the scanned area, where the best spacial 
resolution was achieved. Velocity measurements were made at 5 MHz with a linear array 
transducer (Logiq e9, GE Medical Systems, Milwaukee, WI). Care was taken to avoid 
aliasing the blood velocity spectra by using scale adjustments, especially during exercise. 
All blood velocity measures were obtained with the probe appropriately positioned to 
maintain an insonation angle of 60˚ or less. The sample volume was maximized 
according to the vessel size and was centered within the vessel based on real-time 
ultrasound visualization. Femoral blood velocity was estimated using the commercially 
available software (Logic e9). Femoral blood flow (mL/min) was calculated by 
multiplying the mean blood velocity over 60 seconds by the cross sectional area of the 
common femoral artery during resting baseline measures. The common femoral artery 
diameter during rest was used in the calculation of exercise blood flow as earlier studies 
have indicated that there is a low coefficient of variation (CV ~1.5%) in repeated 
diameter measurements of the common femoral artery during systole and diastole, from 
rest to exercise, at increasing exercise intensities, and between multiple trial days (227, 
249, 275). 
𝐹𝑒𝑚𝑜𝑟𝑎𝑙 𝑏𝑙𝑜𝑜𝑑 𝑓𝑙𝑜𝑤 =  (
diameter
2
)
2
× 𝑚𝑒𝑎𝑛 𝑏𝑙𝑜𝑜𝑑 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 × 60, 
Heart Rate, Arterial Pressure, and Vascular Conductance 
Heart rate was monitored using a three-lead electrocardiogram and arterial 
pressure was measured on the left brachial artery using an automated auscultometric 
sphygmomanometer (Tango+, SunTech Medical, Raleigh, NC, USA). Mean arterial 
pressure was calculated as diastolic pressure plus 1/3 pulse pressure (systolic pressure - 
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diastolic pressure) and reported in mmHg. Leg vascular conductance was calculated as 
blood flow / mean arterial pressure and is expressed in ml·min-1·mmHg-1).  
Cardiac Output 
Cardiac output was estimated non-invasively via finger photoplethysmoraphy 
(Finometer, Finapres Medical Systems BV, Amsterdam, The Netherlands) recorded via a 
data acquisition device (Medwave Vasotrac APM250A; Biopac, Goleta, CA). The 
finapres provides accurate indirect assessment of intraarterial pressure (129). Beat-by-
beat arterial pressure waveforms are used to calculate stroke volume and in conjunction 
with heart rate as inputs in the “modelflow method” can then estimate cardiac output and 
provides reliable values for the changes in cardiac output with exercise (299).  This 
method has a high correlation coefficients (0.91-0.98) and low errors of ~2.0 L compared 
to echocardiography (299).  
Skeletal Muscle pH and Muscle Tissue Oxygenation Index 
Intramuscular microvascular blood pH and tissue oxygenation of the vastus 
lateralis muscle was estimated using near-infrared spectroscopy (Reflectance Medical 
Inc. Oximeter 1100, Westborough, MA). Near-infrared spectroscopy is commonly used 
to estimate capillary oxygen saturation in the muscle (180). Near-infrared spectra in the 
725-880 nm wavelength range are correlated with changes in hydrogen ion 
concentrations. This method of correlated spectra with changed in muscle pH has been 
validated against invasive intramuscular probes during exercise (293).  The sensor was 
placed 1/3 the distance between the knee joint and the greater trochanter and the sensor 
was held in place by a mounting pad that conformed to the shape of the thigh and 
prevented sensor movement on the skin during exercise. The sensor was further held in 
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place with black self-adherent wrap (Coban, 3M, Maplewood MN) that also limited 
ambient luminosity.  
Oxygen Uptake 
Whole-body oxygen uptake (VO2) and carbon dioxide production (VCO2) were 
measured during single-leg knee extension exercise using a mixing chamber system 
(TrueOne 2400, Parvo-Medics, Sandy UT). Respiratory exchange ratio was calculated as 
VCO2/VO2.  
Rating of Perceived Exertion 
A subjective rating of exertion was documented on a 1-10 scale at during the last 
minute of each exercise intensity, as well as at 10, 30, and 50 minutes into steady state 
exercise (31).  
Statistical Analysis 
Statistical inferences were drawn from a combination of paired t-tests and 2 or 3-
way repeated measures ANOVAs with a priori contrasts. Models were run using SAS 
Proc GLMSELECT (Proc MIXED, SAS version 9.2; SAS Institute. Cary, NC, USA). For 
all tests, significance was set at P < 0.05. All data are presented as means ± SEM, except 
for data characterizing the subjects, which are presented as means ± SD. (Table 1).  
 
RESULTS 
Subject characteristics 
Sixteen (7 female, 9 male) healthy, non-smoking individuals volunteered for the 
present study. Subject’s demographic and anthropometric characteristics obtained from 
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the screening visit including age, height, weight, body mass index, knee-extension peak 
power, and 60% workload are presented in Table 10. 
Table 10. Subject Characteristics 
N 16 (7F, 9M) 
Age (years) 25 ± 5 
Height (cm) 174.9 ± 8.1 
Weight (kg) 73. 9 ± 12.7 
Body Mass Index 24.1 ± 3.3 
Knee Extension Peak Power (Watts) 50 ± 10 
60% Workload (Watts) 30 ± 5 
Values are means ± SD.  
 
 
 
 
Two subjects were excluded from blood flow and femoral vascular conductance 
analysis due to large differences (0.07 and 0.08 cm) in resting femoral artery diameter in 
the Placebo and Blockade trials. For comparison, there was a range from 0.00 to 0.02 cm 
in femoral artery diameter for subjects that were included in the analysis. Therefore, 14 
subjects were used in the analysis as we could be confident in that blood velocities were 
being recorded at similar positions of the common femoral artery. 
 
Ramped Exercise Response Pre- and Post- Steady State 
Subject’s workload increased from 10 ± 2, 20 ± 4, 29 ± 6, to 39 ± 9 Watts (Mean 
± SD) for the 20, 40, 60, and 80% workloads. As expected heart rate, mean arterial 
pressure, femoral blood flow, and femoral vascular conductance increased with 
increasing workloads while muscle tissue oxygenation and intramuscular pH decreased 
with increasing workloads (P < 0.05)(Figure 14). Cardiac output increased from rest 
(5.73 ± 0.22 L/min) through each increase in workload (20% 7.57 ± 0.28, 40% 8.00 ± 
0.34, 60% 8.87 ± 0.32, 80% 9.26 ± 0.32 L/min; P < 0.05).  
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Femoral vascular conductance, muscle tissue oxygenation, and intramuscular pH were 
higher in POST compared to PRE (P < 0.05). Blockade resulted in an elevated femoral 
blood flow at all exercise intensities in both PRE and POST compared to Placebo 
(P<0.05). Blood flow was elevated 6.4 ± 5.2, 10.6 ± 5.8, 15.3 ± 5.2, and 9.1 ± 4.8% at 20, 
40, 60, and 80% of peak force, respectively, with Blockade compared to Placebo. In 
addition, Blockade resulted in a lower intramuscular pH in both PRE and POST 
compared to Placebo (P < 0.05). Blockade had no effect on heart rate, mean arterial 
pressure, cardiac output, femoral vascular conductance, or tissue oxygenation compared 
to placebo (Figure 14).  
There was an increase in VO2, ventilation, respiratory exchange ratio, and rating 
of perceived exertion with increased workloads (P < 0.05). Respiratory exchange ratio 
and perceived exertion were elevated during POST compared to PRE (P < 0.05) but there 
was no effect of Blockade compared to Placebo (Figure 15).  
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Figure 14. Hemodynamic measures, muscle tissue oxygenation, and muscle pH 
during pre-steady state (PRE) and post-steady state (POST) conditions. * = P < 0.05 
Exercise vs Resting at specified power outputs; a = P < 0.05 Main effect for POST vs 
PRE; b = P < 0.05 Main effect for Blockade vs Placebo. 
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Figure 15. Metabolic measures during pre-steady state (PRE) and post-steady state 
(POST) conditions. * = P < 0.05 Exercise vs Resting at specified power outputs; a = P < 
0.05 Main effect for POST vs PRE. 
 
Steady State 
Subjects maintained 29 ± 2 watts (mean±SD) for the full 60 minutes of steady 
state knee extension exercise. Heart rate, mean arterial pressure, muscle tissue 
oxygenation, and intramuscular pH were stable throughout the 60 min and were not 
different between Blockade and Placebo conditions (Figure 16). Femoral blood flow and 
femoral vascular conductance did not change over the 60 minutes of steady state exercise 
but femoral blood flow (12.7± 2.8%) and vascular conductance (16.2 ± 3.5%) were 
greater in Blockade compared to placebo (P < 0.05, Figure 16).  
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Figure 16. Hemodynamic measures, muscle tissue oxygenation, and muscle pH 
during 60 min of steady state exercise. b = P < 0.05 Main effect for Blockade vs 
Placebo. 
 
Oxygen consumption and ventilation were stable throughout the 60 minutes and 
were not different between Placebo and Blockade. Respiratory exchange ratio decreased 
throughout the 60 minutes of exercise (P<0.05) and this change was similar between 
Placebo and Blockade (P > 0.05). Rating of perceived exertion increased through the 60 
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minutes of exercise (P < 0.05) and the increase was similar for Placebo and Blockade (P 
> 0.05; Figure 17).  
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Figure 17. Metabolic measures during 60 min of steady state exercise. * = P < 0.05 
Exercise vs Resting at specified power outputs. 
 
DISCUSSION 
The main finding of the present study was that blocking histamine’s actions 
during exercise resulted in an elevation of skeletal muscle blood flow during exercise. 
The elevated skeletal muscle blood flow occurred acutely with increasing exercise 
intensities, during an extended steady state exercise bout, and again with increasing 
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exercise intensities after the extended exercise bout. These findings are opposite of the 
proposed hypotheses, that exercise induced elevations in skeletal muscle histamine 
concentrations aid in the exercise hyperemic response, and are counter to the current 
understanding of histamine’s actions in non-exercise situations.  
 
Legs blood flow during increasing exercise intensities 
It is well documented that femoral blood flow increases linearly with intensity 
during single leg knee-extension exercise (17, 33, 96, 249, 324). Similar to previous 
investigations, the present results show within the Placebo condition, that exercise blood 
flow increased linearly with increasing exercise intensities from 20 to 80% of single-leg 
knee extension peak power (Figure 14). The elevation in blood flow occurred 
concomitantly with linear increases in heart rate, mean arterial pressure, femoral vascular 
conductance, oxygen consumption, ventilation, respiratory exchange ratio, and perceived 
exertion while muscle oxygenation index and pH decreased (P < 0.05; Figure 14 and 
Figure 15).  
 
Leg blood flow during steady state exercise 
To our knowledge, this is the first study that has examined femoral blood flow 
during steady state exercise longer than 25 min in duration. Most examinations of 
femoral blood flow are at fixed workloads for 3 to 10 min in duration and involve short 
rest periods before elevating the work load or administering an intervention (4, 5, 17, 33, 
63, 96, 250) and therefore do not assess the constancy of blood flow over extended 
exercise bouts. In only two known instances has femoral blood flow been examined over 
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a prolonged exercise bout and these were time-controls that were incorporated into larger 
intervention studies. The time-controls were 25 min in duration at 19 Watts in five 
individuals (275) and 60 min in duration at 20W in two individuals (249). These two 
time-controls documented low coefficients of variation (CV ~9 to 14%) in blood flow 
over multiple time points (249, 275).  
In the present study, absolute blood flow values during the 60 min of steady state 
exercise at 60% of peak were similar to those obtained during 60% of peak in the acute 
exercise (Figure 14) and were maintained throughout steady state (Figure 16). Associated 
with the maintained blood flow were constant heart rates, mean arterial pressure, tissue 
oxygen consumption, intramuscular pH, VO2, and ventilator rates (Figure 16, 17). As 
exercise progressed, the respiratory exchange ratio decreased and perceived exertion 
increased (Figure 17).   
 
Leg blood flow during  increasing exercise intensities after prolonged steady state 
exercise 
 Elevations in femoral blood flow from increases in exercise intensity are nearly 
identical before compared to after 120 min of sedentary rest (17, 324). In comparison, 
femoral blood flow after a short exercise shows a faster rise at exercise onset (128) and 
time to reach steady state (88). This suggests that local vasodilators may still be present 
within the exercising skeletal muscle from preceding exercise that may aid in the 
subsequent exercise hyperemic response, but no known study has examined femoral 
blood flow using increases in exercise intensity following a prolonged exercise bout. The 
closest example identified was by Paterson et al. in 2005 (227) where similar elevations 
in femoral blood flow were noted during single-leg knee extension exercises that were 
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alternating 6 min of exercise at 80% of peak power and 6 min of exercise with no 
resistance for a total of 24 min. 
The current study results suggest that after the steady state exercise (POST) blood 
flow increased linearly from 20 to 80% of peak power and the absolute blood flows and 
the rate of rise was not different from PRE (Figure 14). Blood flow and systemic arterial 
pressure were not different PRE to POST steady state but there was a significant rise in 
leg vascular conductance PRE to POST steady state (Figure 14), this indicates that there 
is either a reduced vasorestrictor or increased vasodilator influence on the leg vasculature 
resulting from the extended exercise. A maintained arterial pressure indicates that there 
must have been a decreased conductance in another vascular bed to offset the increased 
conductance in the leg at each exercise intensity.  There was also an attenuated drop in 
intramuscular pH with increasing exercise intensities PRE to POST steady state (P<0.05) 
which may be associated with the increased blood flow (increased nutrient delivery and 
metabolite removal).  
 
Skeletal muscle histamine and its hypothesized influence on exercise hyperemia 
In 1945 Anrep (10) suggested that histamine may mediate exercise hyperemia as 
histamine concentrations were noted to rise in exercising muscles in humans.  Histamine 
concentrations increase within the muscle from mast cell degranulation and increased 
production from HDC (255). The stimuli to cause the degranulation and increase 
production are unknown but in situ and in vitro studies have shown stimuli associated 
with exercise such as hypoxia (138), increased temperature (267, 271), vibration, 
hyperosmolality (190), and decreased pH (267) all act individually to increase histamine 
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release or production. It would be assumed that as exercise intensity and duration 
increased, that the positive allosteric influences of these factors would lead to increased 
skeletal muscle histamine concentrations. In fact microdialysis examination of 
intramuscular histamine concentrations show a 3-4 fold increase with 60 min of activity 
(255). T hese studies indicate that multiple exercise related pathways may contribute to 
the rise of histamine and suggest that it is an important part of the skeletal muscle 
response to endurance or prolonged exercise. Although, the physiological actions of 
histamine during exercise are unknown.  
Based on the vasodilatory actions of histamine in inflammatory and immune 
responses, following tissue damage, in reactive hyperemia, and during sustained post-
exercise vasodilation (58, 69, 70, 80, 177, 178, 187, 188, 226, 266, 271, 273, 290, 321) it 
was hypothesized that exercise associated increases in intramuscular histamine would aid 
in exercise hyperemia. It was also hypothesized that histaminergic vasodilation would 
increase with exercise intensity and duration based on 1) exercise hyperemia is governed 
primarily by mechanical factors at light workloads while vasodilator substances are more 
important for increasing blood flow at higher intensities (250, 284), 2) vasodilatory 
substances, such as prostaglandins and histamine, increase with exercise intensity (11, 33, 
324) and 3) a positive correlation between  exercise duration and histidine decarboxylase 
mRNA transcription and enzymatic activity (14, 82, 212, 254).  
 
Effect of blocking histaminergic signaling on leg blood flow  
Contrary to the hypotheses, blocking histamine did not result in a reduced femoral 
blood flow at any exercise intensity or duration. Blocking histamine’s actions resulted in 
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an increased blood flow response that was similar in magnitude from 20 to 80% of peak 
power output (P < 0.05; Figure 14). The elevated blood flow remained during the steady 
state exercise (Figure 16), and was not further exacerbated at multiple exercise intensities 
following the steady state exercise (Figure 14) (P<0.05). The elevation of blood flow 
occurred without any noticeable change in heart rate, mean arterial pressure,, oxygen 
consumption, ventilation, respiratory exchange ratio, or perceived exertion between 
Placebo and Blockade conditions (P>0.05;Figure 14, 15). Similarly, other studies found 
no discernable effect of  histamine receptor antagonists on heart rate, mean arterial 
pressure, or ventilation during submaximal prolonged exercise compared to Placebo. 
(194, 195, 236) 
 
Microcirculation  
 
Associated with the increased blood flow was a statistically significant reduction 
in intramuscular pH (P<0.05, Figure 14). Histamine is an intrinsic regulator of the 
microvasculature. Histamine initiates the contraction of endothelial and pericyte cells on 
the venule side of the capillary, widening intercellular gaps, resulting in increased 
capillary permeability (41, 42, 101, 155, 270). It is postulated that the rise in skeletal 
muscle histamine concentration is determined by the tissues need for blood to maintain 
circulatory homeostasis (270). In the present study, Blockade resulted in a progressively 
lower pH as exercise intensity increased (Figure 14). It is possible that Blockade altered 
the permeability of the capillaries and reduced hydrogen ion transport/diffusion out of the 
tissue resulting in the lowered tissue pH (Figure 14). Alternatively, blocking histamine 
may have altered skeletal muscle metabolism and shifted the balance of ATP production 
toward glycolysis resulting in elevated hydrogen ion production, but we are unaware of 
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any studies suggesting histamine’s influence of shifting cellular metabolism. Future 
studies combining femoral blood flow (Doppler) and capillary permeability (NIRS+ICG, 
labeled albumin, and/or magnetic resonance spectroscopy) may be necessary to link the 
histaminergic pathway with skeletal muscle blood flow and permeability of the capillary 
during exercise. 
 
Importance 
 
During exercise, skeletal muscle arterioles dilate and blood flow rises in 
proportion to the metabolic demands of the tissue (145). The vasodilation occurs 
primarily through a modulation of neural vasoconstrictor and locally derived vasodilators 
released by or near the active musculature (145).  The primary mediator leading to 
vasodilation is unknown and the current thinking is that there is a redundancy in their 
formation and synergy in their actions. As evidence, blocking the actions of one (324), 
two (33, 275), or even three (198) of these known vasodilators have produced negligible, 
if any reductions in skeletal muscle blood flow during acute exercise (<10 min duration) 
in healthy individuals. The majority of studies have investigated the influence of 
vasodilators on exercise hyperemia at the start of exercise (33, 63, 96, 250) but the factors 
regulating steady state exercise blood flow may be different from those initiating exercise 
hyperemia (283). It is in this context that the examination of histamine was important as 
very few studies have examined the role of vasodilators during prolonged steady state leg 
exercise in humans (275).  
The current study results are important because if histamine plays minor role in 
blood flow during exercise this pathway would have profound effects on individuals with 
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blood flow impairment such as heart failure or peripheral vascular disease. The 
administration of “antihistamines” in these individuals may alter blood flow or perfusion 
responses and impair intramuscular homeostasis and exercise capacity.  
 
Conclusions 
Blocking the actions of histamine, a molecule often associated with inflammatory 
and immune responses, resulted in an increased skeletal muscle blood flow during 
exercise. The elevated blood flow occurred over exercise intensities ranging from 20-
80% of peak force and in exercise of 60 minutes in duration. These results suggest that 
exercise-induced elevations in histamine concentrations are involved in the exercise 
response.  
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CHAPTER VII 
 
HISTAMINE RECEPTOR-ANTAGONISTS DO NOT ALTER THE 
SYSTEMIC INFLAMMATORY RESPONSE OR RECOVERY FROM 
MUSCLE-DAMAGING EXERCISE 
  
This study could not have been completed without the contributions of Karen W. 
Needham, Jonathan K. Ivankovic, Brendan W. Kaiser, Dylan C. Sieck, Joshua E. 
Mangum, Emily A. Larson, and John Halliwill.  Karen provided assistance with the blood 
processing, leukocyte isolation and quantification, and the multi-analyte flow assays. Jon 
assisted with subject visits and data recording. Brendan, Dylan, Josh, and Emily provided 
much needed assistance on all the data collection sessions. John R. Halliwill assisted in 
the intellectual development project. I was involved with all aspects of this project 
including the development of the protocol, completed all data collection, compiled the 
data, analysis of the data, and developed the manuscript.   
 
INTRODUCTION 
 
Following high-intensity exercise, prolonged endurance exercise, or muscle 
damaging exercise there is an increase in the number of circulating white blood cells 
(leukocytosis) (39, 51, 111, 210, 230, 280). Exercise also leads to a transient increase in 
cytokines that are believed to originate from within the contracting skeletal muscle (185, 
232). The combination of increased leukocytes and chemokines create a pro-
inflammatory state with a primary purpose to repair damaged tissue and regenerate 
muscle (174, 231, 289, 307–309). The place of origin of the acute rise in circulating 
leukocytes is unknown (280) but the cells enter the previously active skeletal muscle in 
the hours to days after exercise cessation (39, 66, 173, 231). Although the skeletal muscle 
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leukocytes aid in muscle repair and remodeling, many aspects in the regulation of muscle 
repair are unclear and involve unknown molecules (231).    
Histamine is a molecule that is released and produced within the contracting 
skeletal muscle from mast cell degranulation and de novo production from the enzyme 
histidine decarboxylase (255). Following exercise, histamine mediates a dilation of 
resistance arterioles within the previously active muscle (187, 188, 255). The dilation 
results in an elevation of local blood flow that can last upward of 120 min (187, 188). 
The purpose of the histamine-mediated increase in post-exercise blood flow could be part 
of a post-exercise inflammatory response to deliver the circulating leukocytes to the 
muscle tissue.  
Outside of excise, histamine plays a major role in the inflammatory response. In 
the area surrounding tissue damage, there is a high concentration of histamine (177). The 
histamine initiates the margination of capillary endothelial and pericyte cells to increase 
permeability (22) and permits neutrophil and macrophage infiltration into damaged 
tissues. Histamine is also associated with the expression of adhesion molecules on 
endothelial cells, acts directly and indirectly in the production of cytokines/chemokines, 
and aids in chemotaxis (22, 146, 224). Interestingly, mice bred without histidine 
decarboxylase or treated with H1 receptor antagonists display reduced macrophage 
infiltration and have extended skin wound healing times (166, 214, 221).  
 Exercise resulting in muscle damage can provide a model to study histamine’s 
association with exercise related inflammation and recovery. Following muscle damage 
induced by eccentric contractions, there are disruption of sarcomeres and reduced actin 
and myosin overlap.  These disruptions affect the ability to generate force (231). The 
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change in muscle force is an indicator of the extent of tissue damage and the recovery of 
force signals repair to the tissue (231). The decrease in muscle force may not be limited 
to peripheral factors such as actin and myosin overlap but may also be caused by central 
factors including motor unit recruitment. Sensations of muscle pain/discomfort by 
activation of Groups III/IV afferent nerves following muscle damage decrease motor unit 
recruitment (151, 285). These afferent neurons can be directly stimulated by histamine, 
and histamine may alter two neurotrophic factors that are involved with longer term 
sensitization and activity of these fibers  (78, 181, 237, 279, 298, 318, 327). Monitoring 
muscle pain/discomfort will also be an indication of histamine’s role in the recovery from 
exercise-induced muscle damage.  
 Therefore, the purpose of this study was to gain insight into histamine’s role in 
the exercise inflammatory response and recovery of muscle function from muscle-
damaging exercise. Specifically, human subjects performed unilateral knee-extension 
eccentric contractions to induce muscle damage. Circulating leukocytes and cytokines as 
well as muscle strength were measured periodically for 72 hours after exercise. Subjects 
performed the tests in a condition where histamine’s effects on H1 and H2 receptors were 
blocked and in a placebo condition. It was hypothesized that H1/H2 receptor antagonism 
would result in an extended duration of elevated circulating leukocytes, a reduced 
expression of inflammatory cytokines, and delated recovery of muscle strength.  
 
METHODS 
 
Subjects 
 
This study was approved by the Institutional Review Board of the University of 
the University of Oregon. Each volunteer gave written and informed consent prior to 
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participation and the study conformed to the principles of the Declaration of Helsinki. 
Twelve healthy volunteers (3 female, 9 male) completed the study and were considered 
sedentary or recreationally active based on exercise habits over the previous 12 mo (157). 
No subjects were using over-the-counter or prescription medications at the time of the 
study, with the exception of oral contraceptives. Female participants were studied during 
the early follicular phase of their menstrual cycle or during the placebo phase of their oral 
contraceptive to minimize any potential effects of sex-specific hormones on muscle 
damage and immune responses. Demographic and anthropometric information (age, 
height, weight) including measurement of 3-site skin-fold body-fat estimate (triceps, 
supra-iliac, and mid-thigh for females; chest, abdominal, mid-thigh for males) were made 
prior to the initial study day. All volunteers were required to abstain from caffeine, 
alcohol, and exercise for 24-hr before and for the duration of each observational period. 
 
Experimental Design 
 
The study consisted of two double-blind placebo-controlled testing and 
observation segments that were of 72-h in duration (Figure 18). To avoid possible cross 
limb (e.g. left to right leg) adaptations that protect muscle from damage/soreness 
resulting from eccentric contractions, cross-over trials were separated by at least 30 days. 
A food diary was provided to the subjects prior to the first testing visit. The food diary 
encompassed the 24-h prior to the initial exercise as well as the 72-hr observation period 
after exercise. Participants reported to the laboratory at 0700 after an overnight fast. After 
a confirmed negative pregnancy test for women, subjects were block randomized into one 
of four different testing orders (Table 11) which alternated both the leg to be exercised 
(left or right) as well as drug (placebo or histamine H1 and H2 receptor antagonists 
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(Blockade)) conditions (Table 11). Prior to the second segment of the study, subjects 
were provided with their food diary from the first segment and asked to mimic food 
intake (timing, type, and quantity) as close as possible in order to control potential 
influences of carbohydrate intake on the inflammatory state or protein intake on skeletal 
muscle remodeling (65). 
 
Table 11. Order of testing visits 
 Segment 1 Segment 2  
Testing visit Leg Drug Leg Drug n 
Order A Right Placebo Left Blockade 3 
Order B Left Blockade Right Placebo 3 
Order C Right Blockade Left Placebo 3 
Order D Left Placebo Right Blockade 3 
n = number of subjects per order 
 
 
 
 
 
Figure 18. Study time line. The 72-hr study and observational period was conducted 
twice after the subject consumed either Placebo or Blockade (Rx). Each blood drop () 
indicates a time point at which venous blood was sampled.  The lightning bolt represents 
a time in which a visual analog scale and algometry were used to asses muscle 
pain/discomfort. The arrow () represents a time in which muscle strength was assessed.   
 
Following an initial blood draw and assessment of muscle pain/discomfort, 
subjects  
consumed the Placebo or Blockade pills orally with ~6 oz of water and sat in a padded 
phlebotomy chair for 60-min. Next measurements of muscle strength (MVC) and 
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voluntary activation (interpolated twitch) were taken. Then subjects performed 300 
eccentric contractions of the leg extensors followed another assessment of muscle 
strength, muscle pain/discomfort, and a post-exercise blood draw.  Subjects then went 
about their regular day but came back to the lab at 6, 12, 24, 48, and 72-hrs after the 
completion of exercise for assessment of muscle strength, pain/discomfort, and to provide 
a venous blood sample (Figure 18).    
 
 
Histamine H1- and H2-Receptor Blockade 
 
Oral administration of 540 mg of fexofenadine, a selective H1-receptor antagonist, 
reaches peak plasma concentrations within 1-h and has a 12-h half-life (262). Oral 
administration of 300 mg ranitidine, a selective H2-receptor antagonist, reaches peak 
plasma concentration within 2-h and has a 3-h half-life (93). This dosage of histamine-
receptor antagonists results in more than 90% inhibition of histamine H1 and H2 receptors 
lasting for 6-h after administration (93, 287). Fexofenadine and ranitidine are not thought 
to cross the blood-brain barrier or to have sedative effects (93, 264, 287). Importantly, it 
has been shown that histamine H1- and H2-receptor antagonism does not alter blood flow, 
heart rate, blood pressure, or smooth muscle tone at rest (78, 79, 187, 188, 254).  
Placebo 
 The placebos were manufactured by a compounding pharmacy (Creative 
Compounds, Wilsonville, OR) and contained the inactive ingredients of the fexofenadine 
and ranitidine tablets. 
 
Eccentric Contractions 
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Subjects performed 300 eccentric contractions of the quadriceps on a resistance 
dynamometer (Biodex, System 3, Shirley, NY). The 300 knee-extensions were divided 
into 10 sets of 30 repetitions with a 60-s rest period in between each set. Subjects sat with 
their back supported, pelvis strapped into the seat, and the resistance pad was placed at 
75% of the length of the shank. The knee joint moved through a 75° range from a joint 
angle of 20° to 85° of knee flexion. The angular velocity was set to 60°·s-1 for set 1 and 
110°·s-1 for set 2 through 10. The resistance force of the dynamometer was set at 140% of 
each subject’s maximal isometric force measured at a joint angle of 30° of flexion. 
Subjects were instructed to resist knee flexion as best as they could. Their leg was then 
moved passively by the dynamometer back into the extended position. This protocol is 
modeled after Newham et al. and MacIntyre et al. (173, 207) in which 300 eccentric 
contractions of the quadricep muscles induced a moderate level of muscle damage and 
caused a local inflammatory response. The whole protocol was approximately 40-min in 
duration. 
Measurements 
 
Blood Sampling 
Venous blood (9 ml) was collected from a superficial vein in the antecubital space 
into three 3-ml Vacutainers (BD Vacutainer, Becton, Dickinson and Company, Franklin 
Lakes NJ, USA) for collection plasma (K2 EDTA anticoagulant).  Blood was then 
aliquoted for separation and quantification of white blood cell populations via flow 
cytometry (Gallios, Beckman Coulter Life Sciences, Indianapolis IN, USA) using the 
manufactures data acquisition software (Kaluza, Beckman Coulter Life Sciences, 
Indianapolis IN, USA). Separate aliquots were centrifuged at 1,275 RCF (Marathon 
3200R, Fisher Scientific, Pittsburg PA) and stored in Cryovials at -80˚C until analysis. 
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Plasma was analyzed for creatine kinase using an activity assay (Sigma-Aldrich, St. 
Louis MO, USA). Plasma was also analyzed for inflammatory cytokines via a bead based 
flow cytometry kit (Biolegend, LEGENDplex Human Inflammation Panel 1, multi-
analyte flow assay kit). This method of cytokine identification uses beads of varying size 
coated with antigens specific to cytokines of interest (IL-1B, INFα2, IFN-γ, TNFα, MCP-
1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33). The size and 
fluorescence of the beads allows for separation and quantification of the cytokine by flow 
cytometry (Gallios, Beckman Coulter Life Sciences, Indianapolis IN, USA). 
 
 
Knee extension strength testing 
 
Maximal voluntary isometric force of the knee extensors was determined using a 
resistance dynamometer (Biodex, System 3, Shirley, NY). The knee angle was set to 30˚ 
of knee extension and subjects performed three maximal knee extension contractions 
with 60-s rest between attempts. A single muscle, the vastus lateralis, was evaluated with 
an EMG (Motion Lab Systems Inc. Baton Rouge, LA) during the strength test. The EMG 
unit included a built-in amplifier and ground. The electrode was placed in parallel to the 
approximate axis of the muscle fibers at a distance approximately 25% of the distance 
between the anterior superior iliac spine and the Gerdy prominence (29) and was held in 
place with adhesive tape. The location of the electrode was marked with ink for 
placement of the electrodes on future evaluations. Following the three maximal 
contractions, three further maximal contractions with a superimposed stimulation of the 
femoral nerve (supramaximal stimulation) in combination with an evoked twitch at rest 
were performed (23, 26, 244, 248). The evoked twitch was performed approximately 7-s 
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after the maximal contraction. The evoked twitch and supramaximal stimulation were 
performed to parse out central versus peripheral factors related to the decrease in muscle 
strength experienced following muscle damaging exercise.  Activation of the quadriceps 
during the MVCs were assessed using a superimposed single twitch on the MVC and was 
compared with the force produced by the evoked twitch (3). 
 
Muscle pain and discomfort 
Subjects’ perceived muscle pain and discomfort were evaluated by means of a 
visual analog scale questionnaire. Subjects provided a subjective rating of their general 
muscle soreness by marking a single vertical line along a 100 mm continuous scale with 
descriptive anchors at 0 mm indicating “no pain/discomfort,” 50 mm “moderate 
pain/discomfort,” and 100 mm “worst pain/discomfort”. The distance from the left end (0 
mm) of the scale to the vertical mark allowed for quantification of the pain/discomfort 
level.  
Pain pressure threshold 
 
The minimum pressure that induces pain or discomfort, pain pressure threshold 
(12), was evaluated using algometry at two sites on the subject’s thigh, the vastus lateralis 
and rectus femoris. The vastus lateralis was evaluated 10 to 20 cm above the lateral 
epicondyle of the femur and the rectus femoris was evaluated along the midline of the 
front of the leg between 8 to 15 cm above the patella. The sites were marked with a pen 
for visit-to-visit repeatability. Pain pressure threshold was evaluated with a Wagner 
digital algometer (Model FPX25, Wagner Instruments, Greenwich CT, USA), according 
to the methods of Fischer (86) in which the 1 cm2 flat rubber tip is pressed firmly and 
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perpendicularly into the muscle with an increasing force of approximately 5 N s-1. 
Pressure was stopped when the volunteer indicated the onset of pain/discomfort. Each 
site was evaluated 3 times and values were averaged.  
 
Statistical Analysis 
Statistical inferences were drawn from a combination of paired t-tests and 2 -way 
repeated measures ANOVAs with a priori contrasts (v12, Systat,San Jose, CA, USA). 
For all variables, a separate 2-way repeated measure ANOVA was performed to test for 
differences in testing order to account for any decreased response from a repeated bout 
effect. Significance was set at P < 0.05. All data are presented as means ± SEM, except 
for data characterizing the subjects, which are presented as means ± SD. (Table 12).  
 
RESULTS 
Subject characteristics 
 
Twelve (3 female, 9 male) healthy, non-smoking individuals volunteered for the 
present study. Subject’s demographic and anthropometric characteristics obtained from 
the screening visit including age, height, weight, body mass index, body fat percentage, 
and knee-extension peak power are presented in Table 12. Trial days were separated by 
58 ± 19 days (mean ±SD; range 30-94 days).      
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Table 12. Subject Characteristics 
N 12 (3F, 9M) 
Age (years) 24 ± 3 
Height (cm) 181.9 ± 12.4 
Weight (kg) 78.4 ± 16.4 
Body Mass Index (kg·m-2) 23.5 ± 3.0 
Body Fat (%) 20.5 ± 11.3 
Isometric Knee Strength (N·m) 199 ± 47 
Values are means ± SD.   
 
 
 
 
300 Eccentric contractions 
The amount of work performed in each of the 10 sets of 30 repetitions is shown in 
Figure 19.  By design, the amount of work increased from set 1 to 2. The amount of work 
subjects performed was greater in set 2-5 than set 1 (set effect P<0.05). There were no 
differences between Placebo (64296 ± 5692 N•m) and Blockade (62146 ± 5047 N•m) in 
the total amount of total work performed over the 10 sets (drug effect; P = 0.318) nor was 
there an interaction in the amount of work completed in each set between Placebo and 
Blockade conditions (drug X set effect; P = 0.884).   
 
159 
Set Number
0 2 4 6 8 10
W
o
rk
 (
J
)
5000
5500
6000
6500
7000
7500
8000 Placebo 
Blockade 
* * * *
 
 
Figure 19. Work completed during each set of 30 eccentric contractions of the 
quadricep muscles.  = Placebo;  = H1/H2 Blockade. Values are means ± SEM. 
* P < 0.05 vs set #1 across both groups (main effect of time). There was no drug 
effect nor was there a drug x time interaction. 
 
 
Creatine Kinase 
 
Plasma creatine kinase concentrations were not different pre-exercise between 
Placebo (62.7±9.9 U/l) and Blockade (63.1 ± 10.5 U/l), and increased above preexercise 
concentrations at 6, 12, 24, 48 h after exercise (time effect P<0.05) (Figure 20). Creatine 
kinase concentrations increased similarly between Placebo and Blockade conditions 
(drug effect P = 0.370) and the pattern of change was not different between groups (drug 
x time interaction P = 0.647).  By convention, an area under-the-curve analysis was 
performed to represent the extent of damage. The area under-the-curve analysis indicated 
that there was no difference between Placebo and Blockade in the elevation of creatine 
kinase over 72-hr (P = 0.292) 
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Figure 20. Plasma concentrations of creatine kinase during 72 h of recovery from 
eccentric exercise.  = Placebo;  = H1/H2 Blockade. Values are means ± SEM. * 
P<0.05 vs preexercise.  
 
 
 
 
 
Strength 
 
The isometric torque produced by the quadricep muscles did not differ between 
Placebo and Blockade preexercise (P=0.895, Figure 21). Torque was reduced 
immediately following exercise and returned to preexercise levels 72-h after exercise 
(Figure 21). The torque loss of      -163±8 N•m peaked 24-h after exercise and represents 
a 19.5±3.4% reduction in isometric strength. There were no differences in strength loss 
between Placebo and Blockade (drug effect, P = 0.817) nor in the pattern of strength loss 
between conditions (drug x time interaction P = 0.906).  
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Figure 21.  Quadriceps isometric torque during 72 h of recovery from 
eccentric exercise.  = Placebo;  = H1/H2 Blockade. Values are means ± 
SEM. * P<0.05 vs preexercise. 
 
 
Evoked Twitch 
 
The amount of torque produced by the evoked twitch was similar 
preexercise between Placebo (58.5±3.7N•m) and Blockade days 
(59.1±3.7N•m). Torque decreased after exercise and remained below 
preexercise for 24-hs after exercise (time effect P<0.05). The reduction in 
evoked torque was not different between Placebo and Blockade conditions 
(drug effect P= 0.873) nor was the pattern of change between Placebo and 
Blockade different over the 72 hours (drug X time interaction P = 0.959) 
(Figure 22).  
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Figure 22. Evoked twitch of the quadricep muscles during 72 h of recovery from 
eccentric exercise.  = Placebo;  = H1/H2 Blockade. Values are means ± SEM. * 
P<0.05 vs preexercise across both groups (main effect of time). 
 
Central Activation Ratio 
 
Due to difficultly obtaining a plateau in voluntary force, as most 
subjects produced a peak force early in the contraction which was not 
maintained, a reliable increase in force from a superimposed twitch could 
be only be obtained in 7 individuals in both the Placebo and Blockade 
conditions. Due to high variability in the measures there were no difference 
in the central activation ratio over time (time effect P = 0.476), between 
drug conditions (drug effect P = 0.110), nor an interaction effect (drug X 
time interaction P = 0.578) (Figure 23).  
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Figure 23.  Central activation ratio during 72 h of recovery from eccentric 
exercise.  = Placebo;  = H1/H2 Blockade. Values are means ± SEM, n = 
7.  
 
 
Muscle Pain/Discomfort 
 
Visual analog scale ratings of pain/discomfort were not different between Placebo 
and Blockade preexercise (P=0.805). The pain/discomfort rating was increased following 
exercise (time effect P<0.05). Muscle pain peaked 24 to 48 h after exercise but this 
response was not different between Placebo and Blockade conditions (drug effect P = 
0.239) nor was the pattern of change over the 72 hrs different (drug x time interaction P = 
0.923)(Figure 24).  
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Figure 24. Pain and discomfort rating from a visual analog scale during 72-h after 
eccentric exercise.   = Placebo;  = H1/H2 Blockade. Values are means ± SEM. * 
P<0.05 vs Preexercise, † P<0.05 vs 0, 6, 12, and 72-hr (main effect of time). There was 
no drug effect or drug x time interaction.  
 
 
Algometry 
 
Pain pressure threshold preexercise was not different between Placebo and 
Blockade for the vastus lateralis (P=0.478) or the rectus femoris muscle (P=0.640)(Figure 
25). Pain pressure thresholds were decreased following exercise (more pain) for both 
muscles at 6, 24, 48, and 72-h after exercise (time effect P<0.05) (Figure 25). For 
reference, dashed reference lines in figure 25, defines a decrease in pain pressure 
threshold below 84.1% of baseline as a clinically relevant change in pain sensation (215) 
. These results indicate that the majority of the soreness the subjects experienced was in 
the vastus lateralis and represents a clinically relevant change in pain sensitivity.  
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Figure 25. Pain pressure threshold of the vastus lateralis and rectus femoris muscles 
during 72 h of recovery from eccentric exercise.  = Placebo;  = H1/H2 Blockade. 
Values are means ± SEM. The shaded band represents an increase in pain pressure 
threshold in that it required more point pressure to induce a perception of pain. Dashed 
lines represent a drop in pain pressure threshold of 15.9%, a clinically meaningful change 
in pain perception. There was no drug effect or drug X time interaction. * P<0.05 vs 
preexercise across both groups (main effect of time).  
 
 
Leukocytes 
 
There was no difference in leukocyte count preexercise between placebo and 
blockade. Exercise caused an increase in circulating leukocytes that peaked 6-h after 
exercise (time effect P < 0.05). The rise in leukocytes represents a 74±18% increase over 
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baseline at 6 hours post-exercise. There were no differences between Placebo and 
Blockade (drug effect P = 0.991) nor was there a change in the pattern of change over 
time between Placebo and Blockade (drug X time interaction P = 0.828) (Figure 26A). To 
examine whether testing order may have affected the outcomes between drug conditions 
a 2-way repeated measures ANOVA was run (Figure 25B). There was a larger increase in 
Leukocytes Day 1 compared to Day 2 regardless of drug condition (P<0.05). The 
leukocyte count peaked 6-h after exercise (P<0.05) and then returned to preexercise 
levels. To remove the order effect Placebo versus Blockade was further examined only 
during Day 1 (Figure 25C). This analysis of a sub-set of the data did not indicate a 
difference between Placebo and Blockade (drug effect P = 0.499), over time (time effect 
p=0.161), nor drug X time interaction (P=0.583) (Figure 26C). 
 
Cell Sorting 
 
During cell separation, there were 105,618 ± 7815 singlets counted per time point. 
Monocyte cells were identified and separated by the CD14, CD66 and CD86 surface 
markers and sub populations of monocytes were based off CD 16 and CD 192 surface 
markers. Neutrophils were identified based off CD66B and CD16 surface markers.  
Neutrophils 
The percent of neutrophils in the blood preexercise was not different between 
Placebo (40.6±4.5%) and Blockade at (40.6±1.7%). There were no differences in the 
percent change in neutrophils between Placebo and Blockade conditions (drug Effect 
P=0.330), over the 72 hours (time effect P = 0.063), nor in the pattern of change over 
time between Placebo and Blockade (drug X time interaction P = 0.242)(Figure 27).  
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Figure 26. Total Leukocyte count per ml of blood during 72-hr of recovery from 
eccentric exercise. A. Blockade versus Placebo. B. Day 1 versus Day 2. C. Placebo 
versus Blockade within Day 1 only. * P<0.05 vs preexercise across both groups (main 
effect of time). † = Effect of Day (P<0.05). There were no Drug X time or day X time 
interactions.  = Placebo;  = H1/H2 Blockade. Values are means ± SEM.  
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Figure 27. Neutrophils as a percent of total leukocyte count in the blood over 72-hr after 
exercise.  = Placebo;  = H1/H2 Blockade. Values are means ± SEM. 
 
 
Monocytes 
Total monocyte and monocyte sub-populations were not different between 
Placebo and Blockade conditions before exercise. There was no difference in between 
Placebo and Blockade conditions for monocytes or monocyte sub-populations over time 
nor in the pattern of change over time (Table 13).  
Inflammatory Cytokines 
 
 The Interleukin-12 (IL-12p70) never rose to levels in the blood that exceeded the 
lowest detectable limits of the bead assay. There were no differences between Placebo 
and Blockade for any cytokine (Table 12). Monocyte chemoattractant protein-1 (MCP-1) 
was elevated at 6 and 12 hours after exercise compared to the other time points (P<0.05) 
but the rise was similar between Placebo and Blockade conditions (Table 14). No other 
cytokine changed over time.   
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Table 13. Monocyte and monocyte sub-populations during recovery from eccentric exercise 
 
   Time after exercise (h)  P-Value 
  Pre  0 6 12 24 48 72 Drug Time Drug*Time 
Monocytes 
% of 
Leukocytes 
 
Placebo 5.7±1.0 4.7±1.0 5.7±1.1 4.5±0.8 4.9±0.8 4.6±0.9 3.6±0.6 0.505 0.191 0.616 
Blockade 6.1±1.0 4.8±0.7 4.8±0.8 4.2±0.6 5.2±0.6 6.4±1.4 4.6±0.8    
Mon I 
% of 
Monocytes 
 
Placebo 59.7±9.5 71.2±7.0 65.2±8.9 76.0±8.0 72.5±8.1 65.1±8.6 59.8±7.1 0.743 0.116 0.600 
Blockade 71.8±9.4 71.3±9.3 75.5±9.5 75.3±9.8 68.2±10.9 66.2±9.7 66.0±8.8    
Mon II 
% of 
Monocytes 
 
Placebo 34.3±9.1 25.5±7.2 31.7±9.3 19.8±8.4 23.8±8.2 31.7±8.9 36.6±7.5 0.801 0.067 0.726 
Blockade 25.6±9.6 25.9±9.4 21.4±9.8 20.3±10.3 28.8±11.1 30.1±10.0 31.5±8.9    
Mon III 
% of 
Monocytes 
Placebo 2.4±0.9 2.1±0.6 2.1±0.7 2.6±0.6 2.3±0.5 2.3±0.7 2.4±0.7 0.897 0.605 0.690 
Blockade 1.8±0.3 2.0±0.5 2.1±0.7 2.6±0.7 2.4±0.5 3.1±0.7 1.5±0.5    
Values are means ± SEM          
170 
Table 14. Plasma cytokine changes during recovery from exercise 
 
   Time after exercise (h)  P-Value 
  Pre  0 6 12 24 48 72 Drug Time Drug*Time 
IL-1B (pg/ml) Placebo 7.7±1.9 7.5±2.0 8.1±1.8 7.2±2.0 7.3±1.6 7.1±1.7 7.3±1.8 0.918 0.627 0.739 
Blockade 7.7±2.0 9.0±3.0 8.1±2.5 7.6±2.0 7.3±1.6 6.4±2.0 6.7±1.9    
IFNa2 (pg/ml) Placebo 5.3±1.6 5.9±1.8 5.5±1.4 5.1±1.6 5.1±1.3 5.5±1.3 5.1±1.5 0.699 0.635 0.987 
Blockade 5.7±1.7 6.0±2.3 5.8±1.9 5.2±1.6 5.0±1.4 5.3±1.6 5.0±1.6    
IFN-y (pg/ml) Placebo 3.9±1.0 4.0±1.1 3.7±0.8 3.7±1.0 3.6±0.7 3.7±0.8 3.5±0.9 0.809 0.623 0.959 
Blockade 4.0±0.9 4.1±1.4 4.0±1.2 3.5±0.9 3.3±0.8 3.8±0.9 3.7±1.0    
TNF-a (Pg/ml) Placebo 8.6±2.8 9.5±2.8 8.3±2.8 6.2±1.7 8.0±2.3 7.9±2.0 6.5±1.7 0.508 0.415 0.946 
Blockade 8.1±2.2 8.3±2.6 7.8±2.2 7.0±2.0 6.7±1.7 6.7±1.8 6.2±1.7    
MCP-1 (pg/ml) Placebo 47.7±6.9 42.0±5.6 91.7±20.5* 68.5±10.3* 42.9±6.8 43.8±8.2 37.2±4.5 0.812 <0.05 0.965 
 Blockade 48.2±7.0 41.7±5.6 80.5±12.5* 71.8±11.6* 44.0±7.2 38.2±6.5 36.7±4.3    
IL-6 (pg/ml) Placebo 5.7±1.5 5.8±1.5 5.8±1.3 5.7±1.4 5.6±1.0 5.5±0.9 5.5±1.2 0.807 0.422 0.329 
 Blockade 6.0±1.4 7.7±3.5 6.9±2.5 5.2±1.1 4.7±0.9 5.0±1.3 4.8±1.2    
IL-8 (pg/ml) Placebo 5.1±1.6 5.6±1.5 5.3±1.3 5.0±1.6 5.6±1.7 6.7±2.6 5.2±1.5 0.394 0.879 0.116 
 Blockade 5.7±1.4 4.7±1.3 4.5±1.1 3.9±0.8 4.0±0.7 7.5±3.7 4.0±0.9    
IL-10 (pg/ml) Placebo 4.8±1.6 5.4±2.2 4.7±1.4 4.6±1.6 4.3±0.9 4.5±0.9 4.4±1.3 0.730 0.546 0.732 
 Blockade 4.8±1.7 6.5±3.6 5.8±2.8 4.1±1.1 4.1±1.2 4.5±1.3 4.3±1.7    
IL-17A (pg/ml) Placebo 6.2±1.3 6.3±1.4 6.6±1.3 5.5±1.2 6.3±1.2 6.6±1.4 5.4±1.2 0.721 0.459 0.726 
 Blockade 7.5±2.5 6.8±1.7 6.8±1.7 6.1±1.4 6.2±1.4 5.7±1.4 5.5±1.2    
IL-18 (pg/ml) Placebo 53.4±15.2 55.3±16.0 53.4±11.7 50.6±14.0 50.4±14.0 58.1±16.6 49.2±15.2 0.892 0.565 0.711 
 Blockade 52.2±14.1 57.0±14.6 54.9±15.4 54.6±18.3 53.7±15.0 52.1±16.6 48.5±13.6    
IL-23 (pg/ml) Placebo 4.8±1.4 4.8±1.4 4.8±1.3 4.5±1.5 4.5±1.2 4.4±1.2 4.2±1.3 0.627 0.335 0.593 
 Blockade 4.7±1.4 6.1±2.7 5.8±2.2 4.3±1.2 4.1±1.2 4.2±1.3 4.1±1.3    
Il-33 (pg/ml) Placebo 10.1±3.1 10.7±3.3 10.4±2.7 9.7±3.1 9.7±2.5 9.9±2.5 8.7±2.8 0.350 .0574 0.860 
 Blockade 11.1±3.5 13.9±6.3 12.4±4.5 10.5±3.6 9.5±3.0 10.0±3.5 9.7±3.6    
Interleukin-1B (IL-1B), Interferon alpha 2 (IFNa2), Interferon-gamma (IFN-y), Tumor Necrosis Factor alpha (TNFa), Monocyte Chemoattractant 
Protein-1 (MCP-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Interleukin-17a (IL-17a), Interleukin-18 (IL-18), Interleukin-23 
(IL-23), Interleukin-33 (IL-33). * = elevated over time points, Values are means ± SEM 
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DISCUSSION 
 
The main finding of the present investigation was that taking combined histamine 
H1 and H2 histamine receptor antagonists had no effect on the systemic inflammatory 
response following muscle-damaging exercise. Additionally, these results suggest, at 
least at the systemic level, that antihistamine therapy prior to exercise does not affect the 
functional recovery of the muscle in the ensuing 72 hours. This study does not address 
local repair and remodeling processes within the muscle tissue, where histamine is 
released during exercise.  
 
Exercise Inflammatory Response 
 
It is now generally accepted that a tightly regulated inflammatory response is 
necessary for muscle repair and regeneration following strenuous exercise (231, 307). 
Multiple inflammatory cell types including mast cells, neutrophils, and monocytes aid in 
this response (173, 174, 183, 231, 308, 309). Following exercise, there is an immediate 
and robust increase in circulating leukocytes that wanes in the hours to days  that follow 
(39, 51, 111, 210, 230, 280). Within an hour after exercise neutrophils are observed in the 
extracellular space of skeletal muscle tissue and monocytes/macrophages in hours to days 
that follow (39, 66, 173, 231). There are also large increases in circulating cytokines, 
many released from the contracting muscle, that are part of a paracrine and endocrine 
communication for the coordination of the inflammatory response (229, 232). Once 
inside the muscle tissue, the neutrophils and monocytes/macrophages breakdown 
damaged tissue and begin the repair process.  Although the leukocytes and cytokines aid 
in inflammatory response after exercise, many aspects in the regulation of repair are 
unclear and involve unknown molecules (231). 
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Histamine 
 
Histamine is a molecule that not only has associations to immune and 
inflammatory responses, but is also released and produced within the contracting skeletal 
muscle. Intramuscular histamine concentrations increase ~3 fold during moderate 
intensity endurance exercise (255). It is possible that the exercise-induced rise in 
intramuscular histamine is involved with the exercise inflammatory response in order to 
deliver and direct the circulating leukocytes to the muscle tissue. For example, in immune 
and inflammatory responses, histamine aids in the diapedesis of leukocytes from 
circulation into damaged/infected tissue. The diapedesis occurs through a histamine 
initiated margination of capillary endothelial and pericyte cells, an increased capillary 
permeability, the expression of adhesion molecules on endothelial cells, and in acting as a 
chemoattractant to leukocytes (22, 146, 224). Histamine may also be involved with the 
delivery of immune cells to the muscle as there is a histamine mediated dilation of 
resistance arterioles that results in an elevation of local blood flow that can last upward of 
120 min within the previously active muscle (187, 188, 255). Further evidence that 
histamine is involved with the exercise inflammatory response comes from a recent study 
that documented a down regulation of approximately 800 protein-coding genes within 
muscle tissue with a systemic blocking of histamine actions. Many of the protein-coding 
genes were related to inflammation and cell maintenance (254). Therefore, histamine 
may be the link between exercise and the associated inflammatory response.  
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Research Design 
 
This is the first known investigation to examine the link between histamine and 
the systemic inflammatory response following exercise. Important to the interpretation of 
the results of this study was the selection of an exercise protocol that elicited a rise in 
circulating blood cells, an increase in intramuscular histamine concentrations, and one 
that could be repeated within the same subject to test for changes that occur with a drug 
intervention. Subjects performed 300 unilateral eccentric contractions of the knee-
extensor muscles. The contractions were performed in sets of 30 with little rest between 
sets in an attempt to mimic the mode, type and, duration of endurance type exercise that 
is known to cause an elevation in intramuscular histamine and result in a histamine 
mediate post-exercise dilation (110, 187, 188). Additionally, previous studies using 300 
unilateral eccentric knee-extension contractions have demonstrated a systemic 
leukocytosis and an increase in white blood cells within the muscle 24 hours after 
exercise (173, 207). Importantly, the isolation of single muscle groups on both sides of 
the body were used for comparison between drug conditions. 
Using the unilateral eccentric knee-extension model, the subjects performed a 
similar amount of work between Placebo and Blockade conditions (Figure 19), had 
similar reduction in peak torque (Figure 21), and elevation in plasma creatine kinase 
(Figure 20) in the 72-hrs after exercise. Analysis of evoked twitch potentials and central 
activation indicate that minimal reductions in strength were due to decreased central 
activation (Figure 22, Figure 23). Importantly, these central and peripheral evaluations of 
strength loss did not differ between Placebo and Blockade conditions (Figure 22, Figure 
 174 
 
23). Therefore, it was assumed that the exercise protocol would initiate a similar 
inflammatory response in both testing sessions. 
 
Muscle Pain and Discomfort.  
 
 Pain is interpreted from signals from Group III/IV afferent neurons (151, 217). 
Histamine has the ability to directly sensitize the afferent neurons (151) and may also 
contribute to the upregulation of neurotrophic factors (78, 254) involved with extended 
sensitization and potentiation of the same neurons (237, 298). A previous study found 
that blocking histamine during exercise attenuated the rise muscle pain and the associated 
delayed soreness experienced after muscle-damaging exercise (downhill running) (78). 
The current study, while finding a sharp increase in the subjective assessment of 
quadricep muscle pain and reduction in the pain pressure threshold (more pain) after 
knee-extension exercise did not find a difference in pain sensations between the Placebo 
and Blockade conditions a (Figure 23, Figure 24). A potential explanation for the 
differing outcomes could be attributed to the individual subjective assessment of pain. 
The downhill running study in comparison to the present results compared two separate 
groups of individuals (78) and the difference between groups confounded the results of 
the drug condition. Another possible explanation could relate to the smaller amount of 
muscle mass (quadriceps) exercised in single-leg knee extension exercise compared to 
the whole body exercise of downhill running (78). The subjects in the present study 
experienced greater soreness overall (5/10) than the downhill running (3.5/10).  It is 
possible that greater quadricep muscle damage occurred during the 300 eccentric 
contractions compared to the downhill running and factors other than histamine 
contributed to the activation/sensitization of Group III/IV afferents, which negated the 
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effects of the histamine receptor antagonists.  These muscle pain measurements also 
serve as another indicator that the exercise protocol produced a similar amount of damage 
between Placebo and Blockade conditions.  
 
Inflammatory Response 
 
 Similar to previous reports of muscle damaging exercise, there was a transient 
elevation in circulating leukocytes that peak increase 6 hs after exercise and returned to 
baseline levels approximately 24 hrs after exercise (173, 230, 231) (Figure 26). It was 
hypothesized that exercise-associated elevation of histamine would aid in the migration 
of leukocytes out of circulation and into the previously active skeletal muscle. This 
hypothesis was based on the functions of histamine during inflammation, characterized 
by the vasodilation of blood vessels, increased capillary permeability, and expression of 
endothelial adhesion molecules. Therefore, blocking histaminergic actions during and 
following exercise would result in an extended elevation in leukocyte concentrations. 
Contrary to the hypothesis, blocking histamine’s actions did not affect the systemic 
elevation or the time course leukocytes concentrations in the blood (Figure 26). The time 
course in the rise of leukocytes and the return to baseline between Blockade and Placebo 
conditions were not different. However, it is unknown if the skeletal muscle infiltration 
of the leukocytes was the same between Placebo and Blockade conditions. It is possible 
that the entry of leukocytes into the skeletal muscle was impeded with blockade and a 
separate tissue bed took up the leukocytes.  
Immediately after exercise, there is an increased concentration of circulating 
cytokines such as IL-6, TNFa, IL-1B, MCP-1, IL-8, IL-1ra, and IL-10 (47, 85, 210, 232, 
291). Additionally, studies have documented an association in the rise of cytokines and 
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inflammatory cells with increased creatine kinase levels following muscle damaging 
exercise (66, 202, 210).  In the present study there were no detectable changes in any 
cytokine over the 72-hr recovery period or between Blockade and Placebo conditions 
(Table 12). There was a rise in monocyte chemoattractant protein-1 at 6 and 12 hr but the 
rise was not affected by Blockade. Monocyte chemoattractant protein is involved with  
monocyte recruitment into tissues and is produced by endothelial as well as skeletal 
muscle myocytes during contraction (51, 62). Given that that this protein increased 
similarly in both the Blockade as well as the placebo conditions, it is not surprising that 
the leukocytosis profile was also similar between conditions (Figure 26).  
Studies indicate that the leukocytosis after exercise is not limited to one cell type 
and many cell types may increase in different proportions (122). In addition, cell culture 
experiments with polymorphic mononuclear cells suggest that histamine has the ability to 
shift the expression of interleukin-10 and interleukin-12 (147, 224). These two 
interleukins control the expression cell surface markers and function of monocyte sub-
populations (147, 224). Therefore, it was assumed that blocking histamine during 
exercise may also alter the percentage of monocyte sub-populations and in the leukocyte 
response. Contrary to this hypothesis, neither the percentage of monocytes nor the sub-
population of monocytes were altered over the 72 hrs of recovery from muscle damaging-
exercise in the Placebo or Blockade conditions (Table 11). Interleukin-12 was not 
detected at any time point in the blood and interleukin-10 showed no changes over the 
72- hr recovery period (Table 12), so it is possible that the interleukin stimulus to shift 
monocyte sub-populations was not altered.  
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 Limitations 
 
 The present study was limited in that it only examined the systemic inflammatory 
response and did not examine the skeletal muscle directly. Histamine concentrations are 
increased within the skeletal muscle during repeated contractions (255) and are reduced 
by rapid breakdown through membrane bound and cytosolic enzymes (130). Due to the 
rapid breakdown of histamine, it has a short half-life of approximately 100 seconds and 
any physiological actions of histamine are likely in close proximity to where it is 
released/produced. If histamine is participating in the exercise associated inflammatory 
response; it is at the level of the endothelial, pericyte, mast, and other associated cells 
within the muscle tissue. If this is a reasonable interpretation of the current data and 
known functions of histamine, than the skeletal muscle tissue should be the focus of 
follow up examinations.  
 This study also used an oral dose of histamine H1 and H2 receptor antagonists. 
The antagonists were distributed systemically and do not specifically block histamine 
receptors only within the muscle. It is probable that the antagonists effects were 
concentrated within the active skeletal muscle as it has been previously demonstrated that 
histamine concentrations do not increase within inactive muscle (255). However, it is 
acknowledged that the systemic administration of histamine receptor antagonists may 
have affected other unknown pathways.  
 Lastly, it is possible that the small volume of muscle exercised and resultant 
exercise-induced damaged did not provide enough of a stimulus to induce measureable 
and alterable systemic inflammatory response. Although there was a rise in circulating 
total leukocytes (74±18%) and neutrophils (29±5%), this rise is less than that seen with 
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whole body exercise, such as downhill running where cell counts and cytokines increase 
300-500% (62, 229–231).  
 
Importance 
 
Histamine is a molecule most associated with inflammatory and immune 
responses. The discovery that histamine concentrations are increased within skeletal 
muscle during endurance exercise has led researchers to decipher this odd association. 
The idea that exercise itself initiates a pro-inflammatory state sets the stage to bridge the 
gap between exercise-associated increases in histamine and the exercise associated 
inflammatory response. Although there was no detectable difference in leukocytosis or 
the production of cytokines from muscle-damaging exercise when histaminergic 
signaling was blocked, this study suggests that histamine is exerting a local influence 
within the skeletal muscle and not systemically. Future studies focusing specifically on 
the skeletal muscle, histamine, myokines, and infiltration of leukocytes will provide 
information concerning the regulation of muscle degradation and repair (37). This will 
also shed light on the movement of leukocytes after exercise and as the number of 
circulating leukocytes represent only 1-10% of the total cell population, small 
increases/decreases are of clinical significance (280). Additionally, if disrupting the 
inflammatory process occurs with common “antihistamines” this may delay or prevent 
the repair process, as has been noted with reduced circulating neutrophils and 
inflammatory cytokines, as well as common anti-inflammatory therapies (ibuprofen, 
acetaminophen) (64, 171, 235, 304, 314). Finally, uncovering histamines role in 
inflammation and the recovery from exercise is important as very little is known about 
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the cross talk between muscle and other organs that could underlie the effects of exercise 
on systemic health (185, 205). 
 
Conclusion 
  
This study addresses the issue of pharmacotherapy in the interaction between 
commonly used medications (histamine-receptor antagonists) and exercise-induced 
muscle damage and aids in the identification of histamine’s role as a molecular 
transducer of exercise responses (205). Additionally, the present findings address 
important issues identified by The National Institutes of Health (NIH) on the interaction 
of physical activity, inflammation, and immune function (205). This study demonstrated 
that blocking histaminergic signaling on H1 and H2 receptors did not affect the systemic 
inflammatory response of increased white blood cells or cytokines following muscle-
damaging exercise. Additionally, blocking histaminergic signaling on H1 and H2 
receptors did not affect the functional recovery of muscle from muscle-damaging 
exercise. This study is important to guide the scientific understanding of the exercise-
induced rise in skeletal muscle histamine and its association with inflammation resulting 
from muscle damage.  
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CHAPTER VII 
 
SUMMARY AND FUTURE DIRECTIONS 
 
“It is not without an inner feeling of disappointment that we look upon the possible role 
played by histamine in normal physiology. Here we have a powerful, endogenous, active 
agent, present in almost every organ or tissue of the body in amounts that can produce 
not only physiological but also drastic pathological effects, and yet it appears devoid of 
physiological significance.” 
      –Mauricio Oscar da Rocha e Silva, 1955 (286) 
 
Dr. Silva was one of the original members of the “Histamine Club”, a group of 
scientists studying the presence and role of histamine in the human body. Much of the 
work presented in this dissertation is built upon the pioneering work of these scientists. 
Now, 64 years after Dr. Silva’s statement, we have a better understanding of histamine’s 
role in body processes concerning inflammation, digestion, and as a neurotransmitter, but 
a void still exists in the understanding of its function in the exercise response.  
It is now well established that histamine concentrations increase within skeletal 
muscle tissue during repeated contractions. The rise of intramuscular histamine is at least 
3 fold greater than resting levels during 60 min of exercise (255). The increase in 
histamine concentration comes from degranulation of mast cells and from de novo 
production via the enzyme histidine decarboxylase (255). Although the exact stimulus 
leading to the increased histamine concentration is unknown, in situ and in vitro work 
suggest that multiple stimuli arising from exercise can independently cause mast cell 
degranulation and increased enzymatic activity. The stimuli include hypoxia, 
hyperosmolality, oxidative stress, chemokines, increased temperature, vibration, 
decreased pH, shear stress, substance P, bradykinin, and nerve growth factor (61, 97, 110, 
124, 125, 141, 186, 190, 213, 267, 268, 271, 279, 294). Collectively, the influence of 
even small changes in some or all of these factors must provide a strong stimulus to 
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increase intramuscular histamine concentrations. Additionally, as exercise duration 
increases, the production and activity of the histidine decarboxylase enzyme increase (13, 
14, 320). These findings suggest that histamine is an inherent component of the exercise 
response and it may serve a more prominent role in long duration endurance exercise. 
Previously documented animal and human performance tests mirror the 
suggestion that histamine is important during endurance exercise but not necessarily short 
duration exercise. Studies performed in humans showed that blocking histamine’s actions 
on H1 and H2 receptors had no effect on short-duration high-intensity exercise (≤10 min) 
such as maximal strength tests and sprint performance (194–196). Murine studies 
demonstrated reductions in endurance capacity from hours long gnawing and walking 
tasks with H1 and/or H2 receptor antagonism, in mice bred without H1 receptors, and in 
mice bred without histidine decarboxylase (12, 84, 212, 328). The results of the study 
presented in Chapter IV, “Histamine-receptor antagonists slow 10-km cycling 
performance in competitive cyclists”, is the first known study to examine the effect of 
blocking histamine’s actions on endurance exercise performance in humans. This study 
showed that blocking histamine’s actions slowed performance in competitive cyclists. 
The slowing was ~2% in magnitude of each subject’s completion time. On the surface, a 
2% slowing of performance may not seem like much but it is of similar magnitude of 
performance enhancement seen with caffeine supplementation and altitude training (91, 
140). Although the blockade of histamine actions decreased performance, there were no 
changes in variables known to affect exercise performance such as blood glucose, lactate, 
or muscle strength from before to after the time trial. Additionally, there were no effects 
of blockade on systemic measures relating to hemodynamics (e.g. cardiac output, blood 
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pressure, total peripheral resistance), metabolism (e.g. oxygen consumption, carbon 
dioxide production, blood lactate or glucose), or muscle strength during a 120 min steady 
state cycling exercise. Therefore, while blocking histamine’s actions resulted in a reduced 
endurance performance, it appears to have a localized effect, as systemic values remained 
consistent.  
It is not entirely surprising that systemic hemodynamic, metabolic, and strength 
measures were unaffected by histamine receptor antagonists during exercise. Histamine is 
produced in high amounts within the muscle during contractions. This rise in histamine is 
limited to the contracting muscle, as inactive muscle does not demonstrate an increase in 
histamine (i.e. arms during leg exercise)(109). Also, histamine has a short half-life (~100 
s) as is rapidly degraded by cytosolic and membrane bound enzymes or reabsorbed by 
mast cells, (22, 130, 204). Given that histamine rises locally within exercising muscle and 
is degraded rapidly, it likely exerts an autocrine and paracrine action within skeletal 
muscle during activity (212, 328). The local effects of blocking histamine’s actions are 
likely buffered by other tissues to maintain systemic homeostasis.  
Histamine, when it is produced or released within tissues has a strong vasodilator 
influence which leads to an increased local blood flow. A histamine-related increase in 
blood flow has been demonstrated in inflammatory and immune responses, during 
reactive hyperemia, in the skin during heat stress, in sustained post-exercise-vasodilation, 
and in tumor growth (9, 10, 187, 188, 226, 243, 325).  In skeletal muscle, mast cells are 
located in close proximity to arterioles and HDC is present in high concentrations within 
arterial endothelial cells as well as skeletal muscle myocytes (13, 270, 312). Therefore, it 
was a reasonable premise to believe that the exercise-induced histamine release and 
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production might act as a vasodilator during exercise and contribute to exercise 
hyperemia. This premise, if true, would explain the reduced endurance exercise 
performance with blocking histamine. Adequate blood flow to skeletal muscle during 
endurance exercise is necessary for nutrient delivery and metabolite removal. Blocking 
histamine’s actions may have reduced perfusion, limited nutrient delivery and metabolite 
removal resulting in decreased performance. 
Contrary to this assumption, leg blood flow was elevated during exercise at 
multiple exercise intensities and over a long duration steady state exercise bout when 
histaminergic signaling was blocked during exercise (Chapter V, “Histamine receptor 
antagonism increases leg blood flow during exercise”).  This is the first known study to 
examine systemic blockade of histamine H1 and H2 receptors and limb blood flow during 
exercise. Specifically, the results suggest that femoral artery blood flow, while not 
affected during resting conditions with histamine receptor antagonism, was elevated 
during short exercise bouts (3 min) at low (20% peak) to relatively high (80% peak) 
exercise intensities and during sustained moderate-intensity exercise (60 min at 60% 
peak) compared to placebo conditions. Again, similar to the findings from steady state 
cycling in Chapter IV, there were no effects of histamine receptor blockade on systemic 
measures of blood pressure, ventilation, oxygen consumption, or cardiac output. 
Interestingly, measures of intramuscular pH using near-infrared spectroscopy recorded 
lower pH values as exercise intensity increased in blockade compared to placebo 
conditions. This implies that there was an alteration in either hydrogen ion production or 
removal from the skeletal muscle. It is possible that this increased acidosis stimulated 
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more blood flow, but histamine’s role in capillary permeability did not allow for the 
transfer of nutrients/metabolites between the tissue and blood.  
It is possible that histamine production in during exercise is related to the exercise 
recovery process. The recovery from exercise is synonymous with an inflammatory 
response and histamine has many associations with inflammatory and immune responses. 
For example, histamine directly and indirectly assists in directing leukocytes to areas of 
tissue damage through capillary cell margination, the expression of adhesion molecules, 
and diapedesis of leukocytes (22, 24, 169, 176, 203, 300). Endurance exercise itself 
initiates an inflammatory like state in which there is an increase in circulating white 
blood cells that peak in concentrations 6-12 hours after exercise (39, 51, 210, 230, 280).  
Following arduous exercise that may result in extensive tissue damage, the increase in 
circulating white blood cells is accompanied by muscle pain and soreness. The pain and 
soreness are part of the inflammatory response and it is theorized that perceptions of pain 
are part of a protective mechanism to limit volitional force output to protect from further 
damaged and aid in repair. Therefore, histamine release during exercise was hypothesized 
be a component of the immune response to repair damaged muscle tissue.  
In the study detailed in Chapter VI, “The effect of histamine receptor antagonism 
on the inflammatory response from muscle damaging exercise” there were no differences 
in rise or return to baseline of circulatory leukocytes including sub-populations of 
monocytes and neutrophils, nor of cytokines associated with inflammation (IL-6, I-10, 
IL-12, MCP1). Additionally, in contrast to previous reports H1 and H2 receptor 
antagonism did not affect muscle soreness or leg muscle pain in the hours after exercise 
(78).  Importantly, H1 and H2 receptor antagonism did not affect the recovery of muscle 
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function following muscle-damaging exercise.  This study may have been limited in 
detecting a robust inflammatory response due to the small mass of muscle exercised. 
Both the rise in leukocyte count and the rise in creatine kinase (a marker of muscle 
damage) were approximately 1/4 that reported in the literature resulting from downhill 
running, eccentric cycling, and whole body weight lifting (62, 229–231).  
In total and in keeping with Darwin’s Theory of Evolution, that traits remain 
within a species if they serve a purpose leading to survival across generations, the 
increase of histamine within skeletal muscle during exercise must serve a purpose. It is 
evident that histamine is important for endurance exercise, is involved with exercising 
blood flow regulation, and is involved with inflammation. Although, the exact function or 
functions of histamine in the exercise response still require further investigation and 
clarification. A limitation of this work is the use of systemic blockade of H1 and H2 
receptors rather than a tissue-specific blockade. It is assumed that major function of 
histaminergic signaling is occurring within the exercising skeletal muscle, the only tissue 
with known elevations in histamine during contractions. However, it is acknowledged 
that the systemic blockade could be affecting other unknown pathways during exercise as 
well.  
 It is my hope that the readers walk away with a view completely opposite of Dr. 
Silva that histamine is not “devoid of physiological significance”, but in fact, histamine 
plays vital roles in many physiological pathways associated with the stress of exercise. 
Additionally, given the importance of histamine in the inflammatory response, in 
conjunction with the emerging ideas of good and bad inflammation on health, that this 
little 111 dalton molecule deserves further investigation. 
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Future Directions 
Based on the outcomes of these studies and previous research, histamine’s actions 
during and following exercise are contained within the tissue that it is produced (muscle). 
The direction forward should shift focus toward a localized examination of histamine 
within the muscle tissue and away from a systemic evaluation.  
Broadly, within the following categories, histamine’s role in the exercise response 
should be further assessed.   
1) Endurance exercise performance tasks should be replicated. 
a. Intramuscular pH probes can be used for a direct assessment during 
exercise as pH is implicated in muscular fatigue. 
b. Muscle biopsies should be obtained prior to and following exercise to 
asses intramuscular glycogen concentration changes. A low 
intramuscular glycogen content is associated with muscle fatigue. 
c. Post-performance glucose tolerance test followed by muscle biopsy to 
test for glucose delivery and intramuscular glycogen replenishment. 
 
2) Muscle blood flows should be re-assessed but include a study design where 
rest periods between exercise intensities are removed. This may remove 
variability in blood flow measures and may remove any return to 
intramuscular homeostasis that may occur during the rest period.  
 
3) Examine the changes of inflammatory cells within the muscle (biopsy) in 
conjunction with the systemic concentrations (circulatory). Additionally, 
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labeled white blood cells can be injected into circulation prior to exercise and 
can be quantified within the muscle following exercise to assess histamine’s 
involvement in leukocyte recruitment into the muscle (see MacIntyre 
1996)(173).  
 
4) Assess capillary permeability using the methods of Dr. John Gamble (20, 21, 
35, 90), who is an expert in assessing capillary permeability using step-
changes in venous occlusion and strain gauges (venous occlusion 
plethesmography) to calculate capillary filtration constants (CFC). The 
methods refined by Gamble remove “rest” periods between occlusion 
pressures and allow for truncated assessments of filtration that can then be 
used for multiple assessments during recovery from exercise.  
a. If histamine affects capillary permeability this might be an effective 
countermeasure to acute mountain sickness (AMS) as it is thought that 
altitude increases the permeability of capillaries and that AMS might 
be, in part, due to a reduction in central volume (8, 114, 295).  
b. If histamine affects capillary permeability this might also affect 
plasma volume expansion with heat acclimation. Albumin may leave 
central circulation and accumulate in the interstitial area bringing fluid 
with it. This would stimulate an increase in thirst and protein 
production to replace central volume, therefore increasing total body 
water (114).  
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5) Examine histamine’s potential role in the repeated bout effect.  There is little 
information available on the peripheral adaptation process associated with 
repeated eccentric training (87). This effect is believed to be a reorganization 
of the contractile myofibrils initiated by the inflammatory process (87). If 
histamine disrupts the normal repair and adaptation from exercise, than 
blocking histamine may attenuate the protection afforded by the “repeated 
bout effect”.  
 
6) Studies should be carried out on individuals with exercise induced urticaria 
and asthma (and possibly exercise induced anaphylaxis) as plasma histamine 
concentrations have been reported to reach 26 ng/ml 25-min after starting 
exercise (24, 149). These individuals have excessive histamine release during 
exercise. Examination of systemic inflammatory responses (leukocytosis) in 
these individuals can provide an avenue to study a pathological condition in 
which excessive histamine is released.  
 
7) The pathway associated with chronic pain associated with muscle damage is 
not well characterized and may be associated with NGF/GDNF effects on 
neuronal sodium channels (NaV1.8). The administration of Ambroxol (A-
803467) via microdialysis blocks potentiation of NaV1.8 currents (137) and 
would be a novel way to study DOMS.  
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APPENDIX A 
 
Leukocyte isolation and preparation for flow cytometry 
 
___Take a vial of PFA from the freezer to thaw (may need to put in a beaker of water to 
accelerate) 
___Make dilution of 10x RBC lysis buffer (brown bottle in fridge) - 3 ml + 27 ml H2O in 
a green lid tube 
___Add 2.0 ml fresh whole blood to RBC lysis buffer. ___ Incubate 10 min at RT 
___Wipe down shaft of pipet with disinfectant towel to remove blood splatter 
___Spin tube at 500 x G for 10 min (program 1) 
___Pour off supernatant into beaker with a splash of bleach in hood.  
___Resuspend in 30 mL 1x PBS from fridge. Pipet to break up cell pellet. 
___Pass through 40 micron filter into fresh tube. 
___Spin 10 min @ 500G, discard super into bleach beaker             
___Resuspend in 3-5 ml PBS :_______ml (R) 
___In a tiny tube, mix 10 ul trypan blue with 10 ul cell suspension.            ___Load 10ul 
to each slide well 
___Insert slide into countess and zoom to adjust focus (cells with blue edge with white 
center) 
___Count both sides of slide, record cells/ml alive and %alive. Average two sides. 
 Alive: _________ , ___________  Average ____________cells/ml  (A) 
Initials:__________ 
 % alive: ________ , __________ Average __________% 
___Divide 1,000,000 by A cells/ml = ______________ml for 1,000,000 cells  (B) 
___(One or two unstained samples total per subject-week is enough)Remove B amount 
of suspension to microcentrifuge tube to save as unstained. Store in fridge until fixing 
step 
___Remaining cells  R – B = ______________ml x A cells/ml= 
_______________cells (C) 
Only subtract B if you have removed a sample for “unstained” 
___Dilute cells to 1 x 106 cells/ml with cold PBS (if C is 4.2x106  cells, bring volume up 
to 4.2 ml) (D) 
___If there’s no reconstituted violet dye less than 2 weeks old in the freezer, make a fresh 
tube by adding 50 ul DMSO to lyophilized stain (both DMSO and stain are in 
Invitrogen pouch in freezer. Label stain with date after reconstituting). 
___Add 1 ul violet stain per ml of cell suspension (same as 1 ul per million cells – 
volume D but in ul. Swirl and incubate in the dark at RT for 30 min.  
___Retrieve unstained cells from fridge (if unstained cells were collected at this time 
point). 
___Fill violet stained cells up to 30 ml with PBS to dilute stain before spinning 
___Spin tubes 10 min @ 500G, discard super 
___ To each tube, add 1 ml 4% PFA per million cells (volume D). Pipet to break up cell 
clumps. 
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___Incubate at RT in dark for 10 min 
___Top off cell suspension to 30 ml w/ PBS to dilute PFA. 
___Spin and discard super into Formaldehyde Waste Bottle. 
___Resuspend cells in 2.0 mL PBS. Transfer to 2mL tube with label. 
___Store in the dark in the fridge until ready for staining & cytometering (up to one 
week) 
___Make sure remaining PFA and violet dye solutions are returned to freezer 
___Blood beaker with 10% bleach can be washed down the sink 20 minutes after the last 
addition 
 
Subject ID_________  Time point_______________   
Date_____________________Initials:__________ 
Alive: _________________ , _____________________ Average (A):____________________ cells/mL    
% alive:______________ , ________________  Average:_________________% 
 R:________mL 
B:_________________mL   C:___________________cells    D:____________mL   (added 
____________mL) 
1,000,000/avg live cells       avg live cells x remaining vol              C/106 mL 
 
 
 
Leukocyte Staining for Flow Cytometry      
Tube Channel Antibody Stock 
solution 
(ug/ul) 
Antibody 
volume (ul) 
Stain 
Buffer (ul) 
Master 
cocktail 
       
1 FL1-10 Unstained  0 100  
2-9 FL1 CD62E 0.75ug .100 7.5  60 
 FL2 CD86 1.56ug .200 7.8  62.4 
 FL3 CD309 0.125ug .025 5  40 
 FL4 CD34 5ug .200 25  200 
 FL5 CD192 0.156ug .200 .78  6.24 
 FL6 CD66B 0.5ug .200 2.5  20 
 FL7 CD14 0.625ug .200 3.13  25 
 FL8 CD16 0.156ug .200 .78  6.24 
 FL9 CD3 0.156ug .200 .78  6.24 
  CD19 0.0625ug .050 1.25  10 
  CD56 0.156ug .200 .78  6.24 
 FL10 CD45 0.75ug .100 7.5  60 
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Staining protocol       
 
 Take cell suspensions from fridge and swirl to make sure cells are well 
suspended. Transfer 1.5 x 106 cells  to individual 2.0 ml microcentrifuge tubes for 
each staining sample plus the 106 unstained cells . Pellet cells from suspensions 
500G x 5 min.  
 
 Re-suspend cell pellet in 100 ul of staining buffer (PBS + 1% BSA + 10% FBS =  
Biolegend 420201 + 50 mL FBS -Gibco 26140-129, heat deactivated at 56° for 45 
min) plus 10 ul mouse IgG (Jackson Immuno – ChromPure 015-000-003). 
Incubate for 30 min in dark at RT. In the meantime, make up the staining cocktail. 
 
 
 Wash with 1 mL staining buffer – centrifuge and discard supernatant 
 
 Add 100 µL antibody staining cocktail to appropriate tubes (chart above). 
Incubate 30 min in dark at RT 
 
 
 Add 1mL staining buffer to each tube. Centrifuge/discard supernatant 
 
 Re-suspend in 500uL staining buffer. Read in flow cytometer.    
 
 
 
 
 
The methods of leukocyte isolation and staining in this lab were made with the expertise 
of Karen Needham.  
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